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In Gram-negative bacteria, resistance against β-lactam antibiotics arises most often in 
the form of β-lactamase enzymes. β-Lactamases inactivate these antibiotics by hydrolysing 
their β-lactam pharmacophore. In this thesis, enzymatic drug modification by selected serine 
β-lactamases is studied using combined quantum mechanics/molecular mechanics (QM/MM) 
simulations. 
Carbapenem breakdown by class A β-lactamases is inspected using so-called 
“computational assays”. The assays are simplified simulation protocols, which are still accurate 
enough to distinguish between active and inhibited enzymes. By limiting the simulation time 
and conformational sampling, a >99% reduction in required computational resources was 
achieved (compared to the original protocols), whilst still preserving the predictive power of 
the computational assay. 
Further studies focus on class D β-lactamases, in particular the OXA-48 family. Most 
OXA-48 β-lactamases, including the wildtype OXA-48, are carbapenemases with specific 
preference for imipenem, but some variants have acquired activity against expanded-spectrum 
oxyimino cephalosporins. Ceftazidime breakdown for OXA-48-like enzymes is simulated to 
elicit the origins behind this enhanced cephalosporinase activity. Active site hydration was 
observed to correlate with the energy barriers for the rate-limiting reaction step. In addition to 
ceftazidime breakdown, carbapenem inactivation by OXA-48 is compared for imipenem and 
meropenem. QM/MM simulations are used to identify the preferred substrate orientation for 
deacylation, and to further illustrate that the difference in carbapenem hydrolysis comes from 
a subtle change in the active site hydrogen bonds. 
Lastly, two suggested inhibition mechanisms of the non-β-lactam β-lactamase inhibitor 
avibactam against OXA-48 are compared to deduct the most plausible acylation pathway. The 
QM/MM potential energy profiles show that avibactam most likely utilises a similar 
mechanism to β-lactam substrates, where a carboxylated Lys73 acts as a proton acceptor in 
acylation. Based on these data, it is hypothesised that the avibactam inhibition most likely 
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Chapter 1 - An introduction to antibiotic resistance 
 
1.1 The Antimicrobial Resistance Crisis 
 
Antimicrobial resistance (AMR) conveys all different mechanisms, with which 
pathogens, such as bacteria, viruses, and parasites, resist medical treatments designed to cure 
infections. AMR develops naturally over time through changes in the genetic code, but the 
overuse of antimicrobials in healthcare and agriculture, poor hygiene, lack of proper sanitation, 
as well as lower-quality healthcare accelerate it.1 These factors point strongly towards low- and 
middle-income countries, for example in Asia and Africa, where AMR continues to be a 
constant burden.2-5 However, AMR is also a growing problem in the western world. According 
to the Centers of Disease Control and Prevention (CDC), in the United States alone more than 
2.8 million antibiotic resistant bacterial infections are diagnosed annually, resulting in more 
than 35 000 fatalities.6 Furthermore, according to the English Surveillance Programme for 
Antimicrobial Utilisation and Resistance report from 2019 to 2020 (published by Public Health 
England), there has been an estimated 32% increase in antibiotic resistant blood stream 
infections from 2015 to 2019. This increase is despite the decreased consumption of antibiotics 
during the same time interval, going from 19.4 to 17.9 defined daily doses per 1000 
inhabitants.7 
Evidently, there is a need to combat the evolving AMR problem, and multiple global 
and national initiatives have been propagated to this end. In 2015, a global action plan on AMR 
was established at the World Health Assembly.8 The aims of this plan are focused on spreading 
AMR awareness, endorsing research concerning AMR, strengthening surveillance, optimising 
the use of antimicrobials, and sustainably investing in countering AMR. The World Health 
Organization (WHO) has also multiple additional initiatives: the World Antimicrobial 
Awareness Week (annually between November 18th and 24th),9 the Global Antimicrobial 
Resistance Surveillance System (GLASS),10 and the Global Antibiotic Research and 
Development Partnership (GARDP), to mention a few. In addition to global initiatives, most 
countries have national strategies for controlling the spread of AMR. For example, the UK has 
currently a five-year action plan between 2019-2024 for tackling AMR with three key aims: 
reducing the need and unnecessary exposure to antimicrobials, optimising the use of 
antimicrobials, and investing in new innovations, supply, and access in this field.11 As 




with the overarching national goal being containing and controlling the spread of AMR by 
2040.11 
One central aspect in most action plans is ensuring the research and development work 
necessary for discovering new and effective antibiotics, against which bacteria have not yet 
developed resistance mechanisms. After the considerable successes in antibiotic drug 
discovery in the 20th century, when most currently available antibiotics were first introduced 
into clinical practice, the antibiotic pipeline has dried out. This so-called “antibiotic discovery 
void” is due to the inherent difficult nature of drug discovery and development, as well as the 
reluctance of big pharmaceutical companies to engage in antibiotic research. Many antibiotic 
classes were originally derived from natural products, such as tetracyclines from soil 
Actinomycetes or penicillin from fungi,12, 13 though purely synthetic antibiotic classes, such as 
quinolones, also exist.14 Currently, mining natural sources has mainly led to the re-discovery 
of already existing antibiotics. Additionally, finding possible sources for new antibiotics would 
require assembling and screening a huge library, which is a laboursome and costly task.13 
Antibiotic development is a difficult task, as the drug candidate needs to be potent enough to 
cure the bacterial infection, whilst being non-toxic for humans. Other aspects, such as the drug 
being preferably in an orally bioavailable form, should be considered as well. One bottleneck 
seems to be the lack of compounds able to enter the bacterial cell through the cell envelope.15 
Finally, after the time-consuming development and clinical testing process involved for any 
new drug, any possible profits from the approved antibiotic are most likely to be less than the 
development costs.16 
 
1.2 β-Lactam antibiotics 
 
β-Lactam antibiotics were first discovered in 1929 by Alexander Fleming,17 and the 
large-scale production of these drugs began in the 1940s. Despite their relatively old age, β-
lactams are still the most prescribed group of antibiotics globally due to their non-toxicity in 
human patients and general broad-spectrum antibacterial activity.18 β-Lactams are categorised 
into four classes: penicillins, cephalosporins, carbapenems, and monobactams (Figure 1.1). 
The scaffold in all four groups involves a four-atom β-lactam ring, which is the pharmacophore 
responsible for drug binding. In the first three groups, the β-lactam ring is fused to a second 




carbapenems. Monobactams are monocyclic and the β-lactam ring stands alone (with other 
substituents attached to it). Penicillin antibiotics were initially isolated among the natural 
products of the Penicillium fungi,12 but most commercially available penicillin antibiotics 
today are synthetic penicillin derivatives.19 Cephalosporins are divided into generations based 
on their antibacterial properties. Especially the newer third and fourth generations have broad 
activity against Gram-negative bacteria,20 whilst some fifth generation cephalosporins have 
additional activity against methicillin-resistant Staphylococcus aureus.21, 22 Currently, the only 
commercially available monobactam antibiotic is aztreonam.23 Carbapenems are the newest 
group of β-lactam drugs, and often referred to as “last-resort antibiotics” due to their general 
potency and wider spectrum of use, with respect to cephalosporins and penicillins.24 
 
Figure 1.1 Some clinically used β-lactam antibiotics and β-lactamase inhibitors. Examples of approved 





To combat growing antibiotic resistance against β-lactam drugs, an antibiotic may be 
administered together with a β-lactamase inhibitor (some combinations presented in Figure 
1.1).25 This so-called “combination therapy” is often reserved for multi-drug resistant bacterial 
infections with only limited treatment possibilities. The treatment power of combination 
therapy is illustrated by the WHO model list of essential medicines, which categorises 
necessary drugs into access, watch, and reserve groups. Different examples of β-lactam/β-
lactamase inhibitor combinations are listed in all three aforementioned groups of medicine.26 
β-Lactamase inhibitors essentially block enzymes responsible for β-lactam antibiotic 
inactivation (as outlined in following sections), which allows for the actual antibiotic to bind 
to its ultimate target.27 They can be mechanism-based inhibitors including a β-lactam ring, or 
belong to another functional group. Examples of mechanism-based antibiotic/inhibitor 
combinations include amoxicillin/clavulanic acid (tradename Augmentin or Clavulin),28 
ampicillin/sulbactam (Unasyn),29 and piperacillin/tazobactam (Tazocin, Zosyn),30 which have 
inhibitory activity mainly against some class A penicillinases and extended-spectrum β-
lactamases (ESBLs). As these β-lactam-based β-lactamase inhibitors do not possess very 
broad-spectrum activity, new inhibitor classes including diazabicyclooctanones (DBOs) and 
cyclic boronates have been introduced to the market in the last decade. Avibactam31, 32 was the 
first DBO inhibitor approved in clinical use in combination with ceftazidime (FDA approved 
in 2015, tradename Avycaz),33 and it shows broad inhibition against serine β-lactamases 
(introduced in the following sections).34 Beyond avibactam, the DBO scaffold is undergoing 
extensive research to provide inhibitors with more broad-spectrum activity.35-39 Cyclic 
boronates also show promise as possible broad-spectrum β-lactamase inhibitors.40, 41 The first 
FDA approved cyclic boronate inhibitor was vaborbactam,42 which is approved in clinical use 
together meropenem (Vabomere).43 Boronate inhibitors are also undergoing extensive 
research, and some clinical candidates show promise of ultrabroad-spectrum inhibition against 
all β-lactamases (such as taniborbactam and QPX7728).44, 45 The market for β-lactam 
antibiotics together with β-lactamase inhibitors is growing, with a size of over $27 million in 







1.3 β-Lactamase-mediated antibiotic resistance 
 
Antibiotic resistance is a natural phenomenon, which has been observed since the 
introduction of modern antibiotics: penicillin-resistant Staphylococcus aureus was identified 
only a year after the clinical introduction of penicillin.47 Antibiotic resistance in bacteria is 
manifested in different ways, which include both chromosomal changes (such as efflux pumps) 
and extrachromosomal elements (such as resistance plasmids).48 Focusing on Gram-negative 
bacteria, the main resistance mechanism is enzymatic drug modification by β-lactamase 
enzymes.49 β-lactam compounds mimic the tertiary structure of D-ala-D-ala, which is the 
natural substrate of penicillin-binding proteins (PBPs). PBPs are essential in bacterial cell wall 
biosynthesis, as the D-ala-D-ala-end of pentapeptides is a precursor for peptidoglycan 
formation in the cell wall.50 β-Lactam binding and subsequent long-lived covalent complex 
formation with PBPs inhibits cell wall renewal and eventually leads to bacterial death.51 
Therefore, the sole purpose of β-lactamases is to inactivate β-lactam antibiotics before they 
bind to PBPs, ensuring the survival of the bacteria. β-Lactamases are often encoded on 
plasmids,52-56 which makes for efficient spread of the resistance genes; however, 
chromosomally-encoded β-lactamases exist as well.57-60 The CDC categorises many Gram-
negative bacteria expressing β-lactamases as urgent threats, including carbapenem-resistant 
Acinetobacter and Enterobacterales as well as ESBL-producing Enterobacterales.6 The 
number and variety of identified β-lactamases has increased exponentially after β-lactams were 
introduced as antibacterials,61 and the sequences of over 7000 enzymes are listed in the β-
lactamase database in 2021 (with structural data available for over 1300).62 
β-Lactamases are divided into serine β-lactamases and metallo-β-lactamases based on 
their catalytic mechanism. According to the Ambler classification, serine β-lactamases are 
further grouped into classes A, C, and D, whilst all metallo-β-lactamases comprise class B. The 
Ambler classification is based on sequence similarity between enzymes.63 Serine β-lactamases 
are distant relatives to PBPs,64 and even when the sequence homology between different groups 
of serine β-lactamase is limited, the tertiary structure across the classes is similar (Figure 1.2). 
Generally, penicillin-recognising enzymes (including β-lactamases and PBPs) have a 
conserved Ser-X-X-Lys moiety in their active site, which includes the catalytic serine and a 
lysine (X-X can be any amino acid); the residue numbering is Ser70 in class A, Ser64 in class 
C, and Ser70 or Ser79 in class D, depending on the enzyme. Further, two triads near the active 




recognizing enzymes.65 All serine β-lactamases have an Ω-loop near their active site, even 
though the loop residues and location differs between classes. β-Lactamases in classes A and 
D are widely distributed globally and confer broad-spectrum resistance against cephalosporins, 
carbapenems, and β-lactamase inhibitors.49 The work in this thesis is focused on studying 
selected enzymes from these classes. Class C β-lactamases are mainly chromosomally encoded 
and do not inherently possess activity against the most potent carbapenem antibiotics, as their 
carbapenemase activity is suggested to be a result of reduced permeation into the cell.66 Class 
B β-lactamases are also a clinically significant part of widespread multidrug resistance,67 but 




Figure 1.2 Crystal structures of three unliganded serine β-lactamases (PDB IDs: KPC-2 2OV569, AmpC 
2BLS70, OXA-48 6P9671). Conserved motifs in the tertiary structure highlighted in yellow and the Ω-






In serine β-lactamases, antibiotic inactivation relies on forming a covalent intermediate 
with the drug via the catalytic serine residue. The reaction mechanism follows the general 
mechanism of serine proteases (to which serine β-lactamases belong) illustrated in Figure 1.3. 
First, the nucleophilic serine is activated via proton transfer to a general base in acylation. This 
involves tetrahedral intermediate formation leading to a covalent acylenzyme complex.72 
Subsequently, the covalent acylenzyme undergoes deacylation, where a water acts a 
nucleophile, again leading to tetrahedral intermediate formation. Finally, the hydrolysed 
antibiotic is cleaved. The tetrahedral intermediate formation in both reaction steps is aided by 
the so-called “oxyanion hole”,73 which is formed by the backbone amides of two active site 
residues (the catalytic serine and another one). Hydrogen bonds in the oxyanion hole stabilise 
the negatively charged transition state and subsequent tetrahedral intermediate, which accounts 
for most of the catalytic effect of serine β-lactamases, and serine proteases in general.73 The 
specific residues participating in the hydrolysis reaction vary between different classes. The 
mechanism for class A β-lactamases is described in Section 1.3.1, whereas the mechanism for 
class D β-lactamases is covered in Chapter 4. The mechanism in class C β-lactamases differs 
from classes A and D, as they most likely use a tyrosine residue as the general base in β-lactam 
hydrolysis.74 
 
Figure 1.3 General hydrolysis scheme for serine β-lactamases for a carbapenem substrate. Starting 
from the non-covalent Michaelis’ complex (1), in acylation the catalytic serine nucleophile is activated 
via proton transfer to a general base. This leads to tetrahedral intermediate formation (1 → 2), which 
collapses to form the covalent acylenzyme (2 → 3). In deacylation a water nucleophile is activated to 
form a new tetrahedral intermediate (4 → 5), which yields the final hydrolysis product (6). The 





1.3.1 Class A β-lactamases 
 
Class A β-lactamases are perhaps the most studied group of serine β-lactamases, even 
though some controversies concerning e.g. their catalytic mechanism still remain (discussed 
further below). These enzymes are traditionally characterised as penicillinases, meaning they 
exhibit efficient penicillin breakdown, but a growing array of enzymes capable of 
cephalosporin and carbapenem hydrolysis have emerged. Most encountered class A β-
lactamase families in clinical settings include the TEM (originally identified in Greece in a 
patient named Temoneira),75 SHV (sulfhydryl variant),59 CTX-M (cefotaximase),76 and KPC 
(Klebsiella pneumoniae carbapenemase)77 enzymes. The TEM and SHV families inactivate 
primarily penicillin substrates, although some of their variants have acquired activity against 
oxyimino cephalosporins (e.g. cefotaxime) through point mutations.78 β-Lactamases exhibiting 
activity against broad-spectrum cephalosporins are referred to as extended-spectrum β-
lactamases (EBSLs),79 and as the name cefotaximase suggests, CTX-M enzymes belong to this 
group as well. Moreover, CTX-M enzymes are specifically named in the CDC Antibiotic 
Resistance Threats report under ESBL-producing Enterobacterales.6 Another concerning 
direction exhibited by some class A β-lactamases is carbapenemase activity, i.e. the ability to 
inactivate potent carbapenem antibiotics, which severely limits treatment options.80 Examples 
of class A carbapenemases include e.g. the previously mentioned KPCs, SME (Serratia 
marcescens enzyme),81 NMC-A (non-metallocarbapenemase A),82 and SFC-1 (Serratia 
fonticola carbapenemase)83. KPC enzymes are among the most commonly identified 
carbapenemases in Enterobacterales, and they confer resistance against most carbapenem and 
cephalosporin antibiotics.84 As an example, KPC enzymes accounted for 12.5% of confirmed 
carbapenemase-producing Enterobacterales samples in England according to the 2019 
ESPAUR report.7 Alarmingly, KPC-2 point mutants have also demonstrated resistance against 
new inhibitors such as avibactam,85 and mutants with activity against the 
ceftazidime/avibactam combination have been observed in a laboratory setting.86 
The hydrolysis mechanism in class A β-lactamases follows the general mechanism 
presented in Figure 1.3. However, the residue acting as the general base in acylation remains 
disputed. Two main reaction mechanisms have been proposed in the literature. In the first 
proposal, the serine nucleophile is activated via proton transfer to Glu166 using a bridging 




involves Ser70 nucleophile activation by a proton transfer to Lys73 instead of a water molecule, 
which would require Lys73 in its neutral protonation state. In both proposals, a proton is 
subsequently transferred from Glu166 to Ser130 via Lys73, as Ser130 protonates the β-lactam 
ring nitrogen in the second acylation step, which ultimately yields the covalent acylenzyme 
intermediate. This intermediate is cleaved using a water nucleophile, which is activated by a 
proton transfer to Glu166 (analogous to acylation). Evidence for Glu166 as the (primary) 
general base in acylation is based on information derived both from computational modelling 
and experimental studies.87-89 The proposed role of Lys73 as the general base instead of Glu166 
is based on site-directed mutation studies, as mutants of TEM-1 at position 166 are able to 
undergo acylation, albeit with greatly reduced rates.90 Further studies indicate that Lys73 would 
be in its neutral form if Glu166 is mutated,91 and that proton transfer to Lys73 could be 
feasible.92, 93 However, is it possible that the absence of Glu166 shifts the pKa of Lys73, 
enabling it to be deprotonated and to act as a base, and that the primary base in the wildtype 
enzyme is Glu166. 
 
1.3.2 Class D β-lactamases 
 
The class D β-lactamases studied in this thesis, namely OXA-48 enzymes, are presented 
in a minireview comprising Chapter 4. 
 
1.4 Summary of this thesis 
 
In this thesis, I will present my work on simulating antibiotic breakdown by selected serine 
β-lactamases. This research has two main goals: 
1. Establishing efficient computational protocols, which still accurately distinguish 
between active and inhibited β-lactamases. 
2. Deducting structural and/or mechanistic features contributing to efficient catalysis. 
Computational methods utilised in this thesis, and the theory behind them, are briefly 
introduced in Chapter 2. Chapter 3 focuses on investigating carbapenem hydrolysis by class A 
β-lactamases. This work introduces the term “computational assay”, which accurately 
distinguishes between carbapenemases and carbapenem-inhibited enzymes whilst employing 




lactamases. Chapter 4 consists of a minireview summarising recent research concerning class 
D OXA-48 enzymes. Chapters 5 to 7 are focused on simulating β-lactam degradation by OXA-
48s. Cephalosporin inactivation by OXA-48 and its variants is presented in Chapter 5, whilst 
Chapter 6 discusses carbapenem hydrolysis by OXA-48. Finally, studies on OXA-48 inhibition 
by avibactam are summarised in Chapter 7. Chapters 5 to 7 concentrate on the second goal, 





Chapter 2 - Computational methods 
 
Computational chemistry has paved its way into modern chemical research, as it is 
routinely used in many different applications ranging from materials research to catalyst design 
to studying biological systems.94-98 In this chapter, different computational chemistry methods 
are presented, covering theory from more simplistic molecular mechanics description of atoms 
to computationally more demanding quantum chemical wavefunction-based methods and 
density-functional theory. Semi-empirical methods are also briefly introduced. The theory 
behind biased reaction simulations and the standard techniques used in biomolecular modelling 
are described in the end. 
 
2.1 Molecular mechanics 
 
Due to the relatively large system sizes (ranging usually from tens of thousands to 
millions of atoms) encountered when simulating biological systems, methods based on 
quantum mechanics become too computationally expensive to apply for practical use. Instead, 
a system can be described using molecular mechanics,99 where the general potential energy 
function V(total) for the system includes contributions from both intramolecular and 
intermolecular terms: 
Eq.  2.1 
𝑉(𝑡𝑜𝑡𝑎𝑙)  =  𝑉(𝑏𝑜𝑛𝑑𝑠)  +  𝑉(𝑎𝑛𝑔𝑙𝑒𝑠)  +  𝑉(𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠)  +  𝑉(𝑣𝑑𝑊) +  𝑉(𝑒𝑙) 
where V(bonds), V(angles), and V(dihedrals) form the intramolecular energy contribution from 
bonds, angles, and dihedrals, and the Van der Waals interactions V(vdW) together with the 
electrostatic interaction term V(el) form the intermolecular component. 
The energy contribution arising from bonds between atoms has the following form: 
Eq.  2.2 
𝑉(𝑏𝑜𝑛𝑑𝑠)  =  ∑ 𝑘𝑏(𝑟 − 𝑟0)
2  
where kb corresponds to the bond force constant and r0 the reference bond length. The harmonic 
form of the bond energy expression prohibits bonds from breaking and ensures bond lengths 




The energy expression for angles is analogous to the energy contribution arising from 
bonds, and is: 
Eq.  2.3 
𝑉(𝑎𝑛𝑔𝑙𝑒𝑠) = ∑ 𝑘0(𝜃 − 𝜃0)
2 
where k0 is the force constant, and θ0 the reference angle value. 
The intramolecular energy expression for the dihedrals is slightly more complicated 
than the previous two: 
Eq.  2.4 
𝑉(𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠)  =  ∑ 𝑘𝜙(1 + cos(𝑛𝜙 − 𝛿)) 
where kϕ is the force constant, and n the number of rotational minima between 0° and 360°. 
Additionally, the force field energy expression can include a term for improper torsions. 
These involve four atoms that can form out-of-plane torsions: 
Eq.  2.5 
𝑉(𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟𝑠) = ∑ 𝑘𝜙(𝜙 − 𝜙0)
2
 
where again kϕ is a force constant, and ϕ0 the reference improper value. 
Intermolecular energy terms describe interactions between non-bonded atoms. For the 
Van der Waals component, the interaction energy is often modelled using a 12-6 Lennard-
Jones-type potential: 










where Aij and Bij are atom-pair specific parameters included in the force field, and Rij the 
distance between non-bonded atoms i and j. A 12-6 potential ensures that the interaction energy 
increases steeply as two atoms come too close together (R12 term) and is lowered when they 
are further apart (R6 term). 




Eq.  2.7 





where qi and qj are point charges on atoms i and j, Rij the distance between the atoms, and ϵ the 
effective dielectric constant for the solvent. 
The specific parameter set used when calculating the individual energy terms for a 
certain system configuration is called a force field. In this thesis, the Amber ff14SB force field 
was used in all calculations.100 
 
2.2 Basics of quantum mechanics 
 
Molecular mechanics is a convenient approach for simulating large systems. However, 
quantum mechanics provides a more appropriate description of system behaviour at the 
molecular level. In the heart of quantum mechanics is the Schrödinger equation,101 which tells 
how a system with a state wavefunction ψ(t) evolves with time: 




𝜓(𝑟, 𝑡) =  Ĥ 𝜓(𝑟, 𝑡) 
Here, ψ(t) is the time-dependent wavefunction of the system, and Ĥ the Hamiltonian 
operator corresponding to the total energy of a system. If the Hamiltonian is assumed to be 
time-independent, the Schrödinger equation can be written as: 
Eq.  2.9 
 ?̂? 𝜓(𝑟) = 𝐸𝜓(𝑟) 
where E is the total energy of a system. The total energy is a sum of kinetic and potential energy 
terms for electrons and nuclei, and the molecular Hamiltonian takes the form: 
Eq.  2.10 































where the first and second terms describe the kinetic energies of electrons and nuclei 
(respectively), the third term electron repulsion, the fourth nuclei repulsion, and the last one 
attractive interaction between electrons and nuclei. However, often nuclei are considered as 
fixed point charges in space. This is due to the large mass difference between electrons and 
nuclei. When this so-called Born-Oppenheimer approximation102 is applied, the electronic 
Hamiltonian is obtained: 
Eq.  2.11 















Even with the Born-Oppenheimer approximation, the Schrödinger equation is possible 
to solve analytically only for a hydrogen atom or hydrogen-like molecules (with only one 
electron). Further approximations for obtaining the system energy include separating the full 
electron wavefunction into a product of single-electron wavefunctions: 
Eq.  2.12 
𝜓(𝒓) = |𝜓1𝜓2 … 𝜓𝑛| 
 
As electrons are fermions with a half-integer spin, the Pauli exclusion principle103 states 
that the wavefunction must be antisymmetric with respect to interchanging two electrons 
(fermions), and it is hence described as a determinant. 
Molecular orbitals for a given system are often constructed from atomic orbitals (AOs). 
In the LCAO approximation (linear combination of atomic orbitals), one-electron AOs χ1,…,χn 
are used for describing a MO ϕi: 
Eq.  2.13 
𝜙𝑖 = 𝑐1𝑖χ1 + 𝑐2𝑖χ2+. . . +𝑐𝑛𝑖χn 
 
where coefficients cni correspond to the individual weights of the AOs in the linear combination 
for a particular MO. The AOs used are often referred to as basis functions, which comprise the 
basis set (discussed later in more detail). The system wavefunction can then be constructed by 
finding the AO weights which yield the lowest energy. However, solving the Schrödinger 




knowing the individual AO weights in advance, and hence the weights are solved in an iterative 
way using trial weights as a starting guess. This procedure is called a self-consistent field (SCF) 
calculation.104 
 
2.3 Ab Initio methods 
 
Ab initio translates from Latin as “from first principles”. The oldest ab initio method is 
the Hartree-Fock (HF) method, which is alternatively called the self-consistent field method.105 
Within HF theory, the system wavefunction is expressed as single Slater determinant, and the 
system energy is solved in practice using the Hartree-Fock-Roothan equations.106, 107 The HF 
method scales cubically with respect to system size, i.e. N3. HF formulation follows the 
variational principle, which states that when using a trial wavefunction for finding the energy 
of a ground state, the true ground state energy is never higher than the one obtained with the 
trial wavefunction. Therefore, the HF energy is always an upper-bound limit for the real energy. 
The shortcomings of HF theory include neglecting electron correlation, as the movement of a 
single electron is independent of the other electrons (except for the repulsion arising from the 
average electron positions). The only correlation considered is Fermi correlation, which means 
that the probability of finding two parallel spin electrons in the same point in space is zero. 
This is not true for antiparallel spin electrons, though. Secondly, the single-determinant 
approach is often a poor description of many-body systems. These are also referred to as 
dynamical and statistical correlation, respectively. Neglecting electron correlation is a big 
approximation, which can lead to wrong system descriptions and large deviations of computed 
values from experimentally determined ones.108-111 
Building on the HF theory, the so-called post-HF methods have been developed to 
address the shortcomings of the original formulation, e.g. by adding more dynamical 
correlation. The Møller–Plesset perturbation theory (MP)112 incorporates electron correlation 
through perturbation theory. The Hamiltonian operator is expressed as a sum of the unperturbed 
operator and a small perturbation, and the corresponding energies can be calculated up to the 
second (MP2), third (MP3), or fourth (MP4) order. The first order (MP1) energy equals the 
Hartree-Fock energy (which is also the zeroth order energy with an unperturbed Hamiltonian, 
as the first order correction is zero). Among the different levels of MP theory, MP2 remains 
perhaps as the most utilised method as it is least costly computationally (scaling N5) and 




calculated energies towards a certain value.113 The steep scaling of MP2 can be partly overcome 
by utilising the resolution of identity (RI) approximation.114 In the RI approximation, the 
computationally expensive four index two-electron integrals are approximated as a linear 
combination of three-index integrals; this procedure can be applied to both the SCF part and 
the MP2 correction. One drawback of the MP theory is that it is not variational, i.e. it 
overestimates system stability by underestimating their energies. On the other hand, this can 
be used as an upper bound for stability. One easy way to improve the calculated energies is to 
incorporate empirical scaling factors for energy contributions from same-spin and opposite-
spin electrons, as is done in spin-component-scaled MP2 method (SCS-MP2).115 
Further post-Hartree-Fock ab initio methods include the configuration interaction 
(CI)116 and the coupled cluster (CC)117 methods. Especially the CC method combined with 
perturbation theory (named CCSD(T))118 is currently regarded as the “gold standard” in 
quantum chemistry. However, calculations utilising CCSD(T) are limited to very small 
molecules or only single-point energies, where initial structure optimisation is done using a 
lower level of theory, due to its expensive scaling behaviour of computational time with respect 
to system size (N7). A promising development regarding CC methods is utilising the locality 
of electron correlation. The DLPNO-CCSD(T) (domain based local-pair natural orbital) is a 
linear-scaling method with respect to the system size,119 and based on benchmarking, it is able 
to recover over 99% of the CCSD(T) correlation energy.120 In this thesis, benchmarking of 
semi-empirical methods is most often done against (SCS-)MP2 results for very small gas-phase 
model systems, as routinely utilising ab initio methods for system sizes in biomolecular 
simulations becomes unfeasible. 
 
2.4 Density functional theory 
 
Ab initio methods rely on finding the energy of a molecular system by constructing a 
wavefunction to describe the system and solving the Hamiltonian eigenvalue problem. Density 
functional theory (DFT) approaches the same problem from another angle, as the electron 
density ρ of a system is used for obtaining system energies. DFT is originally built on the 
Hohenberg-Kohn theorems, which state that 1. the ground state electron density of a system 
uniquely determines its energy (and other properties), and 2. only the ground state electron 
density minimises the energy functional for a system.121 In other words, determination of 




the DFT formulation follows the variational principle. However, modern DFT formulation is 
based on later Kohn-Sham equations,122 where the electron density of the full, interacting 
system is matched with the electron density of a fictious, non-interacting system. The total 
energy is then expressed as a sum: 
Eq.  2.14 
𝐸𝐷𝐹𝑇[ρ] = 𝑇𝑒[ρ] + Vne[ρ] + Vee[ρ] + EXC[ρ] 
where Te is the kinetic energy of non-interacting electrons, Vne the attractive Coulomb potential 
between electrons and nuclei, and Vee the repulsive potential between electrons. All the 
unknown interactions terms are grouped into the last EXC term, which is the so-called exchange-
correlation functional. The exchange-correlation functional can be further decomposed into 
separate exchange and correlations terms: the exchange term can be calculated exactly as in 
the HF method. Notably, the theory of DFT is exact, i.e. it yields the exact electronic energy 
of a system. In reality, however, the exact form of the EXC functional is unknown, and some 
approximations need to be introduced. 
As many different approximations have been developed for tackling the problem of the 
unknown exchange-correlation functional, DFT cannot be systematically improved. 
Nonetheless, the Jacob’s ladder framework (proposed by Perdew) rationalises the approaches 
taken in constructing various DFT functionals, as progressing higher on the successive levels 
should improve the functional (and bring the performance closer to the “heaven of chemical 
accuracy”).123 The first rung is the local density approximation (LDA), which is originally 
derived for homogeneous electron gas (electron density identical at every point in space).121 
The energy of a system is given by the electron density at certain point in space, and the density 
is assumed to vary slowly. However, LDA functionals are not widely applied to molecular 
systems as their electron density is often far from spatially uniform. Functionals incorporating 
the generalised gradient approximation (GGA) build on the LDA, but also include the gradient 
of electron density in the EXC functional.
124-126 Analogously, meta-GGA functionals include the 
second derivative of electron density, and examples of meta-GGA functionals include e.g. 
TPSS127 and M06-L128. On the ladder towards the heaven of chemical accuracy, GGA and 
meta-GGA functionals comprise the second and third rung, respectively. On the fourth and 
fifth rungs are hybrid and double hybrid functionals, respectively. Hybrid functionals 
incorporate a certain amount of the exact HF exchange energy into their EXC functional,
129 




B3LYP130-133 is still perhaps the most widely applied hybrid functional, other popular hybrids 
include functionals in the M06 suite134 and the ωB97 family135, 136. Examples of double hybrid 
functionals include B2PLYP137 and ωB97X-2138. A known drawback of most DFT methods is 
the incorrect description of long-range dispersion interactions,139-142 and corrections can be 
added to address this.143 Common ways to account for this error include van der Waals density 
functionals (vdW-DF), where a non-local energy term for dispersion interactions is added to 
the EXC functional.
144 Another example are the semiclassical DFT-D corrections, where the 
dispersion energy is calculated pair-wise in an additive fashion for all atoms and simply added 
to the Kohn-Sham energy.145 
In this thesis, DFT was mainly used for benchmarking purposes due to the 
computational cost of using DFT in conformational sampling for large biomolecular systems. 
The performance of semi-empirical methods in QM/MM calculations was compared against 
DFT results both for model gas-phase systems of the enzyme active site, and for energy 
corrections for structures optimised using semi-empirical methods. Mainly hybrid functionals 
were used, the most utilised one being the meta-GGA hybrid M06-2X.134 M06-2X includes 
54% HF exchange in its EXC formulation, and it is parametrised only for non-metals. Based on 
previously published benchmarking data, M06-2X performs well for thermochemistry and 
barrier heights,134, 146 but may lack proper description of non-covalent interactions.147 Another 
functional of choice was the long-range corrected hybrid GGA ωB97X,135 either as its initial 
formulation or as ωB97X-D136 with dispersion corrections. 
 
2.5 Basis sets 
 
Functions used for constructing the electronic wavefunction are called basis functions, 
and together the functions form a basis set. Approaching the complete basis set limit, i.e. the 
perfect description of a wavefunction, would require an infinite amount of basis functions; in 
practise a finite number of functions is included in each basis set. Basis sets are often 
constructed using AOs, which are combined to yield MO descriptions (as introduced in section 
2.2). Slater-type orbitals (STOs) can be used for describing AOs, as these functions are 
analytical solutions for the Schrödinger equation for one-electron systems. However, 
evaluation of two-electron integrals using STOs can be difficult; therefore, STOs are often 
approximated using a combination of Gaussian-type orbitals (GTOs). Minimal basis sets 




Even when minimal basis sets are computationally efficient, results obtained using them are 
often crude as only one STO is used per orbital. Pople’s split-valence basis sets follow format 
X-YZG, where X tells how many GTOs comprise every core AO, and Y and Z how many 
primitive gaussian are used for the valence orbitals.148 For example, in 3-21G basis set every 
core AO is a linear combination of three primitive gaussians, while the two valence AOs consist 
of two and one primitive gaussians. With split-valence basis, at least two STOs are used for 
each valence electron, which yields a better description of the system than provided by STO-
nG basis sets. Polarisation is indicated by a star after the basis set name and is incorporated by 
including higher angular momentum orbitals in the basis set (for example 1p orbitals for 
hydrogen). Diffuse functions are indicated by a +, and they are used for describing regions 
further away from the nucleus (often called the tail regions). Dunning basis sets,149 or the so-
called correlation-consistent basis sets, are designed to approach the complete basis set limit 
upon adding more basis functions. They follow the format cc-pVnZ, where the prefix cc-p 
indicates the set to be correlation-consistent polarised, and the suffix VnZ tells how many 
functions (n) are used for describing each valence electron. Diffuse functions can be added 
with the aug- suffix. The Karlsruhe def2 basis sets (also named Ahlrichs basis sets) follow the 
same format, where e.g. def2-SVP denotes split valence (two AOs per valence electron) 
polarised.150 
 
2.6 Semi-empirical methods 
 
Semi-empirical quantum chemical methods are based on the HF theory, but skip many 
computationally intensive steps by introducing additional approximations or parametrisation. 
Any parameters used in the formulation are usually empirically derived, i.e. the goal is to fit 
the computed results to match some existing empirical data. Many semi-empirical methods 
employ the neglect of diatomic differential overlap (NDDO) approach, where the simplified 
idea is to reduce the computational overhead by ignoring the two-electron integrals,151 and 
treating remaining one-electron integrals approximately e.g. through parametrisation.152 These 
methods often employ minimal basis sets with only valence electrons, which further speeds up 
the calculations. Popular semi-empirical methods include AM1 (Austin Model 1)153, PMx 
(Parametric Method, x=3,6,7)154-156, and OMx methods (Orthogonalization-corrected Methods, 
x=1,2,3)157. As some methods are formulated against empirical data, they are able to recover 




parametrisation procedure combined with valence-only and minimal basis set approaches 
limits their applicability, and their performance for a given problem should be tested against 
higher-level methods. 
In addition to finding approximate ways to speed up HF-based calculations, density 
functional tight-binding (DFTB) schemes aim to do the same for DFT methods. The electron 
density ρ for a system is expressed as a sum of a reference density and a small fluctuation ρ = 
ρ0 + δρ (ρ0 being the superposition of neutral atomic densities). The energy expression can now 
be expanded as a Taylor series around the reference density. Including only the first order terms 
in the expansion yields the DFTB1 method (alternatively just DFTB), whereas including the 
second order term yields DFTB2. DFTB2 is also called SCC-DFTB, as it introduces calculating 
atomic partial charges self-consistently.158 DFTB3 includes terms up to third order.159 As the 
DFTB1 method is not self-consistent,160 it is advised to be used only for systems where charge 
transfer between atoms is small.161 Both DFTB2 and DFTB3 have been applied widely in 
simulating biological systems,162, 163 and are the semi-empirical methods of choice also in this 
thesis. 
 
2.7 Hybrid quantum mechanics/molecular mechanics methods 
 
State-of-the-art reaction simulations of large biomolecular systems often utilize a 
combined quantum mechanics/molecular mechanics (QM/MM) approach, where a small 
portion of the system is modelled using quantum mechanics, whilst the rest are described by 
molecular mechanics.164 The QM subsystem often consists of ligand and some key active site 
residues (e.g. participating in the catalysed reaction or transition stabilisation). QM/MM 
methods allow simulating chemical reactions within the enzyme, as the bonding situation is 
not fixed, unlike in simulations based on molecular mechanics. 
The total energy for a given system in QM/MM simulations is generally calculated 
using either the additive or subtractive approach.165 In an additive scheme, the total energy 
consists of three terms: 
Eq.  2.15 




where energies for the MM and QM parts of the system are described by E(MM) and E(QM), 
respectively), and the two systems are coupled by the interface energy E(QM-MM). On the 
other hand, in a subtractive QM/MM scheme the total energy is expressed as: 
Eq.  2.16 
𝐸(𝑠𝑢𝑏, 𝑡𝑜𝑡𝑎𝑙) = 𝐸(𝑀𝑀, 𝑤ℎ𝑜𝑙𝑒) + 𝐸(𝑄𝑀) − 𝐸(𝑀𝑀 𝑓𝑜𝑟 𝑄𝑀) 
where first the MM energy is calculated for the whole system (E(MM,whole), including the 
QM region) and QM energy for the QM subsystem (E(QM)). From this total energy, the MM 
energy contribution for the QM region (E(MM for QM)) is then subtracted. The Amber 
software suite utilises the additive scheme in its QM/MM implementation, therefore it shall be 
discussed more in depth below.166 
In an additive QM/MM implementation, calculating energies for the QM and MM 
regions is relatively straightforward, whilst calculating the interaction energy (E(QM-MM)) 
for energy contributions spanning over the two subsystems remains more complicated. In the 
QM/MM implementation in the sander program (part of the Amber software package166, used 
for all QM/MM calculations in this thesis), point charges in the MM system polarise the QM 
system but not vice versa, as this would require a polarisable force field. This approach is also 
referred to as electrostatic embedding. Electrostatics often dominate in the QM-MM interaction 
energy contribution, but also Van der Waals interactions between QM and MM atoms are 
included in the QM-MM interaction energy function. Van der Waals interactions are calculated 
using the 12-6 potential as for MM atoms as discussed in Section 2.1 (equation 2.6). If there 
are no covalent bonds between the QM and MM regions, the interface energy is simply a sum 
of the electrostatic and van der Waals interactions. However, more terms must be included if 
covalent bonds are “cut” when partitioning the system into QM and MM parts. Often the link 
atom approach165 is used for these “broken” covalent bonds (as is done in sander).166 A link 
atom (hydrogen) is added as a cap to any covalent bonds between QM and MM regions to fill 
open valences. It is placed on the bond vector between the bonded QM and MM atoms, 
therefore introducing no new degrees of freedom (as the link atom coordinates depend on the 
QM and MM atom coordinates). In Amber, the link atom bond length is set to the equilibrium 
distance of a methyl C-H bond 1.09 Å. Electrostatics for link atoms are calculated the same 
way as for other QM atoms excluding the MM link pair atoms, whilst no Van der Waals 
interactions are calculated. Additionally, the MM terms for bonds spanning over the QM and 




of the QM/MM energy function, care must be taken when partitioning the system into QM and 
MM regions. Generally, polar bonds should not be broken, and the QM-MM partitioning is 
thus best done across C-C bonds. A compromise between QM system size, accuracy of 
calculated energetics/properties, and computational power needed should be considered. 
 
2.8 System preparation 
 
The starting point for biomolecular simulations is often an experimentally determined 
structure for the system of interest, either unliganded or with a ligand. Structural techniques, 
such as X-ray crystallography, yield the positions of heavy atoms, but the resolution is still 
often too low for observing hydrogens. Hence, hydrogens need to be added to the structure 
prior to performing any calculations, and many simulation programs have an automated way 
of doing this (such as tleap in the Amber suite166). The protonation states as well as residue 
tautomers need to be determined in advance as well, as standard molecular dynamics 
techniques do not allow for bonding changes (e.g. proton transfers). In this thesis, the 
protonation states of ionisable residues are based on empirically predicted pKa values using the 
propKa3.1 software.167 Determining the tautomeric states of histidine residues was done using 
reduce as part of Ambertools 19166. 
The parameters used for standard protein residues to calculate the system energy 
(according to equation 2.1) are included in a force field. For any ligands or non-standard 
residues, new force field parameters and atomic partial charges need to be derived. Specific 
parameter sets are designed to cover most of the chemical space of small organic molecules, 
such as gaff and gaff2,168 which can be used for assigning force field parameters for most small-
molecule organic ligands. For non-covalent ligands, calculating atomic partial charges is rather 
straightforward using e.g. the restrained electrostatic potential (RESP)169 or AM1-BCC 
charges170, 171. However, deriving accurate charges for non-standard residues, which form a 
part of the protein backbone, is not as trivial. Charges for all non-standard residues in this thesis 
are derived using the R.E.D Server,172 which offers an automated way for fragment charge 
derivation using intramolecular charge constraints during charge fitting (the charges on the 
capping groups around the desired non-standard residues are set to zero). Any missing force 





2.9 Water models 
 
To make the simulations more realistic, enzyme models are often solvated in water. The 
applied water model depends on the particular purpose, and generally one can utilise either an 
implicit or an explicit solvent method. Implicit solvents mimic solvation effects by 
approximating the solvent as a continuous medium, whilst in explicit solvent methods actual 
solvent molecules are added around the studied system. Explicit solvation allows for 
calculating e.g. possible active site interactions with solvent, but this model also largely 
increases the number of atoms in the system. Vice versa, implicit solvent models often enhance 
conformational sampling due to smaller system sizes, but do not offer information of protein 
interactions with water. 
With explicit solvation, the solvent molecules tend to “drift off” from their original 
starting positions during the simulation. Therefore, so-called periodic boundary conditions 
(PBCs) are applied, where the simulated system consists of an infinite number of simulation 
cells. Once a solvent molecule exits the original cell from one side, a new solvent molecule 
enters the cell from the opposing side. PBCs ensure that possible surface effects of water are 
avoided, and that the number of particles in the system stays fixed. 
The choice of water model is also important in explicit solvent simulations. These can 
be divided into three-site, four-site, and five-site interaction models. Three-site models (such 
as TIP3P173, SPC174, and SCP/E175) have three interactions points on the three atoms in water, 
and the geometry of water is often rigid. All three atoms have fixed point charges, and the 
oxygen atom has Lennard-Jones parameters for calculating van der Waals interactions. In four-
site models (TIP4P173 and its successors, OPC176, BF177), a dummy atom with a negative charge 
is added next to the oxygen atom on the axis bisecting the HOH angle. Often the geometry of 
solvent molecules is again kept fixed. Correspondingly, five-site water models (TIP5P178 and 
its successors, BNS179, ST2179) mimic the tetrahedral geometry of oxygen lone pairs in water. 
Five-site models tend to have a higher computational cost in simulations, and hence have only 
been developed further in the recent decades. 
All molecular dynamics simulations in this thesis are done using an explicit solvation 
using the TIP3P water model with PBCs, except for the simulation in Chapter 3, where the four 





2.10 Energy minimization 
 
The variation of system energy as a function of atom coordinates can be described as a 
potential energy surface (PES). As a system consisting of N atoms has 3N-6 degrees of 
freedom, PESs are often quite complex. Local minima on the PES respond to stable 
configurations, whereas the global minimum is the overall lowest energy structure. The 
geometry of a system can be optimised when the energy is minimised, which does not 
necessarily yield the global minimum energy structure as the system is optimised to a near-by 
local minimum. This is especially true for large biomolecular systems, where finding the global 
minimum energy structure is impossible. 
Minimisation algorithms often rely on following the gradient of the PES. In the steepest 
descent method only the gradient of the energy is calculated.180 As the net force acting on the 
system is the opposite of the gradient, the atoms are moved parallel to the net force towards the 
nearest PES minimum. A pre-defined step size indicates how far the system is displaced. 
Steepest descent is often combined with another minimisation method to avoid oscillating 
around the energy minimum. The conjugate gradient algorithm is similar to steepest descent, 
but uses additionally information of the previous steps to speed up convergence.180 More 
advanced (and often computationally expensive) minimisation methods can also employ 
second derivatives of the PES, as is done in the Newton-Raphson method. 
 
2.11 Molecular dynamics simulations 
 
To study the time-dependent behaviour of biomolecular systems, molecular dynamics 
(MD) simulations can be performed. Theory behind the equations used in MD simulations 
starts from the Newton’s second law of motion: 
Eq.  2.17 
𝐹 = 𝑚𝑎 
where F is the force acting on a particle, m the mass of a particle, and a acceleration. As force 
is also the gradient of potential energy and acceleration the second gradient of position, 











where V(r) is the potential energy of the system, r(t) the position (in Cartesian coordinates), 
and t time. Combining equations 2.17 and 2.18 yields the expression: 





where Fi is the force acting on atom i and mi its mass. Integrating this equation at certain 
timesteps yields new atomic positions and shows how the system evolves dynamically with 
time. 
As the potential energy is a function of all 3N atom coordinates, the differential equation 
cannot be solved analytically. Different numerical integration algorithms exist, such as the 
Verlet181, velocity Verlet182, and leapfrog183 schemes. In the Verlet algorithm, the new atom 
positions at timepoint t+δt are calculated using information from the two previous timepoints, 
t and t-δt: 
Eq.  2.20 
𝑟(𝑡 + 𝛿𝑡)  =  2𝑟(𝑡)  − 𝑟(𝑡 − 𝛿𝑡)  +  𝑎(𝑡)𝛿𝑡 
where a(t) is the second derivative of position with respect to time (acceleration). The 
expression is derived by combining two Taylor expansions for r(t+δt) and r(t-δt) and ignoring 
higher than the third order terms. As seen in equation 2.20, atom velocities are not explicitly 
solved when using the Verlet algorithm for numerical integration. Instead, they are often 
calculated as a first order central difference based on the atom positions at timepoints t-δt and 
t+δt: 
Eq.  2.21 
𝑣(𝑡) =




The velocity Verlet algorithm is similar to the Verlet algorithm, but incorporates atom 




at the previous timepoint t are needed (instead of positions at two previous timepoints, as in 
Verlet). In the leapfrog algorithm, positions and velocities are updated in a “staggered” fashion 
after each other at certain timepoints. For any integration scheme, the timestep δt needs to be 
shorter than the fastest timescale for system movement to allow for generating a stable 
trajectory. Often a timestep between 0.5-1 fs is used, but it can be increased to 2 fs if stretching 
vibrations of bonds involving hydrogens are restrained. 
System configurations obtained in a molecular dynamics trajectory correspond to a 
certain statistical ensemble. A “standard” simulation with no temperature or pressure control 
is in the microcanonical (NVE) ensemble, where the number of particles N, the volume V, and 
the system energy E stay constant. The canonical (NVT) ensemble corresponds to constant 
temperature, and the isothermal-isobaric (NPT) simulation to constant temperature and 
pressure simulations. The temperature is often controlled by coupling the system to an external 
heat bath, which acts as a thermostat (such as in the Berendsen algorithm184). Analogously, a 
barostat is required to control the system pressure. 
Simulations in this thesis were performed in the NPT ensemble using Langevin 
dynamics for temperature scaling. In Langevin dynamics, the energy expression is modified by 
neglecting some system degrees of freedom, and by introducing the so-called friction and 
random force terms. The friction term mimics system viscosity, and the random force term the 
stochasticity of the system. The Berendsen barostat was used to control the pressure. When 
using the Berendsen barostat, the equations of motion for atoms are scaled according to the 
desired reference pressure, which results in slight changes in the corresponding periodic box 
size.  
 
2.12 Umbrella sampling simulations 
 
To simulate chemical reactions within enzyme active site, often biased simulation 
techniques are applied. In umbrella sampling (US), a biasing potential is added along one or 
two reaction coordinates to force the system to undergo a transition (e.g. a chemical 
reaction).185 Reaction coordinates are parameters describing the system change from its initial 
(reactant) state to the final (product) state and can include for example bond distances or 
torsions.  These two end states are connected via a series of intermediate states, which are 




the restrained reaction coordinate values, and the US windows are placed so that the sampled 
reaction coordinate distribution in each window overlaps with distributions in the adjacent 
windows. To ensure sampling near a desired value for reaction coordinate ξ in the US window 
i, a harmonic biasing potential ωi is added to the overall energy function: 
Eq.  2.22 
𝜔𝑖(𝜉)  =  𝐾(𝜉 − 𝜉𝑖
𝑟𝑒𝑓
) 
where K is a force constant, ξ the reaction coordinate value at a certain time point, and ξi
ref the 
reference reaction coordinate value in ith US window. Care must be taken when choosing a 
value for the force constant K, as its value should both ensure conformational sampling around 
the chosen US window minimum, as well as allow for sufficient overlap of sampled reaction 
coordinate values between adjacent windows. 
With this approach, a biased potential mean force (PMF) along a reaction coordinate(s) 
is obtained. To study the unbiased PMF, the system is assumed to be ergodic (ensemble 
averages for reaction coordinate distribution equal to time averages for the distribution during 
the simulation), and the free energy expression takes the form: 
Eq.  2.23 
𝐴𝑖(𝜉)  =  −(1/𝛽)ln𝑃𝑖
𝑏(𝜉) − 𝜔𝑖(𝜉) + 𝐹𝑖 
where β=1/kBT, Pi
b is the biased distribution for ξ in window i, ωi is the biasing potential, and 
Fi a term to combine free energy distributions from US windows to one global PMF: 
Eq.  2.24 
𝐹𝑖 = −(1/𝛽)ln (∑ 𝑃(𝜉)𝑒
−𝛽𝜔𝑖(𝜉)) 
As Fi cannot be directly estimated from US simulations, another method needs to be 
used for analysing the simulations. The weighted histogram analysis method (WHAM) is a 
popular one,186 where the unbiased distribution is calculated based on a weighted average of 
individual windows. Because Fi depends on the distribution P(ξ), and the given weights depend 
on Fi, the WHAM procedure requires iterating the calculations until convergence. Other 
methods for analysing US simulations are for example the dynamic histogram analysis method 




Chapter 3 – An efficient computational assay for β-lactam antibiotic 
breakdown by class A β-lactamases 
 
This chapter consists of a communication article titled “An efficient computational 
assay for β-lactam antibiotic breakdown by class A β-lactamases”, which was published in 
Journal of Chemical Information and Modelling in 2019.189 This article continues the work by 
E. I. Chudyk et al. published in 2014,190 and builds on the original computational assays by 
reducing both the sampling time and the conformational sampling along the free energy 
surface. By shortening the sampling time from 20 to 2 ps and sampling only along an 
approximate reaction free energy path, the required computational power is reduced by more 
than 99% (compared against the original assays). I performed and analysed all calculations in 
the new, shortened assays, and wrote the manuscript with help from my supervisors. Section 




Class A β-lactamases cause clinically relevant resistance to β-lactam antibiotics. Carbapenem 
degradation is a particular concern. We present an efficient QM/MM molecular simulation 
protocol that accurately predicts the activity of β-lactamases against carbapenems. Simulations 
take <24 CPU hours, a >99% reduction, and do not require fitting against experimental data or 
significant parameterization. The computational assay reveals mechanistic details of β-lactam 





Antibiotic resistance is one of the most concerning phenomena of the 21st century.191, 
192 To some extent, this resistance occurs naturally, but in recent decades its spread has been 
accelerated by the excessive use of antibiotics.61 β-lactam drugs are one of the largest groups 




suffer from increasing clinical resistance.193 The key source for this resistance, especially in 
Gram-negative bacteria, are the β-lactamase enzymes.49, 194, 195 
β-lactamases can be divided into four different classes based on their primary amino 
acid sequence homology (Ambler classification): classes A, C, and D are serine β-lactamases 
with an active site serine residue, whilst class B are metallo-β-lactamases with active site zinc 
ion(s).63 Of the four classes class A β-lactamases are the largest, with many clinically 
significant enzymes. They can inactivate a broad range of β-lactam substrates: in addition to 
hydrolyzing penicillins and cephalosporins, some family members can also mediate resistance 
against carbapenems.27, 196, 197 Carbapenems are mainly used as ‘last resort’ antibiotics or for 
difficult infections,24 hence the Centers for Disease Control and Prevention (CDC) have 
categorized the clinical importance of carbapenemase-producing Enterobacteriaceae (the group 
of Gram-negative bacteria including Escherichia coli and Klebsiella pneumoniae) as “an 
immediate public health threat that requires urgent and aggressive action”.198 
β -lactamases inactivate β-lactam antibiotics by hydrolyzing the β-lactam amide (Figure 
3.1). In serine β-lactamases, this consists of two consecutive reactions: acylation, resulting in 
formation of a covalently-bound acylenzyme, and deacylation.49 In acylation, a nucleophilic 
attack by the active site serine upon the -lactam carbonyl carbon occurs to form the 
acylenzyme, via a tetrahedral intermediate.199 Deacylation is analogous to acylation including 
a tetrahedral intermediate (TI), but the nucleophile is an active site water molecule (the 
deacylating water, DW). In class A enzymes, both nucleophiles are activated via proton 
abstraction by an active site glutamate residue (Glu166 in the class A β-lactamase numbering 
scheme).200, 201 β-lactamases are typically inhibited when the acylenzyme intermediate is long-
lived due to slow deacylation rates.190 For many β-lactam drugs, including carbapenems, TI 
formation in deacylation of the acylenzyme is most likely the rate-limiting step.24 Therefore, 
to determine the carbapenemase activity of class A β-lactamases, only this reaction needs to be 
modelled. 
Previously, a quantum mechanics/molecular mechanics (QM/MM) protocol for 
modelling TI formation in the deacylation step for class A enzymes with meropenem was 
shown to correctly distinguish between carbapenemases and non-carbapenemases.190 Using the 
proposed protocol, carbapenem-inhibited enzymes showed deacylation barriers of 17.0-18.9 
kcal/mol, whilst for carbapenem-hydrolyzing enzymes the values were 7.5-10.5 kcal/mol. A 
similar computational protocol has been used to study class A β-lactamase inhibition by 




lactamase inhibition.202 Despite the promising results of these protocols, the carbapenem assay 
requires significant computational resources due to extensive sampling of the free energy 
surface. Hence, it cannot be used for more rapid, computationally efficient, screening of a 
variety of different enzyme-antibiotic combinations. 
Starting from our previous work, here we present and validate a more rapid 
computational assay that can discriminate between carbapenemase activities using only limited 
computational resources. The resources are minimized first by limiting the area on the free 
energy surfaces (FES) to be sampled, and then by reducing the sampling time. We demonstrate 
that this reduced protocol, requiring less than 1 % of the computational resources of the original 
assay, can still correctly distinguish between carbapenemases and carbapenem-inhibited class 
A β-lactamases. It therefore provides an efficient computational diagnostic towards in silico 





Figure 3.1 A) First step of deacylation in class A β-lactamases. Glu166 acts as a proton acceptor 
allowing the deacylating water to perform nucleophilic attack on the acylenzyme (1), which results in 
tetrahedral intermediate formation (2). B) Full free energy surface of deacylation for KPC-2 with 
meropenem. Red circles show the positions of umbrella sampling windows along the approximate 
“standard” minimum free energy path (MFEP) used for all enzymes. AC = acylenzyme, TS = 
approximate transition state, TI = tetrahedral intermediate. C) Active site of KPC-2 highlighting the 







We investigate eight class A β-lactamases, including the widely distributed K. 
pneumoniae carbapenemase (KPC), and the TEM, SHV and CTX-M enzymes (Table 3.1), 
selected for their clinical relevance and their ability (or inability) to hydrolyze carbapenems. 
Acylenzyme systems were prepared as described previously (details in ESI, Section 3.6).190 
Briefly, structures were solvated in water and minimized, followed by heating to 300 K in 50 
ps. Starting structures for umbrella sampling (US) were then taken after at least 50 ps of 
unrestrained QM/MM MD (with starting points for repeat simulations at least 15 ps apart). 
Two reaction coordinates are used for umbrella sampling: one for the proton transfer between 
DW and Glu166, and one the nucleophilic attack of DW on the acylenzyme carbonyl. The 
DFTB2 method was used for the QM region.162 All calculations were performed with sander 
from AmberTools16.203 The weighted-histogram analysis method (WHAM)186 was used to 
analyze US results and to obtain calculated barriers for each reaction (Δ‡Gcalc). Three 
independent US simulations were run for each acylenzyme to test convergence of Δ‡Gcalc 
(details in the ESI in Section 3.6; meropenem parameters at DOI 
10.6084/m9.figshare.8158097). 
 
3.4 Results and discussion 
 
Several modifications to the protocol were evaluated in order to improve computational 
efficiency. First, the amount of sampling was reduced by sampling only at those US windows 
corresponding to the approximate minimum free energy path (MFEP) on the FES. Based on 
our earlier work,190 the calculated MFEPs on full FESs across all eight studied β-lactamases 
are similar, which implies that only a partial FES needs to be calculated to compare the 
deacylation rates between studied enzymes. The “standard” MFEP used for partial sampling 
along the FES is presented in Figure 3.1 (and in the ESI, Section 3.6). Sampling only in 
windows along this MFEP reduces the number of US calculations from the original 374 to 28 
per (partial) surface. The more limited sampling along the surface does not change the resulting 
Δ‡Gcalc values significantly, with the largest calculated change between full and partial surface 
calculations being 2.5 kcal/mol (Table 3.1). Despite some changes in Δ‡Gcalc values for all 
enzymes, the correct division into two groups is maintained. Carbapenemases (KPC, SFC, 
SME and NMC) have Δ‡Gcalc values between 7.8-10.4 kcal/mol, and carbapenem-inhibited 




standard MFEP describes deacylation sufficiently well for differentiating between different 
carbapenem-hydrolyzing abilities. 
Even when the amount of US windows is significantly reduced, the computational time 
for each window remains high. Hence, the possibility of utilizing shorter sampling times was 
first tested using the original 20 ps US results. This was done by using only the first 0.5, 1, 2, 
5 or 10 ps of each 20 ps US window to calculate Δ‡Gcalc values (Table S2 in Section 5.6). This 
differs from sampling each window for a shorter time only, since the system is still allowed to 
equilibrate for 20 ps before changing the reaction coordinate restraints. Nonetheless, this 
preliminary analysis can be used to study the effects of shorter sampling. The results indicate 
that sampling for only a fraction of 20 ps is enough to distinguish between the two groups of 
β-lactamases. In most cases, the preliminary shorter sampling times yield somewhat higher 
barriers (<2.5 kcal/mol), which is expected due to reduced sampling of the phase space. 
However, this does not affect the distinction between carbapenemases and non-
carbapenemases.  When reducing sampling to 1 ps per window or less, more significant 
increases of the barrier heights (up to 20%) become common. We thus decided to use 2 ps US 
sampling per window. Sampling for 2 ps also ensures enough overlap between sampling in 



















Table 3.1 Comparison of experimental (Δ‡Gexp) and calculated free energies of activation (Δ
‡Gcalc) for 
the first step of deacylation of meropenem by eight enzymes using different protocols. 
β-lactamase kcat (s–1) a 
Δ‡Gexp 
(kcal/mol) b 
Δ‡Gcalc (kcal/mol) c 
Full a MFEP (20ps) 
MFEP 
(2ps) 
KPC-2 3.6 16.8 10.5 (0.9) 8.5 (2.2) 9.1 (1.1) 
SFC-1 6.5 16.6 10.9 (0.9) 10.4 (1.2) 9.9 (1.3) 
SME-1 3.2 16.9 10.3 (2.8) 7.8 (0.2) 9.5 (1.4) 
NMC-A 12.0 16.1 7.5 (0.4) 8.8 (0.4) 
10.4 
(0.7) 
SHV-1 0.0013 21.6 17.0 (0.4) 16.1 (1.0) 
19.5 
(0.5) 
TEM-1 0.0023 22.7 17.1 (0.4) 16.3 (2.2) 
23.6 
(1.4) 
BlaC 0.0017 21.5 17.9 (0.1) 15.5 (2.2) 
24.7 
(1.1) 
CTX-M-16 0.0042 20.8 18.9 (1.1) 16.8 (1.5) 
17.2 
(1.6) 
Computer resource (%) d 100 7.5 0.75 
 
a) Values taken from ref. 19. 
b) Calculated from experimental rate constants using the Eyring equation, see ref. 202. 
c) Barriers are calculated from three simulations using WHAM as described in the ESI, standard 
deviations in parenthesis. 
d) Computer resources required are estimated by extrapolating the time needed for all required QM/MM 
simulations from 2 ps calculations: 374 umbrella sampling windows for the whole surface and 20 ps 
per window (374 x 20) for “Full”, 28 windows x 20 ps for “MFEP (20ps)” and 28 windows x 2 ps for 
“MFEP (2ps)”. 
 
Sampling for only 2 ps per window along the MFEP gives similar overall results to 
sampling for 20 ps (Table 3.1). With the shorter protocol, carbapenemases have Δ‡Gcalc values 




kcal/mol. Shorter US gives higher deacylation Δ‡Gcalc values for all enzymes, with most 
significant increases seen for carbapenem-inhibited enzymes (0.4-9.2 kcal/mol) when 
compared to calculations using 20 ps sampling along the MFEP. However, the increased 
deacylation barriers do not change the division of the enzymes into the two distinct groups. 
Furthermore, the shortened protocol enables all running calculations on modest computing 
resources (e.g. on a desktop with one CPU) in a reasonable time. For the largest system (SFC-
1, containing 54.9k atoms), US takes on average 23 hours to finish on one 2.6 GHz CPU. In 
general, the more efficient assay requires less than 1 % of the computer resources needed for 
the original assay (Table 3.1). 
The efficient assay we have developed can be used to study specific mechanistic details 
of carbapenem hydrolysis. Glu166, the general base in deacylation, has two chemically 
inequivalent carboxylate oxygens: one that forms a hydrogen bond with Asn170 (OΕ1), and 
one that interacts with Lys73 (OΕ2) (Figure 3.1C). The DW hydrogen bonds with OΕ2 in all 
MD simulations, and the US calculations have been performed using this oxygen as the proton 
acceptor. However, proton transfer to OΕ1 might also be relevant for deacylation. We thus 
used our new, efficient protocol to compare the two possible proton acceptors. When forcing 
the proton transfer to OΕ1, the Δ‡Gcalc values increase by >3 kcal/mol for the carbapenemases 
(Table S3, Section 3.6). Significant increases also incur for the carbapenem-inhibited enzymes 
(especially if the barrier with proton transfer to OΕ2 was not very high already). This consistent 
increase implies that the most probable proton transfer pathway in carbapenem hydrolysis is 
via Glu166:OΕ2 that interacts with Lys73, thus indicating an important role for this residue. 
Preference for a certain carboxylate oxygen as the general base has been observed also 
in other enzymes.204 For the β-lactamases, DW is primarily hydrogen bonded with OE2 in the 
acylenzyme MD simulations and this interaction is thus present in all starting structures for US 
calculations. The preference for OE2 acting as the base can be explained by inspecting the 
additional hydrogen bonds formed by the Lys73 and Asn170 side chains. Lys73 interacts with 
Glu166:OΕ2 as well as Asn132, Ser70, meropenem and the Ser130 backbone carbonyl oxygen, 
whilst Asn170 interacts only with Glu166:OΕ1 and the backbone carbonyl of Leu167. Upon a 
proton transfer, other residues can balance the weakening interaction of Lys73 with 









In conclusion, the carbapenemase activity of eight class A β-lactamases was assayed in 
silico using QM/MM reaction simulations with an optimized, efficient computational protocol. 
Assays based on computational simulation are increasingly common and can complement 
traditional experimental assays.98  Assay efficiency is obtained here by using the semi-
empirical DFTB2 method and by limiting both conformational space and time sampled. 
Distinction between four enzymes known to efficiently hydrolyze carbapenems, and four 
enzymes that do not, can be made within a day with very modest computer resources (e.g. one 
CPU per enzyme). Additionally, this efficient assay can be used to inspect mechanistic aspects 
of carbapenem inactivation; exemplified here by comparing the Δ‡Gcalc values of the first 
deacylation step for two possible proton transfer pathways. The short computational assay time 
with moderate computer resources now makes this assay attractive for more rapid in silico 
activity screening of different class A β-lactamase – antibiotic combinations. This will assist 
assessment and understanding of resistance to β-lactam drugs as conferred by β-lactamases, 
e.g. the effect of acquired point mutations on drug hydrolysis. As access to genome sequences 
of pathogen isolates becomes more routine, such information could be used in guiding 
prescription decisions. Furthermore, elucidation of mechanistic details of acyl-enzyme 
hydrolysis, as identified in simulations, may guide the development of new β-lactams or β-
lactamase inhibitors designed to evade the activity of broad-spectrum and carbapenem-
hydrolyzing -lactamases. 
 
3.6 Computational details 
 




Acylenzyme structures were built on available crystal structures (Table S1). For SHV-
1 and BlaC, acylenzyme structure with meropenem was available, for SFC-1 the Glu166Ala 
structure was used (mutated back to wild-type enzyme based on SFC-1 Ser70Ala and 




the crystal structure with imipenem, and then changing the substrate to meropenem. 
Acylenzymes for CTX-M-16, NMC-A, KPC-2, and SME-1 were built by aligning the available 
apoenzyme structures with the SFC-1 and meropenem complex, and by combining the 
coordinates of the antibiotic substrate with the enzyme. 
 
Table S1. Accession codes for acylenzyme structures used in model generation. 
Enzyme PDB code 
KPC-2 2OV5 








Protonation states were calculated using the propKA3.1 program, and hydrogen atoms 
like implemented in tLeap. All crystallogprahic water molecules were deleted from the 
structures excluding the deacylating water, and the structures were solvated in a 10 Å box of 




Systems were minimized, heated and equilibrated as described in the ESI of ref. 190. 
 
QM/MM Free energy calculations 
 
All QM/MM umbrella sampling (US) calculations were done using two reaction 
coordinates: one for describing the nucleophilic attack (NA, d[DW:O - ACA:C]), and one for 
describing the proton transfer (PT, d[Glu:O-DW:H] - d[DW:O-DW:H]).190 Reaction 
coordinate values for the standard MFEP (in Å): 
PT 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.7 0.6 0.5 0.4 0.3 0.2 





PT 0.1 0.0 -0.1 -0.2 -0.2 -0.3 -0.4 -0.5 -0.6 -0.7 -0.8 -0.8 
NA 2.1 2.0 1.9 1.8 1.7 1.7 1.7 1.6 1.6 1.5 1.5 1.4 
 
where PT and NA describe the values for the proton transfer and nucleophilic attack reaction 
coordinates, respectively. The range of both RCs was kept same as in ref. 190.   
 
 Outputs from US calculations were analysed using the weighted histogram analysis 
(WHAM)186 program using 17 bins for PT and 22 bins for NA reaction coordinates. The 
convergence criterium was set to 0.0000000000001. This analysis was done separately for all 
three starting structures, and lastly by combining all three results into one WHAM calculation 
for calculating the overall reaction barrier (as opposed to taking the average of three snapshots). 
However, especially with shorter sampling times WHAM analysis was prone to give false 
minima on the (partial) free energy surface, due to an error in the WHAM code used. This was 
resolved by locating these false minima and deleting the corresponding coordinate lines from 
the input files. Usually the false minima were due to only few coordinates, and in each case 
less than 1 % of data was removed. This problem can be overcome by utilizing a different 
analysis method or by fixing the WHAM code. 
 
The complete efficient assay 
 
The complete efficient assay follows these steps: 
1. Prepare the starting structures for all studied acylenzymes either from crystal structures 
or based on analogous crystal structures (as described above). Solvate all proteins in a 
periodic box of TIP4P-Ew water, neutralize charges with counterions. 
2. Minimize the structures briefly (100 of steepest descent followed by 900 steps of 
conjugate gradient). 
3. Heat the systems from 50 K to 300 K in 50 ps using Langevin dynamics. 
4. Equilibrate the systems in 300 K for 50 ps using unrestrained QM/MM MD 
(DFTB2/ff12SB), afterwards perform 300 ps of further QM/MM MD to generate 




5. Utilize QM/MM US for calculating deacylation barriers for all β-lactamases. Three 
different variations are used in the manuscript as described below: 
a. The original assay: Do US in every window for 20 ps, calculate the whole 
surface (374 windows). 
b. 20 ps along the standard MFEP: Do US in the 29 windows listed above starting 
from the reactant structure, use the restart file from the previous window as a 
starting point for the next one. Sample 20 ps in each window. 
c. 2 ps along the standard MFEP (the efficient assay): The same procedure as 
described in b), except the sampling time is shortened from 20 ps to 2 ps in each 
US window. Repeat a), b), or c) three times using different starting structures to 
test the convergence of calculated deacylation barriers. 
6. Analyse the results of each individual run using WHAM. For the overall barrier, the 
three US calculations were combined into one WHAM run. 
 
WHAM analysis of shorter sampling 
 
To first inspect to possibility of reducing sampling time in each US window, US results 
for 20 ps sampling along the MFEP were inspected by including only the first 10/5/2/1/0.5 ps 
in the WHAM analysis. For all three snapshots, the desired amount of sampling was included 
for each US window, which was followed by the same WHAM analysis as described earlier 
(where the same US windows for three different snapshots were combined into one). Results 
for this analysis are presented in Table S2. 
Table S2. Δ‡Gcalc values calculated using WHAM, where results from three different calculations are 
combined into one WHAM analysis. 
 Δ‡Gcalc (20 ps) Δ‡Gcalc (10 ps) Δ‡Gcalc (5 ps) Δ‡Gcalc (2 ps) Δ‡Gcalc (1 ps) Δ‡Gcalc (0.5 ps) 
KPC-2 8.5 8.9 8.9 9.8 10.2 10.5 
SFC-1 10.9 11.0 10.3 10.8 11.3 12.8 
SME-1 9.5 7.7 7.6 7.6 8.1 8.4 
NMC-A 8.8 8.6 8.9 9.0 9.6 10.5 
SHV-1 16.1 16.5 16.5 16.8 16.7 17.5 
TEM-1 16.3 16.8 16.9 17.2 17.9 18.6 
BlaC 15.5 17.0 17.0 17.9 17.9 18.0 
CTX-M-16 16.8 17.1 17.2 17.6 17.9 17.9 
 





The two possible proton transfer pathways were inspected using the efficient protocol. 
Glu166 acting as the general base has two chemically inequivalent oxygens, which can both 
act as the proton acceptor. As the DW hydrogen bonds with Glu166:OΕ2 in MD simulations, 
it was used as the proton acceptor in all US calculations. However, technically the proton 
acceptor can also be Glu166: OΕ1. A comparison of activation barriers for the two different 
proton transfers are presented in Table S3. Using OE1 as the proton acceptor increases Δ‡Gcalc 
values for all enzymes 2.0-9.7 kcal/mol: new Δ‡Gcalc values for carbapenemases are 2.0 – 7.2 
kcal/mol higher, and for non-carbapenemases 3.0-9.7 kcal/mol. This suggests that Glu166: 
OΕ2 should be used as the proton acceptor when modelling deacylation in class A β-
lactamases, and that the hydrogen bonding interaction with Lys73 is important for efficient 
catalysis. 
 
Table S3. Δ‡Gcalc values for the two possible proton transfer pathways (with 2 ps sampling). All energies 
in kcal/mol, standard deviations in parenthesis. 
 Δ‡Gcalc (OΕ2) Δ‡Gcalc (OΕ1) Difference 
KPC-2 9.1 (1.1) 14.5 (2.2) +5.4 
SFC-1 9.9 (1.3) 17.1 (1.8) +7.2 
SME-1 9.5 (1.4) 15.2 (2.6) +5.7 
NMC-A 10.4 (0.7) 13.8 (2.1) +3.4 
SHV-1 19.5 (0.5) 29.2 (1.2) +9.7 
TEM-1 23.6 (1.4) 26.6 (1.6) +3.0 
BlaC 24.7 (1.1) 26.7 (2.6) +2.0 





Chapter 4 - Antimicrobial resistance conferred by OXA-48 β-
lactamases: towards a detailed mechanistic understanding 
 
The work in this chapter comprises a minireview “Antimicrobial resistance conferred 
by OXA-48 β-lactamases: towards a detailed mechanistic understanding” published in 
Antimicrobial Agents and Chemotherapy.205 The original draft of the review was written by 
myself, and my co-authors Marc van der Kamp and James Spencer provided comments, 




OXA-48-type β-lactamases are now routinely encountered in bacterial infections 
caused by carbapenem-resistant Enterobacterales. These enzymes are of high and growing 
clinical significance due to the importance of carbapenems in treatment of healthcare-
associated infections by Gram-negative bacteria, the wide and increasing dissemination of 
OXA-48 enzymes on plasmids, and the challenges posed by their detection. OXA-48 confers 
resistance to penicillin (which is efficiently hydrolyzed) and carbapenem antibiotics (more 
slowly broken down). In addition to the parent enzyme, a growing array of variants of OXA-
48 is now emerging. The spectrum of activity of these variants varies, with some hydrolyzing 
expanded-spectrum oxyimino-cephalosporins. The growth in importance and diversity of the 
OXA-48 group has motivated increasing numbers of studies that aim to elucidate the 
relationship between structure and specificity and establish the mechanistic basis for β-lactam 
turnover in this enzyme family. In this review we collate recently published structural, kinetic, 
and mechanistic information on the interactions between clinically relevant β-lactam 
antibiotics and inhibitors with OXA-48 β-lactamases. Collectively, these studies are starting to 
form a detailed picture of the underlying bases for the differences in β-lactam specificity 
between OXA-48 variants, and the consequent differences in resistance phenotype. We focus 
specifically on aspects of carbapenemase and cephalosporinase activities of OXA-48 β-
lactamases and discuss β-lactamase inhibitor development in this context. Throughout the 







Antimicrobial resistance has been recognized globally as one of the most serious threats 
to modern medicine. According to the 2014 UK Review on Antimicrobial Resistance, 
antibiotic resistant bacterial infections are predicted to result in 10 million deaths annually by 
2050 if no preventative measures are taken.206 β-lactams are the single most prescribed 
antibiotic class, accounting for over half of all antibiotic prescriptions in human patients,18 thus 
the consequences of widespread resistance to these agents are especially severe. Resistance 
against carbapenems is a particular concern, as these drugs are the most recently introduced 
and potent class of b-lactams; they are for example favored treatments for opportunistic 
infections of secondary care patients by Gram-negative bacteria resistant to other agents.24 
Furthermore, the continuing weakness of the antibacterial pipeline means that alternative 
treatments are limited.207 This existing threat is highlighted by the Centers for Disease Control 
and Prevention, who classified carbapenem-resistant Enterobacterales as an urgent antibiotic 
resistance threat in the United States in 2019.6 
Since the initial introduction of β-lactam antibiotics in the 1940s, bacteria have 
developed many different mechanisms to bypass their effect; these include changes in 
expression levels of porins and efflux pumps, target modification through gene acquisition or 
mutation, and enzymatic drug modification.48 In Gram-negative bacteria, β-lactamase enzymes 
are the main resistance mechanism against β-lactam antibiotics. β-Lactamases modify the 
antibiotic by hydrolytic cleavage of the β-lactam amide bond;49 as β-lactams work by binding 
to penicillin-binding proteins (PBPs) and disrupting bacterial cell wall biosynthesis,50, 208 
degrading the β-lactam pharmacophore renders these antibiotics inactive. Over 4500 β-
lactamases have now been identified (see www.bldb.eu for details),62 with the continuing 
explosion of genomic data driving further discovery of new enzymes from both environmental 
and clinical sources. 
According to the Ambler classification, β-lactamases are divided into four groups: 
classes A, C, and D are serine β-lactamases (SBLs), which utilize an active site serine 
nucleophile to hydrolyze β-lactams via a covalent acylenzyme intermediate, while class B 
metallo-β-lactamases (MBLs) utilize zinc cofactors to activate a water molecule to undertake 
antibiotic inactivation.49 Within SBLs, class D β-lactamases form a structurally diverse group 
of enzymes, which were first identified as having enhanced hydrolytic activity towards 




compared against class A β-lactamases).75, 209 Subsequently, they were named as oxacillinases, 
or OXAs for short. OXA β-lactamases include five recognized subgroups of carbapenem-
hydrolyzing enzymes: four of these, namely OXA-23-like, OXA-24/40-like, OXA-51-like, and 
OXA-58-like β-lactamases, are largely restricted to Acinetobacter baumannii, while OXA-48-
like β-lactamases are most commonly encountered in the Enterobacterales.32, 206, 210-216 
Additionally, some OXA enzymes (OXA-2, OXA-10) classified as narrow-spectrum β-
lactamases have demonstrated comparable rates of carbapenem hydrolysis to recognized 
carbapenem-hydrolyzing OXAs, which could imply that most OXAs can (to some extent) be 
considered carbapenemases.217 OXA-48 β-lactamases are now among the most common 
carbapenemases218 and are often co-produced with other β-lactamases (MBLs or ESBLs).219 
For an in-depth overview of the global epidemiology of β-lactamase, specifically OXA-48-
type, producing pathogens we refer the reader to recent reviews by Bush and Bradford220 and 
Pitout et al.221 
 
Figure 4.1 Structure of OXA-48. Cartoon shows unliganded OXA-48 (PDB ID 6P96)71 with selected 
elements of the structure highlighted. The three conserved motifs within class D β-lactamases are shown 
in blue shades, the Ω-loop in yellow, and the β5-β6-loop in orange. Selected OXA-48 variants are listed 
according to their primary hydrolysis phenotype, and their amino acid substitutions or deletions 
highlighted in the corresponding color in the amino acid sequence. Carbapenemase = efficient 
imipenem hydrolysis, some activity towards other carbapenem substrates. ESBL-like = only weak 





Even though OXA-48 β-lactamases are not closely related in sequence to other class D 
β-lactamases (less than 50 % amino acid identity), their sequences include three active site 
motifs that are broadly conserved within class D enzymes.222 Motif I (SxxK) includes the 
nucleophilic Ser70 and the catalytically important Lys73, which needs to be carboxylated for 
efficient hydrolysis to take place (Figure 4.1).222, 223 Motifs II and III are in the vicinity of these 
key catalytic residues and include residues Ser118-Val119-Val120 and Lys208-Thr209-
Gly210, respectively, in OXA-48-like enzymes. Additionally, the Ω-loop (residues 143-165) 
and β5-β6-loop (residues 213-218) bordering the active site seem to be important determinants 
of OXA-48 activity, as discussed below. According to the β-lactamase database, at least 15 
plasmid-encoded OXA-48 β-lactamases have been identified and validated (with further 
variants chromosomally encoded mainly in different Shewanella species224, 225). These variants 
differ from wild-type OXA-48 by certain amino acid substitutions or deletions. Selected key 
family members along with their hydrolytic profiles are listed in Figure 4.1. 
As mentioned above, OXA-48 enzymes degrade a variety of β-lactam antibiotics, 
including ampicillin and oxacillin (more efficiently than e.g. temocillin),222, 226  and perhaps 
most notably the “last-resort antibiotics” carbapenems (Figure 4.2).227 However, there are large 
phenotypic variations within the enzyme family. Compared to the parent OXA-48 enzyme, 
some variants have enhanced carbapenemase activity (like OXA-162228 and OXA-181229), 
while others have expanded their hydrolysis profile to better accommodate expanded-spectrum 
oxyimino cephalosporins (such as OXA-163230 and OXA-405231). OXA-48 carbapenemases 
tend to favour imipenem over other carbapenems and display only low-level meropenem and 
ertapenem hydrolysis (Table 4.1). Weak carbapenem hydrolysis can complicate diagnosis and 
treatment of bacterial infections involving OXA-48 producers, as their activity can be below 
the detection limit of clinical tests but still sufficient to confer resistance, especially in strains 
with reduced antibiotic permeability.232 OXA-48 itself shows varying activity against 
cephalosporins; e.g. cefalotin and cefotaxime are inactivated readily, whereas minimal (or no) 






Table 4.1. Kinetic parameters for OXA-48, OXA-163, OXA-181, and OXA-232 with different β-lactam 
antibiotics. Presented values taken from ref. 226, and more comprehensive data of enzyme kinetics is 
provided as part of the SI. 
 OXA-48a OXA-163 OXA-181 OXA-232 
 kcat (s–1) Km (μM) kcat (s–1) Km (μM) kcat (s–1) Km (μM) kcat (s–1) Km (μM) 
Imipenem 5 13 0.03 520 7.5 13 0.2 9 
Meropenem 0.07 10 >0.1 >2000 0.1 70 0.03 100 
Ertapenem 0.13 100 0.05 130 0.2 100 0.04 110 
Doripenem -b -b NH NH 0.04 55 0.005 10 
Ceftazidime NH NH 8 >1000 - - >0.6 >1000 
Cefotaxime >9 >900 10 45 >62 >1000 >6.5 >1000 
Cefalotin 44 195 3 10 13 250 13 125 
Benzylpenicillin -c -c 23 13 444 90 125 60 
Ampicillin 955 400 23 315 218 170 132 220 
Temocillin 0.3 45 NH NH 0.3 60 0.03 60 
Oxacillin 130 95 34 90 90 80 156 130 
a Values for OXA-48 in ref. 226 are from ref. 222. 
b Data from ref. 228 do not show doripenem hydrolysis by OXA-48, but kinetic data from ref. 217 indicate weak 
doripenem hydrolysis. 





Figure 4.2. β-lactam antibiotics as substrates for OXA-48. Examples of penicillin, cephalosporin, and 
carbapenem antibiotics (left, middle, and right respectively), which are generally ineffective against 
OXA-48 producers (red box), and which can be used to treat OXA-48-producing infections (green box). 
Notably, activity profiles vary within the OXA-48 family, as e.g. the ESBL-like OXA-163 has acquired 
activity against expanded-spectrum oxyimino cephalosporins (ceftazidime). 
 
4.3 General hydrolysis mechanism 
 
In SBLs, the overall hydrolysis reaction consists of two parts, acylation followed by 
deacylation (Figure 4.3).49 After initial formation of the non-covalent Michaelis complex, the 
β-lactamase is acylated by the antibiotic resulting in covalent bond formation between Ser70 
and the carbonyl carbon of the β-lactam ring. This covalent acylenzyme structure is hydrolyzed 
in the deacylation step, where an active site water molecule (the so-called deacylating water) 
acts as the nucleophile to attack the acylenzyme carbonyl. Both acylation and deacylation 
involve formation of short-lived tetrahedral intermediate (TI) structures. For OXA-48-like β-





Figure 4.3. Hydrolysis mechanism of OXA-48 β-lactamases. Starting from the formation of a Michaelis 
complex for a general carbapenem substrate (1), the substrate is acylated (tetrahedral intermediate 
formation in 1 → 2), which yields a covalent acylenzyme structure (3). The bound antibiotic is 
subsequently deacylated (4 & tetrahedral deacylation intermediate 5) resulting in the final hydrolysis 
product (6). 
As depicted in Figure 4.3, both acylation and deacylation involve a negatively charged 
general base. For class A β-lactamases, this residue is largely accepted to be Glu166,89, 201 but 
for OXA enzymes, the general base is a carboxylated lysine (Lys73 in OXA-48 numbering).222, 
234 This post-translational carboxylation is needed for efficient hydrolysis to take place, as 
mutating Lys73 results in enzymes incapable of substrate turnover.223 The degree of 
carboxylation increases with pH, and preparation of catalytically competent enzymes can be 
ensured by adding a suitable CO2 source for carboxylation (bicarbonate), even though 
atmospheric CO2 may also be enough.
235 This carboxylation is reversible, and it has been 
monitored with 19F NMR spectroscopy in the presence of different inhibitors to understand 
how (de)carboxylation contributes to enzyme inhibition.236 The results indicate that Lys73 is 
carboxylated to a lesser extent with some covalently-bound inhibitors (like avibactam), which 






4.4 Carbapenemase activity 
 
 
Figure 4.4. Divergent active sites of carbapenem-hydrolyzing OXA enzymes. Active sites of OXA-48 
(PDB ID 6P96, left)71 and OXA-23 (PDB ID 4K0X, right)237 highlight the missing hydrophobic bridge 
in OXA-48 with respect to other class D carbapenemases. In OXA-23, the hydrophobic bridge is formed 
by residues Phe110 and Met221, while the corresponding residues in OXA-48 are Ile102 and Thr213, 
which leave the active site more open. Additionally, residues forming the so-called “deacylating water 
channel” are also highlighted in sticks (V120 and L158 for OXA-48, V128 and L166 for OXA-23). 
 
OXA-48 enzymes are carbapenemases or, more specifically, imipenemases with weak 
turnover rates for other carbapenems such as meropenem and ertapenem (Table 4.1). Based on 
the structural information originally derived from other carbapenem-hydrolyzing OXAs,238 
carbapenemase activity in class D -lactamases was hypothesized to originate from a 
hydrophobic bridge spanning the active site (Phe110 and Met221 for OXA-23, Tyr112 and 
Met223 for OXA-24). However, structural comparisons between OXA-48 and other OXA 
carbapenemases show OXA-48 to be lacking this hydrophobic bridge,222 which implies that 
the OXA-48 group has evolutionally diverged from other class D β-lactamases and acquired 
carbapenemase activity by other means (Figure 4.4). Fortunately, within the last years a 
plethora of new crystal structures of OXA-48s complexed with carbapenems have been 





Figure 4.5. Carbapenem, cephalosporin, and diazabicyclooctanone (DBO) scaffolds with atom 
numbering. The 6α-hydroxyethyl group (C6 substituent) in the carbapenem scaffold is shown in red. 
 
The first carbapenem acylenzyme structure of OXA-48 (with imipenem) was released 
in 2018 (PDB ID 5QB4) alongside multiple structures with small inhibitor fragments.239 From 
2019 onward, further acylenzyme structures have been deposited with imipenem (PDB IDs 
6P97, 6PTU, and 7KH9),71, 233, 240 meropenem (PDB IDs 6P98, 6PT1, and 7KHQ),71, 233, 240 
doripenem (PDB IDs 6P9C and 6PXX),71, 241 ertapenem (PDB ID 6P99),71 and faropenem 
(PDB ID 6PSG)240. Additionally, two acylenzyme structures of inactivated OXA-163 (K73A) 
with imipenem and meropenem are available (PDB IDs 7KHZ and 7KHY, respectively)233. 
Common features in these structures include a covalent bond between Ser70 and the substrate 
and hydrogen bonds between Thr209/Arg250 and the carbapenem C3 carboxylate (Figure 4.5). 
The carbonyl oxygen of the cleaved β-lactam ring is positioned in the oxyanion hole formed 
by the backbone amides of Ser70 and Tyr211, active site interactions in selected crystallized 
carbapenem acylenzyme complexes are presented in Figures 4.6 and 4.7. Carbapenem “tail” 
groups (C2 substituents) are not anchored by any strong interactions, which implies that they 
are dynamic and do not need to adopt any one specific orientation. This likely disorder was 
also inspected by Papp-Wallace et al., who further refined previously deposited imipenem and 
doripenem complexes (PDB IDs 5QB4 and 6P9C, respectively).241 Their analysis of the re-
refined structures supports the presence of a covalent bond between Ser70 and the antibiotic, 
but observation of weak or absent density for the pyrroline ring and C2 tail groups indicates 
disorder (i.e. multiple conformations) for these regions. In addition to previously mentioned 
covalent complexes, a structure of OXA-48 with hydrolyzed imipenem has also been published 
(PDB ID 6PK0).240 Non-covalently bonded hydrolyzed imipenem forms similar interactions 




carboxylate group is hydrogen bonded to Ser70, Lys73, and Tyr211 (Figure 4.6). Although the 
deacylating water is not present in any acylenzyme structure, the orientation of hydrolyzed 
imipenem (specifically coordination of the C7 carboxylate to Ser70 and Lys73) indicates the 
possible position of the deacylating water molecule prior to deacylation. 
 
Figure 4.6. Carbapenem complexes of OXA-48. Top left: Imipenem acylenzyme (PDB ID 6P97)71, 
interactions with active site residues highlighted. Imipenem pyrroline ring modelled as the Δ2 tautomer. 
Top middle: Imipenem acylenzyme (PDB ID 6PTU)240, with the pyrroline ring as the (R)-Δ1 tautomer. 
Top right: Hydrolyzed imipenem (PDB ID 6PK0)240, with the pyrroline ring as the (S)-Δ1 tautomer. 
Bottom left: Doripenem acylenzyme (PDB ID 6P9C)71, with the pyrroline ring as the Δ2 tautomer. 
Bottom right: Doripenem acylenzyme (PDB ID 6PXX)241, with the pyrroline ring as the (R)-Δ1 tautomer. 
 
In OXA-48 enzymes the basis for carbapenemase activity has been attributed to the 
presence of the β5-β6 loop bordering the active site, as for example engineering this loop from 
OXA-48 into the non-carbapenemase OXA-10 changes its phenotype to hydrolyze imipenem 
at higher rates than native OXA-48.242 The specific role of Arg214 (in the β5-β6 loop) was 
studied by comparing hydrolysis kinetics and crystal structures of OXA-181 and OXA-232, 




232).243 OXA-181 is a slightly better carbapenemase than OXA-48,229 whilst OXA-232 has 
decreased carbapenem hydrolysis rates but has also acquired weak activity against ceftazidime 
(Table 4.1).244 The authors suggest that the presence of Arg214 is crucial for carbapenem 
hydrolysis by OXA-48, as it aids in the formation of a productive binding pose for imipenem. 
Replacing this arginine with a negatively charged residue (Glu) results in poor affinity, which 
was reasoned to be due to unproductive binding pose of imipenem (both hypotheses based on 
molecular docking). Similar results were found by Dabos et al., who substituted the β5-β6 loop 
of OXA-18 into OXA-48.245 Steady-state kinetics of the OXA-48loop18 variant showed 
decreased ampicillin and imipenem hydrolysis and elevated ceftazidime hydrolysis. The 
importance of the β5-β6 loop for the hydrolysis profile indicated by these studies is further 
emphasized by the decrease in imipenem hydrolysis and increase in ceftazidime hydrolysis in 
OXA-163 (Table 4.1),226, 230 in which the loop is partially deleted (Figure 4.1). Pre-steady state 
kinetics indicate that the loss of efficient imipenemase activity in OXA-163 is due to decreased 
deacylation rates.233 However, even though the β5-β6 loop is evidently important for 
carbapenem hydrolysis, the specific origin of imipenemase activity in OXA-48 enzymes (e.g. 
over meropenem hydrolysis) remains to be investigated. The presence of the 1β-methyl group 
e.g. in meropenem and doripenem (instead of the 1β-proton in imipenem) has been suggested 
to impair hydrolysis, as this methyl group might prevent deacylation by disfavoring rotation of 
the carbapenem 6α-hydroxyethyl moiety (attached to C6, Figure 4.5), which would in turn 
prohibit the nucleophilic attack.240 In all OXA-48/carbapenem crystal structures (excluding 
5QB4), the 6α-hydroxyethyl sidechain adopts a similar orientation where its methyl group 
points towards Leu158 and Arg214 and values for the C7-C6-C-O dihedral angle are between 
147°-192° (Figure 4.7). However, for hydrolyzed imipenem this orientation has changed, and 
the methyl group points out of the active site towards bulk solvent (with the same dihedral 
angle being between 275°-292° depending on the protein chain). As the 6α-hydroxyethyl group 
is likely able to rotate in the acylenzyme, verifying the extent of its influence on e.g. positioning 







Figure 4.7. Further carbapenem complexes of OXA-48. Acylenzyme structures with meropenem (left, 
PDB ID 6P98)71 and faropenem (right, PDB ID 6PSG)240. The pyrroline ring is present as the Δ2 
tautomer in both structures. 
The pyrroline ring of carbapenem acylenzymes can exist as two different tautomers: Δ2 
or Δ1, the latter of which also has two stereoisomers (R)-Δ1 and (S)-Δ
1
 (Figure 4.8). For class 
A β-lactamases, the Δ2 tautomer has been proposed to be the catalytically competent form,
246, 
247 and the Δ1 to not deacylate efficiently (potentially due to displacement of the deacylating 
water from the active site248 or loss of stabilizing interactions with the oxyanion hole249). The 
same has been suggested for class D enzymes when comparing the doripenem complex of 
carbapenem-hydrolyzing OXA-24 against carbapenem-inhibited OXA-1.250 The tautomeric 
form can be identified in crystal structures with sufficiently strong electron density for the 
ligand, as the pyrroline ring C2 – sulphur bond present in all carbapenems is planar (sp2 
hybridized) in the case of the Δ2, and sp3 hybridized for the Δ1 forms. For previous class D β-
lactamases complexed with carbapenems, all three tautomers have been observed.250, 251 In the 
case of OXA-48, the Δ2 form was assigned in the first deposited imipenem complex,
239 and the 
same tautomer was subsequently observed for the meropenem, imipenem, doripenem, and 
ertapenem acylenzymes published by C. A. Smith et al. (structures prepared by soaking crystals 
of apo-OXA-48 with 50 mM carbapenem solution over time scales between 30 seconds and 10 
minutes).71 The same authors inspected the possibility of accommodating ligands in the active 
site in the Δ1 form by superimposition of their structures onto OXA-23 with (R)-Δ1 and (S)-Δ
1 




the (R)-Δ1 conformer would clash sterically with Tyr211. Shortly after the publication of these 
carbapenem acylenzymes, a new structure of deacylation-deficient OXA-48 (Lys73Ala) in 
complex with doripenem was released (also prepared using crystal soaking).241 The doripenem 
acylenzyme was observed as both (R)-Δ1 and (S)-Δ1 tautomers (Figure 4.6), and only a partial 
salt bridge with Arg250 is formed, which most likely prevents any severe steric clashes 
between doripenem and Tyr211 for either tautomer. In further structures deposited by Akhtar 
et al., different carbapenems have different tautomers present: the meropenem acylenzyme is 
in the Δ2 form (as depicted for another crystal structure in Figure 4.7), imipenem and faropenem 
are found as (R)-Δ1 (Figures 4.6 and 4.7), and the imipenem hydrolysis product as the (S)-Δ1 
tautomer (Figure 4.6, structures prepared by soaking OXA-48 crystal with a solution containing 
the ligand for 30 minutes, or for the OXA-48 imipenem product complex for 2 hours).240 
Characterization of the enzyme-hydrolyzed products by NMR spectroscopy implies that for 
OXA-48 (as well as all other tested SBLs and MBLs) the preferred hydrolysis product would 
be either in the Δ2 or (R)-Δ
1  form, but deducing the exact enzyme-catalyzed reaction product 
was not feasible due to the ability of released products to undergo tautomerization in 
solution.252 
 
Figure 4.8. Mechanism for carbapenem side product formation by OXA-48. The pyrroline ring in 
carbapenem substrates can undergo Δ2→ Δ1 tautomerization (7 → 8) post-acylation. In addition to the 
general hydrolysis mechanism (7 → 10), 1β-methyl carbapenems such as meropenem can form a 1β-





In addition to the generic hydrolysis mechanism of serine β-lactamases, OXA-48 
enzymes were shown to possess an additional mechanism for carbapenem breakdown that 
involves the formation of a β-lactone product, as illustrated in Figure 4.8.253, 254 Starting from 
the acylenzyme, the β-lactone is suggested to form by intramolecular cyclization, where the 
hydroxyl group of the carbapenem 6α-hydroxyethyl sidechain donates a proton to the 
carboxylated lysine (Lys73) and attacks the same electrophilic C7 carbon as in deacylation. 
This results in formation of a four-membered lactone ring, which is structurally close to the 
original β-lactam ring and capable of reacting further to give (unidentified) reaction products. 
Interestingly, β-lactone formation by OXA-48 appears carbapenem-dependent, as it was 
observed only for 1β-methyl carbapenems (such as meropenem, doripenem, and ertapenem), 
but not for carbapenems with a 1β-hydrogen (imipenem and biapenem). The reason for this 
dependence on the presence of the 1β-substituent was studied by simulating the dynamics of 
OXA-1 (one 100ns simulation), and suggested to be due to more favorable conformational 
sampling of the 6α-hydroxyethyl sidechain: with a 1β-methyl group, bound carbapenems 
formed closer interactions with the carboxylated lysine, which would aid in proton transfer 
from the hydroxyl group to the lysine carboxylate oxygen.253 More recently, however, lactone 
formation was shown to also depend upon the structure of the active site: OXA-519 
(Val120Leu variant of OXA-48) demonstrated both an increase in the proportion of the lactone 
product as well as generated lactones from both of 1β-proton and 1β-methyl carbapenems.254 
 
4.5 Cephalosporinase activity 
 
While OXA-48 is considered of particular importance as a result of its carbapenemase 
activity, there are variations in hydrolytic phenotypes between different OXA-48 variants. 
OXA-48 itself does hydrolyze some cephalosporin antibiotics, such as cefalotin and 
cefotaxime, but shows no significant hydrolysis of the expanded-spectrum oxyimino 
cephalosporin ceftazidime or the fourth-generation cephalosporin cefepime.226 However, 
variants such as OXA-163 and OXA-405 (that contain partial deletions in the β5-β6 loop) are 
capable of hydrolyzing ceftazidime, at the expense of efficient imipenem breakdown (Figure 
4.1, Table 4.1).230, 231 Interestingly, their hydrolysis rates for other carbapenems (such as 
meropenem) seem to be on the same low level as for OXA-48. 
In 2019, the structure of an OXA-48 (Pro68Ala) ceftazidime acylenzyme was deposited 




OXA-48 producer strain against increasing concentrations of ceftazidime. Comparison of this 
OXA-48 structure with previously deposited OXA/ceftazidime complexes (OXA-225 and 
OXA-160, PDB IDs 4X55 and 4X56, respectively)256 shows that ceftazidime exhibits a 
different binding pose in OXA-48 than observed in the OXA-23 or OXA-24/40 variants, the 
difference being in the orientation of the C7 substituents (carboxypropyl oxyimino and thiazole 
groups, Figure 4.5). Another distinct feature in the OXA-48/ceftazidime structure was the lack 
of interpretable electron density for the Ω-loop (including residues Leu158 and Asp159, Figure 
4.1). The authors suggested ceftazidime binding to displace Arg214, which in turn results in a 
distorted (and thus flexible) Ω-loop; the Pro68Ala mutation might then contribute to Ω-loop 
distortion by increasing flexibility of the active site. Molecular dynamics simulations and 
QM/MM reaction modelling of ceftazidime deacylation by OXA-48, OXA-163, and OXA-181 
suggest that in addition to the β5-β6 loop and Arg214, Leu158 could also play an important 
role in determining the efficiency of ceftazidime turnover.257 The orientation of Leu158 was 
observed to correlate with active site hydration, and an increase in water molecules in the active 
site was observed to impair deacylation efficiency in OXA-48. Additionally, the study 
proposed that distorting the Ω-loop, as is implied by the absence of electron density for this 
region in the OXA-48 ceftazidime crystal structure, would fully open the active site to bulk 
water and diminish deacylation rates. Although some consideration has been given to the routes 
by which the water molecule necessary for deacylation may enter the active site,71, 251 the 
importance of active site hydration to the activity of OXA-48 β-lactamases (or of SBLs in 
general) has to date not been extensively discussed in the literature. 
 
 
Figure 4.9. Cephalosporin acylenzyme complexes of OXA-48. Hydrogen bonds between the substrate 
and active site residues highlighted with dashed lines. Left: ceftazidime (CAZ, PDB ID 6Q5F)255, 





In addition to ceftazidime, structures of OXA-48 acylenzyme complexes with 
cefotaxime and cefoxitin have also been determined (PDB IDs 6PT5 and 6PQI for cefoxitin 
and cefotaxime, respectively).240 Cefotaxime has a similar binding pose to ceftazidime, where 
the thiazole ring orients to make stacking interactions with Tyr211 and the oxyimino group 
occupies a pocket between residues Leu158, Thr213, and Arg214 (Figure 4.9). Unlike the 
ceftazidime complexes, the Ω-loop remains ordered, as found in the apoenzyme, and the salt 
bridge between Asp159 and Arg214 is preserved. This is most likely due to the smaller size of 
the cefotaxime C7 methoxyimino group, compared to the equivalent carboxypropyl oxyimino 
group of ceftazidime. In the case of cefoxitin, the thiophene ring is rotated towards Leu158, 
breaking the Asp159-Arg214 salt bridge. Low cefotaxime hydrolysis rates are hypothesized to 
be due to limited access of potential deacylating water molecules to the active site, while 
cefoxitin hydrolysis (kcat > 0.05 s
–1 and Km > 200 μM, SI) is essentially hindered by the presence 
of its 7-α-methoxy group, which would sterically clash with any active site water molecules.240 
Additionally, carboxylation of Lys73 could lead to further steric clashes with the 7-α-methoxy 
group, which could increase preference for lysine decarboxylation in the presence of cefoxitin 
(Lys73 is decarboxylated in the crystal structure). 
 
4.6 OXA-48 inhibitors 
 
A common strategy for treating challenging, -lactam resistant bacterial infections is 
to prescribe a β-lactam antibiotic together with a β-lactamase inhibitor.27, 258 FDA approved 
antibiotic/inhibitor combinations include e.g. amoxicillin/clavulanate, piperacillin/tazobactam, 
ceftazidime/avibactam, and meropenem/vaborbactam.25, 27, 33, 258 In general,  OXA-48 β-
lactamases are not susceptible to traditional β-lactamase inhibitors like sulbactam, tazobactam, 
and clavulanate (except for some exceptions like OXA-163).259 Of the new generation β-
lactamase inhibitors, avibactam31, 32 shows efficacy against OXA-48.34, 260 Avibactam belongs 
to the diazabicyclooctanone (DBO) class and exhibits broad-spectrum inhibition of SBLs. The 
ceftazidime/avibactam combination specifically shows promise as an effective therapy against 
OXA-48 producers in both in vitro testing and clinical practice.219, 259, 261-263 When compared 
with other OXAs, it appears that DBOs such as avibactam inhibit OXA-48 better than enzymes 
with more hydrophobic active site residues.36 Several crystal structures of OXA-48 with 




IDs 6Q5B255, 4WMC,264 4S2J235, 4S2K235, and 4S2N235), with the carbamate carbonyl 
positioned in the oxyanion hole (analogous to the position of the ester carbonyl carbon in β-
lactam antibiotics), and the sulfonate group positioned towards motif II and Arg250 (Figure 
4.10). The amide group of avibactam is positioned towards Leu158 on the Ω-loop. Based on 
the published OXA-48/avibactam structures, the presence of avibactam seems to favour Lys73 
decarboxylation: for structures crystallized at pH 6.5 or 7.5 (PDB IDs 4S2J and 4S2K), no 
carboxylation was observed, and at pH 8.5 only partial occupancy of the carboxylate was seen 
in two out of four monomers in the asymmetric unit (PDB ID 4S2N).235 Partial carboxylation 
of Lys73 was also observed in another study, where only two out of eight monomers displayed 
electron density for carboxylated Lys73 (PDB ID 4WMC).264 
 
 
Figure 4.10. Crystal structure of the avibactam-OXA-48 acylenzyme at pH 7.5 (PDB ID 4S2K)235. 
Inhibition kinetics indicate that avibactam readily acylates OXA-48, but that its 
recyclization to release intact avibactam happens very slowly (whilst no analogue for the  
‘standard’ -lactam ring-opened hydrolysis product is observed).264 In acylation, the C7-N6 
bond in the five-membered ring structure is broken (as opposed to the C7-N1 bond, Figure 4.5), 
likely due to the N6-sulphate moiety being a better leaving group than N1-R group.235 At least 
two different reaction mechanisms for avibactam with OXA-48 have been proposed in the 
literature (Figure 4.11). King et al. proposed a general mechanism for all SBLs, which involves 




subsequently protonate the N6 ring nitrogen via Ser118.235 Recyclization occurs as the reverse 
reaction (Figure 4.11, pathway 1). This mechanism was based on the preference for Lys73 to 
be decarboxylated in the presence of avibactam. Additionally, mutational studies of the class 
A ESBL CTXM-15 identified Lys73 to be the most likely general base in avibactam 
acylation.235 Since decarboxylated Lys73 was observed to form a hydrogen bond with Ser118 
(Figure 4.10), it is possible it has a similar role in class D and class A SBLs. 
The second proposed mechanism for avibactam inhibition in Figure 4.11 (pathway 2) 
was suggested by Lahiri et al.; in this case, Lys73 is indicated to be carboxylated for the whole 
reaction cycle.264 Carboxylated Lys73 acts as the general base in acylation, and Lys208 
protonates N6 via Ser118. Recyclization takes place similarly but in reverse, where N6 first 
donates a proton back to Lys208 via Ser118, and Lys73 acts as a general acid protonating 
Ser70. As the authors also observed decarboxylation of Lys73 in the presence of avibactam, 
they attribute the slow avibactam recyclization rates to Lys73 decarboxylation, which hinders 
reactivity. In addition to these crystal structures, decarboxylation of Lys73 in the presence of 
covalently bound avibactam has also been measured using NMR spectroscopy.236 The authors 
observed that Lys73 favors the decarboxylated form when OXA-48 is complexed with 
avibactam (or the related DBO inhibitors relebactam and zidebactam). The extent of Lys73 







Figure 4.11. Two proposed reaction pathways for the avibactam inhibition mechanism with OXA-48. 
Left: Pathway 1, based on a “universal” avibactam reaction scheme for SBLs, adapted from ref. 235. 
Neutral Lys73 is suggested to act as a general base in acylation and recyclization, whilst Ser118 
(de)protonates the ring nitrogen. Right: Pathway 2, where carboxylated Lys73 is proposed to act as the 
general base in acylation, and as the general acid in recyclization, adapted from ref. 264. Ser118 has 
the same role as in pathway 1, except it donates a proton to Lys208 instead of Lys73 during 
recyclization. 
 
To study the possible emergence of resistance to avibactam, OXA-48 producers were 
passaged against a combination of ceftazidime and avibactam.255 Resistance was observed to 
develop as a result of two amino acid substitutions: Pro68Ala (as discussed above in the section 
“Cephalosporinase activity”), and Tyr211Ser. The catalytic efficiency of ceftazidime turnover 
increased >10-fold and >20-fold for the single and double substituted variants, respectively. 
Inhibitory activity of avibactam stayed on the same level as for OXA-48 for the Pro68Ala 
variant, but for Pro68Ala/Tyr211Ser the activity of avibactam decreased >5-fold. Tyr211 is 
known to be a key residue in stabilizing tetrahedral intermediates in -lactam hydrolysis 
through the formation of an oxyanion hole (together with the backbone amide of Ser70). 
Additionally, Tyr211 was suggested to possibly aid in the formation of a Michaelis complex. 
Notably, however, the observed evolutionary trajectory towards ceftazidime/avibactam 
resistance comes at a fitness cost, as the enzyme thermostability is reduced and the primary 





Figure 4.12. Examples of β-lactamase inhibitors in different inhibitor classes: β-lactam ring-based 
inhibitors, DBO = diazabicyclooctanones, and boronates, each block divided into investigational 
compounds (top), compounds in clinical trials (middle), and inhibitors approved in clinical use 
(bottom). Inhibitors in red and cursive do not effectively inhibit OXA-48, inhibitors in black show 
inhibitory activity. 
 
Other β-lactamase inhibitors with a DBO scaffold include relebactam, nacubactam, 
zidebactam, durlobactam (previously ETX2514), ARX-1796 and the investigational compound 
BOS-752 (Figure 4.12). The relebactam/imipenem combination has been approved for clinical 
use, but this inhibitor does not effectively inhibit OXA-48; measured MICs for carbapenems 
do not change (or change only slightly) in the presence of relebactam.265-267 Based on MICs, 
zidebactam combined with cefepime shows inhibitory activity against OXA-48.268 This is due 
to OXA-48 inhibition by cefepime, as in vitro kinetics indicate that zidebactam on its own does 
not inhibit OXA-48.37 Similarly, nacubactam inhibits class A and C SBLs, but in vitro data on 
its activity against OXA-48 are sparse. In MIC tests, bacterial isolates expressing OXA-48 
were susceptible to aztreonam/nacubactam and cefepime/nacubactam, but the potentiation of 
antibiotic activity by nacubactam was concluded to be mainly due to inhibition of co-expressed 
ESBLs and AmpC β-lactamases.269 Durlobactam was originally developed to combat 
infections involving OXA enzymes in Acinetobacter baumannii,36 and this compound inhibits 




restored imipenem potency against OXA-48 better than avibactam.35 Durlobactam is currently 
in Phase III clinical trials in combination with sulbactam.4 New β-lactamase inhibitors utilizing 
the DBO scaffold have been synthesized by substituting the avibactam C2 carboxamide (Figure 
4.5) with new functional groups.37, 270 The size of the C2 substituent appears to correlate with 
β-lactamase inhibitory activity: new DBO compounds with larger C2 groups (with respect to 
avibactam) have approximately an order of magnitude slower on-rates and faster off-rates for 
OXA-48.270 However, the studied derivatives with larger C2 substituents inhibit PBPs in 
bacterial cells. OXA-48 complexes with avibactam derivatives (PDB IDs 5FAQ, 5FAS, and 
5FAT)270 show essentially the same binding pose as observed for avibactam, the main 
differences being in the respective C2 substituents. Avibactam itself has poor oral 
bioavailability, but the avibactam prodrug ARX-1796 can be administered orally and 
subsequently metabolized in the body to produce avibactam.271 ARX-1796 differs from 
avibactam through the addition of a neopentyl ester protecting group on the N6 sulfate moiety. 
Recent data show DBO inhibitory activity towards OXA-48 to be dependent upon the N6 
substituent, as replacing the durlobactam N6 sulfate with fluoroacetate reduces potency but can 
form the basis for an orally available therapy.39 Another investigational β-lactamase inhibitor 
in the DBO group is BOS-752, which has a third ring fused to the DBO scaffold (making it a 
dioxotriazatricyclohendecane).38 BOS-752 does not possess antibacterial activity on its own, 
but combined with piperacillin it lowered measured MICs against SBLs including OXA-48.38 
In addition to DBOs, other -lactamase inhibitors currently in clinical development 
include mechanism-based β-lactam inhibitors and boronic acid compounds (Figure 4.12). An 
example of a β-lactam inhibitor is enmetazobactam, which is a penicillanic acid sulfone 
currently developed in combination with cefepime.272, 273 This combination was found to be 
effective against OXA-48 producers, but the efficacy is most likely again attributed to the 
activity of cefepime and not to efficient inhibition by enmetazobactam, which is active 
primarily against ESBLs.273, 274 On the other hand, boronates show promise as broad-spectrum 
β-lactamase inhibitors. In particular, cyclic boronates can act as analogues of the tetrahedral 
acylation transition state of SBLs,41 and have potential for at least moderate activity against 
MBLs.40, 275 The first boronic acid inhibitor approved in clinical use was vaborbactam 
(originally RPX7009),42 which is currently administered in combination with meropenem.43, 
276 Vaborbactam is a monocyclic boronic acid compound showing inhibition mainly against 
class A and C SBLs, and it is not able to effectively inhibit OXA-48 based on both biochemical 




of boronic acid derivatives as β-lactamase inhibitors includes taniborbactam (VNRX-5133), 
which is a bicyclic boronate.278 Based on both in vitro and whole cell assay data, taniborbactam 
exhibits pan--lactamase inhibition (i.e. is able to inhibit all four Ambler classes) including 
moderate inhibition of OXA-48 (with an IC50 value of approximately 0.54 μM).
44 
Taniborbactam is currently in clinical development in combination with cefepime.279 Another 
potent bicyclic boronate with ultrabroad-spectrum β-lactamase inhibition is the compound 
QPX7728, which can efficiently inhibit carbapenem-resistant Enterobacterales and restore the 
potency of meropenem against OXA-48.45, 280 QPX7728 entered Phase I clinical trials in 
December 2020.281, 282 VNRX-7145, which is orally bioavailable, also demonstrates OXA-48 
inhibition and has entered Phase I clinical trials in 2020 combined with ceftibuten.22, 283, 284 In 
addition to boronates, other cyclic compounds mimicking the tetrahedral intermediate (such as 
phosphonates, sulfonates, and sulfonamides), may also provide a source of future inhibitors, 
but these are yet to be explored in detail.41 Growing appreciation of the clinical importance of 
OXA-48 has also motivated exploration of other routes to inhibitors, such as the use of DNA-
encoded libraries, but these too remain at an early stage.285 
 
4.7 Conclusions 
Carbapenem-hydrolyzing Enterobacterales are classified as an urgent global threat to 
modern medicine, while OXA-48 β-lactamases are endemic in some regions (especially Turkey 
and the Mediterranean) and continue to disseminate. In general, OXA-48 enzymes convey 
penicillin and low-level carbapenem resistance; their weak carbapenem hydrolysis often 
complicates diagnosis and subsequent treatment of infections involving OXA-48 producers. 
Most variants within the OXA-48 family are imipenemases with slow turnover rates for other 
carbapenems, and resist established mechanism-based β-lactam inhibitors. However, certain 
variants (such as OXA-163 and OXA-405) have acquired a more ESBL-like hydrolysis profile 
with activity against expanded spectrum oxyimino-cephalosporins (such as ceftazidime) and 
significantly decreased imipenemase activity. The extent to which further evolution of the 
OXA-48 scaffold towards genuinely broad-spectrum activity is possible remains to be 
established. 
Recent crystallographic efforts have yielded structures of acylenzyme complexes of 
OXA-48 not only with clinically relevant carbapenem and cephalosporin substrates, but also 




regarding the interactions of substrates and inhibitors with the OXA-48 active site, including 
the importance of active site structure (specifically the -loop), hydration and, with respect to 
carbapenems, rearrangements such as tautomerization and lactone formation that occur after 
-lactam cleavage. The origin of preferential activity towards imipenem over other 
carbapenems, however, remains to be verified. Importantly, structural data for other OXA-48-
like enzymes has started to emerge too, which is important to increase understanding of how 
substitutions affect specificity across the enzyme group. Combining knowledge from 
biochemical characterization, X-ray crystallography as well as atomistic computational 
modelling will likely lead to a detailed picture of the origin of activity and specificity in OXA-
48 enzymes, ultimately benefitting design of inhibitors effective against this widespread and 




Chapter 5 – Small changes in hydration determine cephalosporinase 
activity of OXA-48 β-lactamases 
 
This chapter contains the article titled “Small changes in hydration determine 
cephalosporinase activity of OXA-48 β-lactamases” published in ACS Catalysis in 2020.257 
The aim of this article is to compare ceftazidime hydrolysis for selected OXA-48 β-lactamases, 
which are either known to be cephalosporin-inhibited or cephalosporinases, to illustrate any 
possible determinants behind efficient ceftazidime breakdown. A comparison of OXA-48 
(inhibited) and OXA-163 (cephalosporinase) reveals active site hydration to be a key factor 
correlating with the calculated free energy barriers: increased hydration near the catalytic base 
(carboxylated Lys73) impairs catalysis by raising the energy barrier. I performed all the 
simulations and analysed the data together with my co-authors. I also wrote the original draft 
of the manuscript, and others provided comments and text editing at later stages. Section 5.6 




β-lactamase mediated antibiotic resistance threatens treatment of bacterial infections. 
OXA-48 enzymes are clinically important class D serine β-lactamases (SBLs) that confer 
resistance to most β-lactam antibiotics, including carbapenems. However, OXA-48 and related 
enzymes vary widely in their activity towards different substrates: OXA-48 primarily 
hydrolyzes carbapenems, whereas the OXA-163 variant is a cephalosporinase with minimal 
carbapenemase activity. The basis of cephalosporinase activity in OXA-163 remains elusive. 
Here we use QM/MM reaction simulations (umbrella sampling molecular dynamics) to study 
breakdown of the cephalosporin antibiotic ceftazidime, a key antibiotic for healthcare-
associated infections, by selected OXA-48 variants. Calculated free energy barriers for 
ceftazidime deacylation correctly capture the differing catalytic efficiencies of the studied 
enzymes and identify the catalytically competent orientation for bound ceftazidime. 
Additionally, we show that high flexibility of the Ω-loop bordering the active site, a 
determinant of specificity in many SBLs, is not required for efficient deacylation. Based on our 
simulations, cephalosporin breakdown in OXA-163 is efficient due to subtle control of active 




further predict that a single mutation in the OXA-48 β5 - β6 loop (Arg214Ser) will increase the 
efficiency of ceftazidime deacylation to that of OXA-163. The finding that the hydration of the 
general base in the active site determines deacylation efficiency is possibly important in other 




Antimicrobial resistance is a complex phenomenon requiring urgent global action.286, 
287 For example, it is estimated that if no preventive measures are taken, antibiotic resistance 
will result in 10 million deaths annually by 2050.206 From their initial clinical introduction in 
the 1940s, β-lactam antibiotics remain the most important drugs for treating bacterial 
infections.18 They are the oldest and largest group of commercially available antibiotics, and 
have undergone continuous development, but their efficacy is threatened by growing resistance 
especially in Gram-negative bacteria, in which breakdown by β-lactamase enzymes are the 
major resistance mechanism.49 β-lactamases hydrolyze β-lactams by opening the β-lactam 
amide, which inactivates the antibiotic as it prevents binding to its bacterial transpeptidase 
target.208 
According to the Ambler classification, β-lactamases can be divided into four classes 
based on specific sequence motifs. Classes A, C and D are serine β-lactamases (SBLs), and 
class B zinc-dependent metallo-β-lactamases (MBLs).63 Serine β-lactamases have an active 
site serine residue (part of the invariant S-X-X-K motif common to SBLs and transpeptidases) 
that acts as the essential reaction nucleophile, whilst class B enzymes have a different 
mechanism that employs zinc-activated water. OXA-48 β-lactamases are class D SBLs, and 
are now common on mobile genetic elements (plasmids) in Enterobacteriaceae responsible for 
healthcare-associated infections in Europe (especially Mediterranean countries) and 
worldwide.216, 288, 289 This resistance to broad spectrum β-lactams in Enterobacteriaceae is now 
a major public health challenge.290 OXA-48 confers resistance to carbapenems (especially 
imipenem),222, 291, 292 but some variants have acquired cephalosporinase activity (especially 
against the oxyiminocephalosporin ceftazidime) through amino acid deletions and 
substitutions.226 For example, OXA-163 has increased cephalosporinase and decreased 
carbapenemase activities; it differs from OXA-48 by four amino acid deletions and one 






Figure 5.1 Comparison of class D β-lactamase structures. Left inset: Comparison of two OXA-
ceftazidime acylenzyme crystal structures, where the ceftazidime binding pose differs. For OXA-48 
(PDB: 6Q5F), the ceftazidime oxyimino group is between the β5 - β6 and Ω-loops (binding pose 1 in 
turquoise),255 whilst for OXA-225 (PDB: 4X55),256 this space is occupied by the thiazole ring (binding 
pose 2 in purple). Right inset: Apoenzyme structures of OXA-48 (turquoise, PDB:4S2P) and OXA-163 
(gray, PDB: 4S2L) showing the partly deleted β5 - β6 loop (R214-P217) and the S212D mutation in 
OXA-163 with respect to OXA-48. 
 
The hydrolysis mechanism of serine β-lactamases consists of acylation and subsequent 
deacylation;49 between these two reactions the antibiotic is covalently bound to the enzyme via 
the active site Ser70. Both acylation and deacylation involve formation of a tetrahedral 
intermediate (TI) via attack of a nucleophile upon the carbonyl carbon of the scissile bond. In 
the acylation reaction the unstable tetrahedral intermediate (TI) collapses to form the covalent 
acylenzyme intermediate (AE); after TI formation in the deacylation reaction, turnover is 
completed when the hydrolyzed drug is cleaved from the enzyme (the complete hydrolysis 
reaction is illustrated in scheme S1 in Section 5.6). Often only the first step in deacylation 
needs to be modelled to distinguish β-lactamase activities, as this is frequently the rate-limiting 
step in hydrolysis.190, 202 Furthermore, β-lactamases are inhibited when the AE intermediate 
persists, with high energetic barriers for deacylation. For class D enzymes, a carboxylated 
lysine (Lys73) acts as a general base in both acylation and deacylation;234 in deacylation, the 








Scheme 5.1. Tetrahedral intermediate formation in ceftazidime deacylation. AE=acylenzyme, 
TI=tetrahedral intermediate. 
 
The structural determinants of cephalosporinase activity in OXA-48 and its variants 
remain unclear. The β5 - β6 loop near the active site has been demonstrated to be important for 
carbapenem breakdown,242 and most likely has some effect on cephalosporin hydrolysis e.g. 
by limiting available space in the active site. It has been suggested that the cephalosporinase 
phenotype of OXA-163 originates from increased enzyme flexibility due to the loss of two salt 
bridge interactions upon amino acid deletions.293 Cephalosporin breakdown was also studied 
by Fröhlich et al., where serial passage of OXA-48 producers against ceftazidime resulted in a 
single amino acid mutation (Pro68Ala).255 Based on crystal structures of the ceftazidime AE, 
the authors hypothesize that upon ceftazidime binding and hydrolysis in OXA-48, Arg214 (part 
of the β5 - β6 loop) is displaced, thus breaking the salt bridge between Arg214 and Asp159 
(part of the Ω-loop that is a major determinant of substrate binding and specificity across 
multiple β -lactamase classes). The Pro68Ala substitution was in turn reasoned to facilitate 
ceftazidime binding, and subsequent loop displacement, by providing more flexibility in the 
active site. Notably, similar results have been observed with two other class D carbapenemases, 
OXA-23 and OXA-24/40. Two of their subfamily members, namely OXA-160 (a variant of 
OXA-24/40) and OXA-225 (a variant of OXA-23), have single proline to serine substitutions 
(Pro225Ser and Pro227Ser, respectively)256 that enhance their hydrolytic activities against 
oxyimino cephalosporins e.g. ceftazidime and cefotaxime. Interestingly, however, comparison 
of the crystal structures shows two different binding poses for ceftazidime in OXA-48 and 




oriented towards the β5 - β6 and Ω-loops (referred to as binding pose 1), whilst for both OXA-
160 and OXA-225 the thiazole ring occupies this area (binding pose 2, Figure 5.1). 
Current hypotheses regarding the origin of cephalosporinase activity in OXA-163 
ascribe increased hydrolysis to more favorable substrate binding made possible by residue 
deletions near the active site. Changes in substrate binding alone, however, may not explain 
why ceftazidime turnover by OXA-163 is greatly increased compared to OXA-48: reported 
ceftazidime kcat values for OXA-48 range from unmeasurably low to 3 s
−1,226, 255 whilst those 
for OXA-163 range from 8 to 200 s−1.226, 230 Hence, to complement and extend existing 
experimental work, here we study ceftazidime breakdown by OXA-48 variants using combined 
quantum mechanical / molecular mechanical (QM/MM) reaction simulations. QM/MM 
simulations can provide a good approach to examine enzyme-catalyzed reaction mechanisms 
(including in β-lactamases189, 190, 201, 247, 294) and can identify e.g. determinants of activity and 
effects of mutation.97 Starting from a covalent AE model, TI formation in deacylation (Scheme 
5.1) is simulated using QM/MM umbrella sampling (US) molecular dynamics simulations, 
resulting in free energy barriers for this reaction for different AE complexes. Additionally, AE 
dynamics are simulated using classical MM molecular dynamics. Our simulations reveal that 
structural features of the OXA-163-ceftazidime complex impair the ability of extra water 
molecules to enter the active site, accelerating ceftazidime breakdown. In OXA-48, an 
increased number of water molecules near the carboxylated lysine decreases ceftazidime 
turnover. Simulations of the OXA-48 Arg214Ser point mutant identify deletion of Arg214 as 
the major contributor to increased ceftazidime turnover by OXA-163 as a result of desolvation 
of the catalytic base. Our findings suggest that reactivity of other serine β-lactamases with 




Computational details and system set-up are described in detail in the Supporting 
Information (Section 5.6). We applied QM/MM and MD simulation protocols similar to those 
we have applied successfully previously to other serine β-lactamases.189, 190, 202 In short, AE 
starting structures were built using the crystal structure of OXA-48 in complex with imipenem 
(PDB: 5QB4)239 and replacing imipenem with ceftazidime as found in complexes with OXA-
225 (PDB: 4X55)256 or OXA-48 (PDB: 6Q5F)255. Starting models of the OXA-163 ceftazidime 
complex were built using the apoenzyme crystal structure (PDB: 4S2L)295 and the same 




the OXA-48 and ceftazidime crystal structure using MODELLER296 as described in the 
Supporting Information, along with further details of system setup and non-standard residue 
parameter generation. All systems were initially minimized, followed by heating from 50 K to 
300 K in 20 ps molecular dynamics (MD), followed by further MD for a total of 1 ns, to 
generate starting structures for QM/MM calculations. Four different starting structures for 
QM/MM umbrella sampling (US) calculations were taken from the last 500 ps of each 1 ns run 
(at least 50 ps apart). We used short equilibrations prior to the umbrella sampling to ensure that 
there are no significant changes away from the starting structures (e.g. a change in binding 
pose), and to test whether efficient computational 'assays' are feasible.189 Extended MD 
simulations (5x 120ns) and additional QM/MM MD US simulations (one profile each) were 
performed for OXA-48, OXA-48 R214S and OXA-163 with the acylenzyme in binding mode 
1 (see Supporting Information in Section 5.6, section “Extended MD Simulations: Stability, 
Loop Conformation, and Free Energy Barriers”). These simulations verified that (1) the 
systems remain conformationally stable over longer timescales (Figure S16, Section 5.6); (2) 
the R214S mutation does not cause a large shift in β5 - β6 loop conformation (Figure S17, 
Section 5.6); and (3) the free energy barriers obtained from QM/MM reaction simulations are 
not significantly affected by longer MM MD equilibration beforehand (Table S7, Section 5.6). 
Two-dimensional US was performed using two reaction coordinates (Figure S3, Section 5.6): 
one describing proton transfer between DW and the carboxylated lysine (Lys73) general base 
(defined as the difference in the carboxylate oxygen – proton distance and the water oxygen - 
proton distance), and one for the nucleophilic attack between DW and the electrophilic 
carbonyl carbon in the acylenzyme (oxygen-carbon distance). DFTB3159 was used as the QM 
method for a QM region consisting of the reactive part of the ceftazidime acylenzyme, DW, 
and the carboxylated lysine (Figure S4 in Section 5.6). US was run initially for 2 ps on the 
whole surface, consisting of 525 US windows, and afterwards the restart files for this surface 
were used as starting structures for more extensive sampling. Further US was run for 20 ps in 
windows corresponding to an approximate minimum energy path on the surface, and for 2 ps 
in the rest of the windows. Calculations were done using the sander program as implemented 
in the AmberTools16 package.203, 297 Results of US calculations were analysed using 
WHAM186 with 21 and 25 bins for proton transfer and nucleophilic attack coordinates, 
respectively, and a convergence criterium of 10−13. Minimum free energy paths on calculated 
surfaces were constructed using the MEPSA code.298 Extended MM MD simulations of AE 
models were each run for 50 ns (at least five independent simulations per model, trajectory 




interaction strengths were calculated using BioSimSpace302 with the Sire303 biomolecular 
simulation program. 
 
5.4 Results and discussion 
 
We first set out to calculate (relative) free energy barriers for cephalosporin deacylation 
in OXA-48 enzymes using reaction simulations by comparing several different models of the 
acylenzyme complex (Table 5.1). Using QM/MM umbrella sampling molecular dynamics 
simulations along the two reaction coordinates (one for nucleophilic attack of the deacylating 
water DW and the acylenzyme and one for proton transfer from DW to the carboxylated lysine; 
see Methods and Figure S3 in Section 5.6), we calculated free energy surfaces and 
corresponding free energy barriers for the first step of the AE deacylation (i.e. TI formation, 
Figure 5.2). Altogether, three AE models were prepared for OXA-48 due to differences 
between existing crystal structures. The most recent crystal structure255 suggests disorder in the 
Ω-loop, which was not observed in previous OXA-48 structures.71, 222, 239 Additionally, prior to 
publication of the OXA-48:ceftazidime complex, previously available OXA:ceftazidime 
structures256 indicate a different binding pose for the substrate from that observed in the 
crystallized OXA-48 complex. To establish both the effect of Ω-loop disorder on reactivity (as 
opposed to drug binding), and the extent of preference for a particular binding pose, three 
models were built: 1. OXA-48 complex with ceftazidime AE as found in the crystal structure 
complex (binding pose 1, enzyme modelled as found in the imipenem complex239), but with 
the Ω-loop as in the apoenzyme structure; 2. ceftazidime AE oriented as in the OXA-225 
complex structure (binding pose 2) with the same apoenzyme Ω-loop as in model 1; and 3. 
‘disordered’ Ω-loop constructed using MODELLER296 and AE as in OXA-48 and ceftazidime 
complex (binding pose 1). Two models with the different ceftazidime binding poses 1 and 2 
were also prepared for OXA-163, but no model with a disordered Ω-loop (as there is no 
evidence of Ω-loop distortion for this enzyme). Models for OXA-48 and OXA-163 are 
illustrated in Figure S1 in the Supporting Information (Section 5.6). Two models equivalent to 
those generated for OXA-163 were also prepared for OXA-181, which has a similar resistance 







5.4.1 Comparison of the binding poses 
 
Comparison of Δ‡Gcalc values for formation of the TI in ceftazidime deacylation shows 
that the orientation of the bulky ceftazidime C7 substituents has a large effect on overall 
hydrolysis. AE models constructed with ceftazidime oriented as in the OXA-225 co-crystal 
structure (binding pose 2, Figure 5.1), in which the thiazole ring is positioned between the Ω- 
and β5 - β6 loops, yield relatively high Δ‡Gcalc values of 19.0 and 16.0 kcal/mol for OXA-48 
and OXA-163, respectively. This is a large increase over Δ‡Gcalc values for the binding pose 
observed in the OXA-48 structure (binding pose 1), with deacylation barriers for these models 
are 12.5 and 7.3 kcal/mol for OXA-48 and OXA-163, respectively. Deacylation barriers for 
OXA-181 are similar albeit slightly lower to OXA-48 (17.9 kcal/mol for binding pose 2, 11.1 
kcal/mol for binding pose 1). We note that the absolute values of the barriers are underestimated 
when compared to rates of turnover, due to the approximate semi-empirical QM method used. 
Benchmarking calculations against DFT and ab initio methods (M06-2X & SCS-MP2; see 
Supporting Information, section “Benchmarking”) indicate that the use of DFTB3 may lead to 
underestimation of (at least) 7 kcal/mol. The reaction mechanism is similarly concerted with 
DFTB3 or more accurate DFT treatment (indicated both by M06-2X and BLYP small model 
transition state optimizations and a M06-2X corrected DFTB3/MM potential energy profile; 
see Figures S5 and S6, Table S2 in Section 5.6). The relative differences in our semi-empirical 
free energy barriers, therefore, give a good indication of the reaction feasibility. The 
consistently and significantly higher barriers for binding pose 2 compared to binding pose 1 (at 
least 6.5 kcal/mol), indicate that for all three OXA-48 variants studied, binding pose 1 is more 
competent for deacylation. Further, it is highly likely that binding pose 1 is also the 
thermodynamic minimum for the acylenzyme conformation, as it is found in the X-ray 
structure of OXA-48 and it remains in this pose in extended MD simulations of the solvated 
enzyme (see Supporting Information in Section 5.6, “Extended MD Simulations: Stability, 
Loop Conformation and Free Energy Barriers”). Any correction for a difference in free energy 
between poses 1 and 2 should therefore be in favor of binding pose 1. The fact that the 
acylenzyme pose found in a homologous enzyme (binding pose 2, found in OXA-225, which 
has 41% sequence identity to OXA-48) is not likely to undergo deacylation highlights the 
importance of determining AE crystal structures for specific OXA families and family 
members as a prerequisite for analyzing and understanding catalytic turnover. An assumption 




2) indicates the conformation found in OXA-48 would result in calculated barriers that are too 
high, and thus inconsistent with experimental assays. 
 
5.4.2 Comparison of OXA-48 variants 
 
For binding pose 1, a consistent difference of approximately 5 kcal/mol is seen between 
OXA-48 (with an ordered Ω-loop) and OXA-163 (Figure 5.2); the same trend as for OXA-48 
is also observed for OXA-181. As OXA-163 has moderate cephalosporinase activity, whereas 
OXA-48 has essentially no activity against ceftazidime, this difference is consistent with 
experimental observations (Table 5.1).226 Based on our previous work on class A β-lactamases, 
we would expect semiempirical DFTB methods to underestimate the magnitude of deacylation 
barriers, which would explain the deviation of calculated Δ‡Gcalc values from deacylation 
barriers determined from the experimental kcat values using transition state theory.
189 As 
illustrated in the Supporting Information (Table S1 in Section 5.6), differences in calculated 
barriers obtained by shorter sampling (only 2 ps sampling per umbrella sampling window, 
without equilibration) are minor (< 0.5 kcal/mol difference). This indicates that 
cephalosporinase activity of OXA-48-like enzymes could be assayed by efficient QM/MM 
protocols in a similar fashion to carbapenem turnover by class A carbapenemases.189, 190 
 
 
Figure 5.2 Calculated free energy surfaces for ceftazidime deacylation in binding pose 1 by OXA-48 
(left) and OXA-163 (right). Red dots indicate the minimum free energy path on the surface. 





Table 5.1 Calculated free energy barriers for deacylation for all acylenzyme models (standard 






Δ‡Gcalc (kcal/mol), wildtype 
Binding 
pose 1 a 
Binding 
pose 2 b 
New Ω-loop c 


















- 6.6 (0.3) - - 
 
NH = No hydrolysis detected. ND = Not determined. N/A = Not applicable (Ω-loop not present). 
a Acylenzyme orientation as found in the crystal structure for OXA-48 with ceftazidime (see Figure 
5.1). 
b Acylenzyme as found in OXA-225 K82D structure with ceftazidime (see Figure 5.1). 
c Ω-loop representative of a disordered loop, constructed using MODELLER as described in the 
Supporting Information (Section 5.6). 
d Corresponds to Δ‡Gexp =16.3 kcal/mol, as estimated with transition state theory. 
e Transition state could not be located on the free energy surface, with energy values rising to above 
20 kcal/mol near the TI. 
 
5.4.3 Role of the Ω-loop 
 
Recently published crystal structures support the hypothesis that ceftazidime binding 
disrupts the Ω-loop in OXA-48-like enzymes.255 We thus studied the effect of Ω-loop distortion 
by constructing a possible model for the “disordered” Ω-loop variant of OXA-48 in silico; MM 




flexibility, consistent with the lack of density for this region in structures obtained by X-ray 
crystallography (Supporting Information Figure S2). Notably, deacylation Δ‡Gcalc values for 
the “disordered” Ω-loop variants show no hydrolysis for OXA-48, as free energy minima 
representing the deacylation TI could not be located on the calculated free energy surfaces, and 
therefore nor can transition states (surfaces show an increase in energy from AE to >20 
kcal/mol when approaching the TI structure). This is perhaps not surprising as crystal structures 
tend to capture the thermodynamic minimum free energy structure, which may be catalytically 
deficient.304, 305 Additionally, in the OXA-48-ceftazidime complex structure, triethylene glycol 
is co-crystallized in the space occupied by the Ω-loop in the apoenzyme, which might in turn 
contribute to the disorder and consequent lack of density for this loop in experimental crystal 
structures. Our simulations thus indicate that a more disordered Ω-loop conformation (different 
from the conformation found in the OXA-48 apoenzyme structure) is not necessary to increase 
the rate of deacylation and may indeed decrease it. It is possible, however, that Ω-loop disorder 
aids in the formation of the initial Michaelis complex and possibly acylation by expanding the 
active site to better accommodate ceftazidime. For example, Fröhlich et al. argued that 
ceftazidime binding is likely favoured in OXA-48 P68A due to increased Ω-loop flexibility; 
Ω-loop disorder was observed in the crystal structure of this variant.17 
 
5.4.4. Comparison of acylenzyme dynamics 
 
To further elucidate the reason for the difference in cephalosporinase activity in OXA-
48-related enzymes, the ceftazidime AE complexes of OXA-48 and OXA-163 were studied by 
extended MM MD and QM/MM MD simulations. At least five independent 50 ns MD 
simulations of each AE model with binding pose 1 were run in order to inspect the dynamics 
and possible catalytically relevant interactions between ceftazidime and the protein. 
Additionally, 20 ps of QM/MM MD were run for selected US windows close to the calculated 
AE and TI minima. It is well known that interactions with an oxyanion hole,73 in OXA-48 
formed by the backbone amides of Ser70 and Tyr211,222 stabilize TI formation in β-lactamases 
(similar to many other co-factor independent hydrolases). Thus, hydrogen bond distances 
between these residues and the ceftazidime AE were measured in both the extended MM MD 
and QM/MM MD simulations and are shown in the Supporting Information (S8-S11, Section 
5.6). Additionally, electrostatic interactions between the quantum region (Figure S4, Section 
5.6) used for QM/MM simulations and Tyr211 as part of the oxyanion hole were quantified by 




neither the distance nor the electrostatic analyses reveal any significant difference between 
OXA-48 (disordered/ordered Ω-loop), and OXA-163. Electrostatic interactions of each 
enzyme with the modelled TI show the measured stabilization to be similar in all systems tested 
(Figure 5.3). Hence, our simulations do not provide evidence that enhanced ceftazidime 
hydrolysis by OXA-163 is a result of stronger stabilizing interactions in the oxyanion hole than 
take place in OXA-48. The population of different ceftazidime conformers was also 
investigated using clustering analysis of the sampled AE orientations; this revealed that 
variation in ceftazidime orientations in the different enzymes is largely confined to the 
oxyimino group, which interacts mainly with bulk solvent (details of clustering can be found 
in Section 5.6, Figure S8). These data indicate that increased ceftazidime hydrolysis by OXA-
163 is unlikely to be due to a more favorable orientation of the AE that results from partial 
deletion of the β5 - β6 loop. 
 
 
Figure 5.3 Top: Oxyanion hole interaction strength in the tetrahedral intermediate structure between 
the QM region and Tyr211 residue (the ceftazidime atoms part of the QM region are depicted with ball 
and sticks, and relevant MM atoms in licorice). Bottom: Average number of hydrogen bonds between 
the carboxylated lysine OQ1 oxygen and solvent water molecules measured from the acylenzyme 





5.4.5 Role of Leu158 
 
One structural difference apparent from the OXA-48 and OXA-163 MD simulations is 
the rotation of Leu158 in the Ω-loop. The C-Cα-Cβ-Cγ (χ1) dihedral angle for Leu158 in the 
starting models is approximately 170°, and in OXA-48 it rotates to around 50° (i.e. it changes 
from t to g+ according to the leucine rotamer naming convention; see Supporting Information 
Figures S14 and S15 in Section 5.6). This rotation happens both in the short 1 ns MD simulation 
used for generating starting structures for US, and in most of the 50 ns MD trajectories (for 
OXA-48, a total of seven 50 ns trajectories were run, Leu158 rotation was seen in five of these). 
For OXA-163, Leu158 rotation was not seen in the short 1 ns trajectory, but it was occasionally 
observed in the longer 50 ns simulations. However, OXA-48 samples this rotated Leu158 
orientation (g+) more than OXA-163, as well as the orientation around 290° (g-). In the 
distorted Ω-loop variant of OXA-48, Leu158 is part of the newly constructed loop and is thus 
free to move in the disordered structure. Another structural feature that distinguishes OXA-48 
is formation of a salt bridge between Asp159 and Arg214, as Arg214 is one of the residues 
deleted in OXA-163. This salt bridge extends “over” the active site from the β5-β6 loop to the 
Ω-loop and is present in the apoenzyme crystal structures of OXA-48 as well as in some 
complexes with different substrates.71, 222, 226 In starting structures for simulations of OXA-48, 
Arg214 is initially rotated towards bulk solvent (thus breaking the salt bridge) in order to avoid 
any possible steric clashes in the AE starting model, but it (re-)forms a salt bridge with Asp159 
upon simulation either during or soon after the heating phase. 
Importantly, in MM MD trajectories and in QM/MM US simulations, rotation of 
Leu158 correlates with the number of solvent molecules present around the carboxylated lysine 
(Lys73). Accordingly, we inspected possible differences in active site solvation by measuring 
the average number of hydrogen bonds formed between the carboxylated lysine oxygens (OQ1 
as the proton acceptor in deacylation, and OQ2) and possible active site water molecules. In 
OXA-48 MM MD trajectories where Leu158 rotates (five out of seven 50 ns simulations), OQ1 
forms on average 1.64 ± 0.17 hydrogen bonds (with standard deviation) with a solvent 
molecule. This is a large increase over the OXA-48 trajectories where Leu158 does not rotate 
(two 50 ns simulations), in which the average number of hydrogen bonds to OQ1 drops to 1.09 
± 0.12. In the simulations of OXA-163 (five 50 ns simulations), lysine OQ1 forms on average 
1.20 ± 0.14 hydrogen bonds. This indicates that the hydrogen bonding environment around the 
general base differs between the ceftazidime AEs of OXA-48 and OXA-163. This difference 




DW during US, whereas for OXA-48, Lys73:OQ1 forms a hydrogen bond both to the DW and 
to an additional water molecule for the majority of the time (Figure 5.3 and 5.4). In the distorted 
Ω-loop of OXA-48, the active site is fully open for water molecules and on average 3.8 solvent 
hydrogen bonds are calculated (Figure 5.3). In contrast to class A β-lactamases, where both 
carboxylate oxygens of the general base (Glu166) form hydrogen bonds with other active site 
residues in a relatively organized manner,189 the carboxylate moiety in Lys73 is hydrogen 
bonded only to Trp157 (Figure 5.4). Therefore, any additional water molecules hydrogen 
bonding to the general base can affect the reactivity of the enzyme. 
 
5.4.6 Role of Arg214 
 
Arg214 is one of the four residues present in the OXA-48 β5-β6 loop that is deleted in 
OXA-163. Its absence could play an important role in the increased cephalosporin hydrolysis 
in OXA-163, for example by affecting the number of hydrogen bonds between the catalytic 
base and water molecules. Therefore, we hypothesize that deletion of Arg214 could be an 
important determinant of increased ceftazidime turnover by OXA-163. However, it remains 
possible that the four-residue deletion in the OXA-163 β5-β6 loop is necessary to enhance 
initial substrate binding (i.e. Michaelis complex and subsequent acylenzyme formation). To 
investigate the importance of Arg214 to ceftazidime AE deacylation, we constructed an in 
silico Arg214Ser point mutant of OXA-48. Interestingly, Δ‡Gcalc values for ceftazidime 
deacylation for this point mutant drop to the same level as those for OXA-163 (6.9 and 7.3 
kcal/mol for OXA-48 R214S and OXA-163, respectively), a 5.6 kcal/mol decrease in 
comparison with wild-type OXA-48 (Table 5.1; this difference may be overestimated due to 
the simulation approach, see discussion in the next section). The calculated energetics imply 
that point substitution of OXA-48 Arg214 would result in an enzyme with deacylation rates 
comparable to those observed in OXA-163. Moreover, in OXA-48 Arg214Ser both the 
conformational dynamics of Leu158 and the population dynamics of active-site water 
molecules resemble those observed for OXA-163, rather than the wild-type enzyme (Figures 
S14 and S15 in Section 5.6). In the absence of the Asp159 - Arg214 salt bridge, Leu158 prefers 
to stay in its original orientation, as was observed for OXA-163. In the reaction simulations, 
again only the DW is hydrogen bonded to the reactive oxygen of the carboxylated lysine 
(Lys73, see Figure 5.4), with lysine OQ1 forming on average 1.08 ± 0.07 hydrogen bonds with 
water molecules during extended MM MD simulations of the AE (five 50 ns simulations). 




indicates that a difference in the environment, rather than a difference in QM region geometry, 
leads to a difference in electron distribution (with the DW more polarized when no additional 
hydrogen bonds between water and OQ1 are present, see Tables S2-S5 in Section 5.6). 
Therefore, we hypothesize that deletion of Arg214 is an important determinant of increased 
ceftazidime turnover by OXA-163, due to its effect on the Leu158 conformation which in turn 
changes the accessibility of water to the catalytic base. 
 
 
Figure 5.4 Examples of acylenzyme structures from US for OXA-48 (cyan, left) and OXA-163 (magenta, 
right). Water molecules within 4 Å of carboxylated lysine (Lys73) are illustrated. In OXA-48, the 
carboxylate oxygen participating in deacylation is hydrogen bonded with two water molecules, whereas 
in OXA-163 it is interacting only with the DW. Two different leucine orientations are highlighted for 
OXA-48: the orientation found in the apoenzyme (t), and the rotated orientation used in all reaction 
simulations (g+). 
 
5.4.7 Relation between active site hydration and Leu158 
 
To further investigate the role of active site water molecules in deacylation, and the role 
of Leu158, additional reaction simulations (2 ps per US window) were carried out for OXA-
48 on starting structures taken from the two 50 ns MD trajectories where Leu158 does not 
rotate (Figure 5.3). In the chosen structures, each oxygen of the carboxylated lysine (Lys73) 
was hydrogen bonded to a single water molecule. The new deacylation Δ‡Gcalc value was 6.5 




reaction simulations), a similar decrease as observed with the R214S mutation. Ergo, we 
hypothesize that rotation of Leu158 enables more water molecules to enter the active site, thus 
impairing ceftazidime deacylation by stabilizing the general base in the AE complex. Clearly, 
the reactivity of the carboxylated lysine is affected by the level of solvation. A reduction in 
hydration of key active site residues, such as the catalytic base involved in proton 
abstraction, also plays an important role in other enzymes. Several enzymes appear to 
have evolved such that water is excluded from the active site to aid in efficient catalysis of the 
chemical step.306, 307  For example, in ketosteroid isomerase and triosephosphate isomerase, 
where proton transfer to a catalytic base is the rate-determining step, any increase in solvation 
of the catalytic base (e.g. due to partial opening of the active site) leads to a significant increase 
in barrier,308, 309  so small changes in solvation (at the level of individual water molecules) have 
a significant effect on reactivity. In dihydrofolate reductase isoforms, higher catalytic rates due 
to enhanced dehydration appear directly related to evolution: more efficient, evolved 
enzymes have increased the substrate basicity (i.e. reactivity) by expelling water from the 
active site.310 In the case of these other enzymes, significant loop motions are involved (e.g. 
triosephosphate isomerase, dihydrofolate reductase), or at least a closing of the substrate cleft 
(as in ketosteroid isomerase), whereas the effect found here in the OXA-48 type β-lactamases 
appears more subtle, primarily related to the rotational freedom of a single residue (Leu158). 
We note, however, that the energetic effect of an additional water molecule found here, around 
6 kcal/mole, is likely to be overestimated due to the simulation approach. The additional water 
is modelled using TIP3P, i.e. a standard fix-point charge MM description. The lack of 
polarization, perhaps combined with a too short hydrogen bond, may cause this overestimation; 
a similar large effect was observed in potential energy profiles for ketosteroid isomerase with 
one additional water, treated MM, hydrogen bonding to the catalytic base.309 
In our original US simulations for OXA-48, all the starting structures involved a rotated 
Leu158. Conversely, for OXA-163 all starting structures include Leu158 in the original 
rotamer. Interestingly, the role of water movement into the active site has recently been 
examined in carbapenem AE structures of OXA-48.71 Based on these crystallized AE 
complexes, carbapenemase activity in OXA-48 is suggested to be largely dependent on an open 
“deacylating water channel”, which allows water molecules to enter the active site. This water 
channel, consisting of Leu158 and Val120, is permanently “open” in OXA-48 and requires 
only slight shifts in residue positions upon carbapenem binding (unlike the case for other 
carbapenem-hydrolyzing Class D enzymes such as OXA-23,251 where more substantial 




binding). However, our results indicate that, while water access to the active site is necessary 
for the deacylating water to participate in deacylation, the deacylation efficiency is also 
affected by the level of solvation of the carboxylated lysine. Specifically, ingress of additional 
solvent molecules able to readily hydrogen bond with the carboxylate moiety would reduce its 




Here, we have modeled ceftazidime hydrolysis by the OXA-48-family class D β-
lactamase enzymes, using QM/MM reaction simulations. Our QM/MM protocol successfully 
distinguishes cephalosporinases (such as OXA-163) from non-cephalosporinases (such as 
OXA-48) by showing a consistent ~5 kcal/mol difference in calculated deacylation free energy 
barriers. It reveals the reactive ceftazidime AE conformation, and shows that the Ω-loop should 
not be disordered for efficient deacylation. This QM/MM protocol can be used for predictions 
of deacylation barriers (and, potentially, hydrolysis rates) for new and emerging OXA-48 
mutants (as for OXA-48 Arg214Ser here). Analysis of our simulations reveals that the 
calculated cephalosporinase efficiency correlates with active site solvation. In OXA-48, more 
water molecules can hydrogen bond with the general base (carboxylated lysine), which likely 
stabilizes the AE intermediate and diminishes deacylation rates. Correspondingly, the absence 
of active site water molecules other than the deacylating water in simulations of OXA-163 and 
OXA-48 Arg214Ser aids deacylation. Active site solvation is influenced by the orientation of 
Leu158 (part of the Ω-loop), whilst the local dynamics of Leu158 and the rest of the Ω-loop 
are likely to be affected by the β5-β6-loop, the site of a four residue deletion in OXA-163. Our 
findings that active site solvation in the AE affects the reactivity may be also applicable to 
other OXA enzymes and potentially to other serine β-lactamases where the general base is not 
a part of an organized hydrogen bonding network in the active site. This study also highlights 
the importance of modeling enzyme dynamics to understand reactivity, as active site solvation 
is difficult to reliably assess from static crystal structures that rarely yield information on 
conformational and solvation dynamics. The combination of experimental structures with 
detailed computational simulation techniques employed here thus enables deeper 
understanding of the mechanistic details of β-lactamase-mediated resistance, as well as 
prediction of activities of new drug-resistant enzyme variants.98 Ultimately, the availability of 




will aid identification of new β-lactams that exploit the resulting mechanistic understanding to 
evade deacylation, as well as design of new mechanism-based β-lactamase inhibitors. 
 
5.6 Computational details 
 
This section comprises the Supporting Information for the publication presented in 
Chapter 5. 
 
System Set-up and Parameterisation 
 
OXA-48 with ceftazidime was originally set-up using OXA-48 acylenzyme structure 
with imipenem as the template (PDB:5QB4)239, and by replacing imipenem with ceftazidime 
as found in OXA-225 K82D structure (PDB: 4X55)256. Upon the publication of OXA-48 P68A 
with ceftazidime crystal structure (PDB: 6Q5F),255 further models were built based on the new 
binding pose of ceftazidime either by taking the new binding pose and combining it with the 
protein structure used with the first model (with the Ω-loop and β5-β6 loops as found in the 
apoenzyme), or by mutating the new crystal structure back to the wild-type enzyme and 
reconstructing the Ω-loop in a disordered state using Modeller (described below). For OXA-
163 models, the apoenzyme crystal structure (PDB: 4S2L)295 was used with both CTZ binding 
poses. For OXA-181, four residues were mutated with respect to the OXA-48 model, all 
mutations were performed using the mutagenesis wizard in PyMol (OXA-181 and OXA-48 
Arg214Ser). DW was manually added to the active site for all models, and all crystallographic 
water molecules were kept excluding the ones clashing with the acylenzyme (closer than 2.5 
Å from any acylenzyme atom). Carboxylated lysine (Lys73) was kept as found in the OXA-48 
and imipenem structure, which is essentially the same as in the OXA-48 apoenzyme structure 
(PDB: 4S2P)235. To avoid any possible steric clashes between the acylenzyme and the rest of 
the protein, Arg214 was rotated towards bulk solvent in all starting structures. All starting 
structures are available to download from Supporting Information as a zip file. Ceftazidime in 
the acylenzyme was modelled without the pyridine ring, as its elimination has been observed 
experimentally.311 
Protonation states of titratable residues were determined using propKa3.1.167, 312 Based 




deprotonated, all Lys protonated). Histidine tautomers were predicted using reduce as 
implemented in the Amber program package (all histidines were singly protonated, are solvent 
exposed and distant from the active site). Hydrogen atoms were then added and all systems 
were solvated in a 10 Å box of TIP3P water using tLeap, with overall charge neutralized by 
replacing bulk water molecules with Na+ ions. The ff14SB force field was used to describe the 
protein, and the TIP3P compatible parameters were used for the counterions.100 Charge 
parametrization for non-standard residues (carboxylated lysine, KCX, and ceftazidime 
acylenzyme, CTZ – without the pyridine ring) was done using restrained electrostatic potential 
(RESP) fitting as implemented in the RED Server.172 Missing force field parameters were taken 
from analogous GAFF parameters.168 Parameter files for both fragments are available as part 
of the Supporting information zip file. 
 
Figure S1. Different models built for OXA-48 and OXA-163 with ceftazidime.  A. OXA-48 with Ω-loop 
as found in the apoenzyme and ceftazidime binding pose as in the OXA-48 and ceftazidime crystal 
structure (binding pose 1). B. OXA-48 with Ω-loop as found in the apoenzyme and ceftazidime binding 
pose as in the OXA-225 and ceftazidime complex (binding pose 2). C. OXA-48 with a disordered Ω-
loop built using MODELLER and ceftazidime binding pose as in the OXA-48 and ceftazidime complex. 
D. OXA-163 and ceftazidime binding pose as in the OXA-48 and ceftazidime crystal structure (binding 
pose 1). E. OXA-163 and ceftazidime binding pose as in the OXA-225 and ceftazidime structure 








In the OXA-48 structure complexed with CTZ (PDB ID: 6Q5F),255 electron density was 
not found for residues between Asp148 and Ile162 (ISGNVDSFWLDGGIR, 13 residue gap). 
250 new models for the “disordered” Ω-loop were reconstructed using MODELLER296 with 
slow loop refinement, whilst the rest of the atoms in the apoenzyme were kept fixed. (KCX 
was mutated back to lysine and CTZ removed for model generation to avoid parameter 
problems with non-standard residues.) Models were initially inspected using both the DOPE 
and molpdf scores, and 25 models were chosen for visual inspection (all models were in the 
top 50 for at least one scoring method, emphasis was given for DOPE scores to include more 
realistic loop conformations). The final loop model was chosen based on the following criteria: 
loop residues do not clash with bound ceftazidime in the active site, the new loop does not form 
interactions with Arg214, and loop reaches in the cavity near the active site (where the 
“ordered” loop is in the apoenzyme) rather than fully into bulk solvent. All crystallographic 
waters closer than 2.5 Å to the new loop were deleted to avoid possible clashes. 
The “disordered” Ω-loop is not seen in the crystal structure of OXA-48 and ceftazidime 
(lacking electron density), and it is therefore predicted to be highly flexible compared to the 
surrounding structural elements. The chosen loop model was validated by measuring Cα-atom 
RMSF values for three 100 ns molecular dynamics simulations and by comparing the 
calculated fluctuations of the new Ω-loop against fluctuations in rest of the protein. The first 
10 ns of each simulation were excluded from RMSF calculations to allow for system 
equilibration. RMSF values for each simulation are presented in Figure S2, and they indicate 
that the newly constructed loop region is the most flexible part of the protein. Loop flexibility 
is somewhat exaggerated in simulation 2, as it is observed to move into bulk solvent and then 






Figure S2. RMSF measurement for Cα-atoms for the distorted Ω-loop model of OXA-48. RMSF was 
measured from three 100 ns MD simulations and compared against the average RMSF for OXA-48 






Scheme S1. Schematic illustration of the complete hydrolysis reaction in serine β-lactamases.49 After 
the initial Michaelis complex formation, the antibiotic is acylated (1) and a tetrahedral intermediate is 
formed (2), which collapses to give the acylenzyme structure (3). Subsequently, the acylenzyme is 
deacylated forming a second unstable tetrahedral intermediate (4), which collapses to the final 




After initial preparation, all structures were briefly minimized (1000 and 1000 steps of 
steepest descent and conjugate gradient, respectively) and heated from 50 K to 300 K in 20 ps. 
After heating, 1 ns MM MD was run to generate starting structures for umbrella sampling (US) 
calculations. Classical MD simulations were run using Langevin dynamics with a 2 fs timestep 
constraining all bonds involving hydrogen atoms with the SHAKE algorithm. All starting 
structures were chosen from the last 500 ps of the 1 ns run to allow for system equilibration 
during the first half (starting structures at least 50 ps apart). (Tests were also performed using 
starting structures after at least 50 ns of MM MD, see section “Extended MD Simulations: 
Stability, Loop Conformation and Free Energy Barriers”.)  All MM MD simulations were 
performed using a 2 fs timestep, Langevin dynamics with a collision frequency of 0.2, and 
periodic boundary conditions. The SHAKE algorithm was applied for all bonds involving 
hydrogen atoms. QM/MM simulations were performed under the same conditions, but with a 
1 fs timestep and SHAKE turned off for the QM region. The Amber program package was used 




QM/MM Free Energy Calculations 
 
QM/MM US185, 297 MD simulations were done using two analogous reaction 
coordinates as for class A enzymes: one for describing the proton transfer from DW to the 
general base, and one for describing the nucleophilic attack (Figure S3). The proton transfer 
reaction coordinate was sampled from 1.0 to −1.0 Å, and the nucleophilic attack coordinate 
from 3.8 to 1.4 Å, both in 0.1 Å increments with a 100 kcal mol−1 Å−2 force constant. First, US 
was performed along an approximate (see below) minimum free energy path (MFEP) from AE 
to TI on the 2D free energy surface (FES) in 33 US windows, and afterwards sampling along 
the rest of the surface was performed using these windows as starting points (altogether 525 
US windows). US was first done for in each window for 2 ps for equilibration, followed by a 
further 20 ps along the approximate MFEP and a further 2 ps in all other windows. This 
approach should ensure enough sampling near the true reaction path, whilst minimizing 
sampling in high energy regions on the FES. US was done for four different starting structures 
taken from a 1 ns MM/MD run. The QM region consists of the deacylating water (DW), KCX, 
and a part of the covalently bound drug (38 atoms, Figure S4), and DFTB3159 was used as the 
QM method with a 1 fs timestep. Covalent bonds between the QM and MM regions were 
treated using the hydrogen link atom scheme implemented in sander (Amber). A one-sided 
restraint was added for the ester bond between Ser70 and the substrate to ensure it does not 
elongate above 1.6 A (Figure S4). All US results were analysed and FESs constructed using 
WHAM186 with 21 and 25 bins for the proton transfer and nucleophilic attack coordinates 
respectively, with a convergence criterium set to 1x10−13. Calculations were done for four 
snapshots, and the overall energy barriers were obtained by combining all sampling from these 
four US calculations into one WHAM calculation. True MFEPs on the FESs were calculated 





Figure S3. Illustration of the reaction coordinates used in umbrella sampling describing the changed 
in bonding during the tetrahedral intermediate formation. The proton transfer coordinate is defined 
with dark blue arrows as the difference d1-d2 (d[Lys73:O, DW:H] – d[DW:O, DW:H]). The 
nucleophilic attack coordinate is depicted as the red arrow, distance d3 (d[DW:O, CTZ:C]). 
 
The approximate minimum energy path for OXA-48 variants was constructed based on 
calculated class A deacylation surfaces, and consists of 33 initial US windows (PT=proton 
transfer, NA=nucleophilic attack): 
 
PT 1.0 0.9 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.7 0.6 
NA 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 
 
PT 0.5 0.4 0.3 0.2 0.1 0.0 -0.1 -0.2 -0.3 -0.4 -0.5 -0.6 -0.7 
NA 2.3 2.2 2.2 2.1 2.1 2.0 1.9 1.8 1.7 1.7 1.6 1.6 1.5 
 
PT -0.8 -0.8 -0.9 -1.0 






Figure S4. QM region used in US calculations; QM atoms in red, MM atoms in black; location of link 
atoms indicated with squiggly lines. The ester bond in blue was restrained to be less than (or equal to) 
1.6 Å during US to avoid sampling the next step. 
 
Free Energy Surfaces – short sampling 
 
Free energy barriers for deacylation (Δ‡Gcalc values) in Table 1 (main manuscript) were 
calculated by sampling 20 ps near the approximate minimum energy path and 2 ps elsewhere 
on the free energy surface (as described above, from now on referred to as 20 + 2 ps sampling). 
The 2 ps ‘equilibration’ sampling in each window (prior to the US used for the free energy 
analysis reported in Table 1) was also used directly for the calculation of free energy surfaces 
using WHAM (as detailed above). Notably, Δ‡Gcalc values based on the 2 ps surfaces (without 
equilibration) do not largely differ from the 20 + 2 ps results (largest difference 0.5 kcal/mol; 













Table S1. Deacylation free energy barriers calculated from 2 ps sampling. All values in kcal/mol, 
standard deviations in parenthesis. 








OXA-48 NH 12.4 (0.8) 18.5 (1.0) >20a 
OXA-48 
R214S 
- 6.9 (0.5) 14.0 (1.4) >20a 
OXA-163 8 7.2 (0.3) 15.7 (1.4) - 
OXA-181 ND 11.0 (1.9) 17.7 (0.6) - 
OXA-181 
R214S 
- 6.4 (0.3) - - 
NH = No hydrolysis detected. ND = Not determined. 




For the QM/MM MD umbrella sampling simulations, the semi-empirical DFTB3 
method was used. The free energy surface indicates a concerted mechanism with a barrier lower 
than that expected from experiment. Here, we perform more accurate DFT calculations (and 
ab initio single-point energy calculations) using a small gas-phase system representing the 
quantum region used in our QM/MM simulations (Figure S5). Transition states (TS) were 
optimised on both the M06-2X/6-31+G(d)134, 148 and BLYP/6-31G+(d)130, 131 levels using the 







Figure S5. Left: Small molecule model representing the QM region used in benchmarking calculations. 
Right: M06-2X/6-31+G(d) optimized transition state of the small molecule model. Red arrows: proton 
transfer reaction coordinate, blue arrow: nucleophilic attack reaction coordinate. 
 
TSs were characterized by frequency calculations, and the TS on the M06-2X level 
corresponded to one imaginary frequency (-293.2677), whilst TS optimized using the BLYP 
functional yielded two imaginary frequencies (-107.3119 corresponding to the reaction, and 
one at -1.8944, corresponding to an overall bend/twist motion). IRC calculations starting from 
the M06-2X TS structure were performed in both directions to obtain the reactant and product 
minima, and the end structures where further optimised on the M06-2X/6-31+G(d) level. 
Reactants and products were optimised also with BLYP (starting from the M06-2X optimised 
structures). The reaction coordinate values of the TSs indicate that the reaction proceeds 
through a concerted mechanism, similar to that predicted by the DFTB3/ff14SB free energy 
surface (Table S2). Calculated activation energies (Table S2) indicate that DFTB3 significantly 
underestimates this value. RI-SCS-MP2/aug-cc-pVTZ314-316 single-point energies were 
calculated on the M06-2X optimized structures using Orca 4.2317, 318 (using the RIJK 
approximation and aug-cc-pVTZ/C and aug-cc-pVQZ/JK auxiliary basis sets319). DFTB3 
single-point energies were calculated for BLYP optimized structures using sqm as part of the 
Amber package.297 Comparison of these RI-SCS-MP2/aug-cc-pVTZ and DFTB3 activation 
energies shows that, based on these potential energies only, DFTB3 underestimates the 





Table S2. Location of the transition state for M06-2X and BLYP optimized small QM model (Figure 
S5), and calculated activation energy barrier. NA RC = nucleophilic attack reaction coordinate, PT 
RC = proton transfer reaction coordinate. 
Method NA RC (Å) PT RC (Å) Δ‡Gcalc (kcal/mol) 
M06-2X/6-31+G(d) 1.97 -0.35 14.85 
RI-SCS-MP2/aug-cc-pVTZa - - 16.63 
BLYP/6-31+G(d) 1.83 -0.51 15.53 
DFTB3b - - 9.65 
DFTB3/ff14SB FES (OXA-48)c 1.7 -0.5  
a Energy difference from single-point energies on M06-2X/6-31+G(d) optimized AE and TS structures. 
b Energy difference from single-point energies on BLYP/6-31+G(d) optimised AE and TS structures; A transition 
state could not be optimized in the gas-phase with DFTB3 as no saddle point is indicated between the AE 
minimum and the tetrahedral intermediate. 
c For reference, the approximate TS location obtained from the QM/MM free energy surface (see Figure 2) is 
indicated. 
 
For the purpose of comparing the in-enzyme energy surface shape and energies, a 
QM/MM potential energy surface was obtained (Figure S6). Starting from a snapshot of one 
OXA-48 US simulation in the window corresponding to the (approximate) transition state, a 
potential energy surface (PES) was calculated for the deacylation reaction. The LBFGS method 
was used for minimization (with convergence criterium of 0.01 mol−1 Å−1 for energy gradients). 
Residues further than 5 Å away from ceftazidime were restrained with a restraint weight of 50 
kcal mol−1 Å−2 (to avoid discontinuities). Single-point energy corrections were calculated by 
taking the difference in the QM region energies calculated at the M06-2X/def2-TZVP level 
(using the RIJK approximation with def2/JK auxiliary basis set) with Orca 4.2 and the DFTB3 





Figure S6. Left: Potential energy surface for ceftazidime deacylation calculated with DFTB3; energy 
at -0.5,1.6 (location of the free energy surface TS) is 13.4 kcal/mole. Right: DFTB3 potential energy 
surface with M06-2X/def2-TZVP energy corrections; approximate TS at -0.3,1.9 is 19.4 kcal/mole. The 
difference of 6 kcal/mole is in line with the small model calculations (Table S2). 
 
Mulliken Charge Calculations 
 
Mulliken charges for the QM region were calculated from extended US in both 
acylenzyme and tetrahedral intermediate minima from one individual US free energy surface. 
Charge values were calculated as an average from 1000 frames over 20 ps (i.e. snapshots 
recorded every 20 fs). Mulliken charges are presented for OXA-48 (both ordered and 
disordered Ω-loop), OXA-48 Arg214Ser, and OXA-163. All four models show the same trend, 
where largest charge variations are observed for the atoms that directly take part in deacylation 
or are near the reactive parts (Figure S7). Mulliken charges were recorded for the QM atoms 
in both the enzyme environment and in the gas-phase. For the gas-phase charge calculations, 
each frame of the QM/MM MD trajectory was extracted as a separate structure and pseudo-
minimized (minimization with 0 steps) to obtain the QM region with link atoms. Subsequently, 
a single-point QM calculation was done for each QM region structure using sqm (as 
implemented in Amber) to obtain the Mulliken charges. The results on key atoms are reported 






Figure S7. QM region with link atoms (in green). Atom names shown for selected heavy atoms, whose 




Table S3. Mulliken charges for WT OXA-48 and ceftazidime. 
QM atom 







KCX-OQ1 -1.01 -0.59 0.41 -0.93 -0.56 0.36 
KCX-OQ2 -0.91 -0.80 0.11 -0.86 -0.74 0.12 
KCX-C 0.98 0.83 -0.15 0.94 0.81 -0.13 
DW-O -0.85 -0.76 0.09 -0.84 -0.73 0.11 
CTZ-O -0.65 -1.0 -0.35 -0.56 -0.92 -0.37 
CTZ-C 0.71 0.91 0.20 0.69 0.89 0.20 
CTZ-OG -0.34 -0.59 -0.26 -0.34 -0.6 -0.26 
 
Table S4. Mulliken charges for WT OXA-48 with a ‘disordered’ Ω-loop and ceftazidime. 
QM atom 







KCX-OQ1 -1.01 -0.59 0.41 -0.93 -0.56 0.36 
KCX-OQ2 -0.91 -0.80 0.11 -0.86 -0.74 0.12 
KCX-C 0.98 0.83 -0.15 0.94 0.81 -0.13 
DW-O -0.85 -0.76 0.09 -0.84 -0.73 0.11 
CTZ-O -0.65 -1.0 -0.35 -0.56 -0.92 -0.37 
CTZ-C 0.71 0.91 0.20 0.69 0.89 0.20 





Table S5. Mulliken charges for R214S OXA-48 and ceftazidime. 
QM atom 







KCX-OQ1 -0.94 -0.59 0.35 -0.89 -0.56 0.33 
KCX-OQ2 -0.89 -0.78 0.11 -0.86 -0.74 0.12 
KCX-C 0.96 0.83 -0.14 0.94 0.81 -0.13 
DW-O -0.93 -0.79 0.14 -0.87 -0.76 0.11 
CTZ-O -0.69 -1.00 -0.31 -0.56 -0.88 -0.32 
CTZ-C 0.73 0.93 0.20 0.70 0.91 0.21 
CTZ-OG -0.32 -0.60 -0.27 -0.34 -0.62 -0.28 
 
Table S6. Mulliken charges for OXA-163 and ceftazidime. 
QM atom 







KCX-OQ1 -0.94 -0.61 0.33 -0.90 -0.59 0.32 
KCX-OQ2 -0.89 -0.79 0.10 -0.86 -0.75 0.11 
KCX-C 0.97 0.84 -0.13 0.94 0.82 -0.12 
DW-O -0.92 -0.82 0.10 -0.88 -0.81 0.06 
CTZ-O -0.67 -1.00 -0.33 -0.57 -0.90 -0.33 
CTZ-C 0.73 0.92 0.20 0.70 0.90 0.21 




Clustering of the acylenzyme was done based on five 50 ns MD simulations (1250 
frames/simulation) per acylenzyme model (OXA-48 with (dis)ordered Ω-loop, OXA-48 
Arg214Ser, OXA-163). All MD simulations were combined into one clustering calculation by 
stripping all solvent molecules and parts of the protein that did not match between all enzymes 
(e.g β5 - β6 loop in OXA-48). Trajectories were aligned based on Cα-atoms of 12 residues near 
the active site (CTZ, Thr71-Pro75, Ser118, Lys208-Tyr211, Lys218), and the substrate 
orientations were clustered into four clusters (using a sieve of 20) based on the RMSD of CTZ 
heavy atoms. The clustering analysis does not show any significant differences between the 
different enzyme models near the formed ester bond and the electrophilic carbon, but larger 
deviations between enzymes are seen for the oxyimino and thiazole groups. As depicted in 
Figure S8, OXA-48 with a newly constructed Ω-loop is seen to sample one orientation not 
observed for other enzymes (green cluster), as it has more space in the active site for substrate 






Figure S8. Acylenzyme orientations during extended MD from k-means clustering analysis. 
Representative structures (cluster centroids) are shown of the largest clusters (most sampled 
orientations) for OXA-48 (grey), OXA-163 (magenta), OXA-48 Arg214Ser (cyan), and OXA-48 with 
distorted Ω-loop (cyan & green). 
 
Oxyanion Hole Hydrogen Bond Distances 
 
 
Figure S9. The oxyanion hole, formed by backbones of Ser70 (the AE) and Tyr211, stabilises the 
formation of a tetrahedral intermediate (hydrogen bonds highlighted in violet). 
 
Because oxyanion hole interactions are known to stabilise the forming tetrahedral 
intermediate structure, distances of these hydrogen bonds (formed by the backbones of Ser70 




MM MD simulations per enzyme (for the acylenzyme), and from four 20 ps QM/MM MD 
simulations per enzyme (for the tetrahedral intermediate). Distance measurements are 
presented in Figures S10-S13. Overall, distances are very similar, and do not correlate with 
differences in the reaction barrier between the different enzyme models. 
 
 
Figure S10. Hydrogen bond distances between the mainchain of Tyr211 and ceftazidime in the oxyanion 






Figure S11. Hydrogen bond distances between the mainchain of Ser70 and ceftazidime in the oxyanion 
hole from 50 ns MM/MD (measured from five MD simulations per acylenzyme model). 
 
Figure S12. Oxyanion hole distances between Ser70 backbone and ceftazidime in the tetrahedral 





Figure S13. Oxyanion hole distances between Tyr211 backbone and ceftazidime in the tetrahedral 




Figure S14. Three observed rotamers of Leu158. Representative structures are highlighted for 
structures where the C-Cα-Cβ-Cγ dihedral angle (χ1) is approximately 50° (g+; cyan), 170° (t; grey), 





Figure S15. Leu158 C-Cα-Cβ-Cγ dihedral (χ1) values measured from five 50 ns MD simulations for 
each enzyme. Three different rotamers are observed for each enzyme during MD simulations: around 
50°, 170° and 290° (g+, t, and g-, respectively).  The orientation found in the apoenzyme corresponds 
to the 170° orientation, and the two different orientations mainly occur for OXA-48. 
 
Extended MD Simulations: Stability, Loop Conformation and Free Energy Barriers 
 
To further inspect the stability of the simulation systems and check for possible of 
conformational changes in the studied OXA-48 variants, we ran five additional independent 
120 ns MD simulations each for the acylenzymes of OXA-48, OXA-163 and OXA-48 R241S 
(in binding mode 1 and with the ordered Ω-loop). Measurement of the RMSD for Cα-atoms 
(excluding the first flexible five residues in the N terminus) indicates that all three systems are 





Figure S16. Cα-RMSD of five 120 ns MM MD simulations for OXA-48 (left), OXA-48 Arg214Ser 
(middle), and OXA-163 (right). 
 
The β5 – β6 loop movement in OXA-48 and OXA-48 R214S was further inspected 
from the 120 ns MD simulations by clustering the sampled loop orientations based on Cα-
RMSD. All five OXA-48 trajectories and five OXA-48 R214S trajectories were aligned on Cα-
atoms of residues 29-211 & 219-265 (excluding five residues from the N-terminal end), and 
then divided in 5 clusters based on Cα-RMSD of the β5 – β6 loop (residues 212-218). 
Clustering was performed with the k-means algorithm as implemented in cpptraj with a sieve 
of 20. For the majority of simulation time, the β5 - β6 loop in OXA-48 and in OXA-48 R214S 
sample the same conformational space (70% and 76% in clusters 1-3 for OXA-48 and OXA-
48 R214S, respectively, with populations ≥ 20% for each enzyme/cluster). Although the 
remainder of the time (30% and 23% for OXA-48 and OXA-48 R214S, respectively) the loop 
conformations are slightly different, it is clear that the mutation does not lead to a significant 





Figure S17. Clustering of the β5 - β6 loop (k-means clustering based on loop backbone RMSD after 
alignment on the rest of the protein, into 5 clusters) of 5x 120ns simulations of both OXA-48 and OXA-
48 R214S. Loop carbons are coloured by cluster as follows: 1 green, 2 magenta, 3 yellow, 4 cyan and 
5 orange. Ceftazidime acylenzyme and the Ω-loop are also shown, for reference. 
Additionally, we performed one QM/MM (DFTB3/ff14SB) US simulation per enzyme 
variant by taking a starting structure from the 120 ns MD simulations. To make the calculated 
energetics comparable with the ones calculated for starting structures taken from 1 ns MD 
simulation, the structure for each variant was chosen so that Leu158 conformation and active 
site hydration replicate the ones observed in the original starting structures (i.e. Leu158 
dihedral is 50° for OXA-48, and 170° for OXA-48 Arg214Ser and OXA-163). Results from 2 
ps QM/MM US simulations, using the same procedure as applied previously, indicate similar 
free energies are obtained as with snapshots from the initial short 1 ns MD simulation (Table 
S7). 
Table S7. Free energy barriers calculated with DFTB3/ff14SB umbrella sampling from extended MD 
snapshots. 
Enzyme Time Δ‡Gcalc 
(kcal/mol) 
OXA-48 50 ns 12.42 
OXA-48 
R214S 
120 ns 7.45 




Chapter 6 – Dissection of carbapenem hydrolysis by the OXA-48 β-
lactamase reveals the origin of difference in efficiency 
 
 Chapter 6 comprises a draft manuscript titled “Dissection of carbapenem hydrolysis by 
the OXA-48 β-lactamase reveals the origin of difference in efficiency”. The following version, 
i.e. the first draft, was written by myself with text editing from my supervisor Marc van der 




OXA-48 β-lactamases are frequently encountered in bacterial infections caused by 
carbapenem-resistant Gram-negative bacteria. Due to the importance of carbapenems in 
treatment of healthcare-associated infections and the increasingly wide dissemination of OXA-
48 enzymes on plasmids, these enzymes are of high clinical significance. Notably, OXA-48 
hydrolyses imipenem more efficiently than other common carbapenems, such as meropenem. 
Here, we use extensive multi-scale simulations of imipenem and meropenem hydrolysis to 
dissect the differences in reactivity of possible conformational substates of the carbapenem 
acylenzymes. We highlight in detail which active site interactions lead to most efficient 
hydrolysis, including the orientation of the carbapenem 6α-hydroxyethyl group, and we 
correctly identify the experimentally observed difference in hydrolysis efficiency. In addition 
to increased insights into carbapenem breakdown by OXA β-lactamases, which may aid design 
of new antibiotics, our approach exemplifies the combined use of atomistic dynamics 
simulations and multi-scale reaction simulations to determine different possible enzyme-





The World Health organization describes antibiotic resistance as “...one of the biggest 
threats to global health, food security, and development today.”320 Antibiotic resistance arises 
naturally,321 but it is considerably accelerated by the current excessive use of antibacterial 




medicine, but has additionally expensive implications e.g. for global economy and food 
production.206, 323, 324 Moreover, we are currently living in the so-called antibiotic discovery 
void: discovering new and safe antibacterials, especially against Gram-negative bacteria, is 
difficult, time-consuming, and often unprofitable for big pharmaceutical companies.13, 325 β-
Lactam antibiotics offer broad-spectrum antibacterial activity against Gram-negative bacteria 
and persist as the most prescribed drugs in clinical practice.18 The significance of β-lactams in 
healthcare is highlighted by the World Health Organization, who has included multiple 
different β-lactam antibiotics in the Model List of Essential Medicine.26 All these antibiotics 
contain a four-membered β-lactam ring, which ensures antibiotic binding to penicillin-binding 
proteins and consequently inhibition of bacterial cell wall biosynthesis.50, 326 Clinically used β-
lactam compounds can be divided into four different groups: penicillins, cephalosporins, 
carbapenems, and monobactams, of which especially carbapenems play a critical role as potent 
“last resort” antibiotics.24 
Emerging resistance against β-lactams is evident, and currently β-lactamase enzymes 
are the main resistance mechanism against these drugs (especially in Gram-negative 
bacteria).49 β-Lactamases prevent antibiotic action by hydrolysing the β-lactam ring, which 
prevents antibiotic binding to their ultimate target in cells. According to the Ambler 
classification, β-lactamases are divided into four major subgroups: serine-β-lactamases (SBLs) 
are classes A, C, and D, and metallo-β-lactamases (MBLs) class B.63 The hydrolysis 
mechanism differs between SBLs and MBLs, as SBLs utilise a nucleophilic serine residue and 
MBLs employ zinc cofactors.49 Class D SBLs are referred to as OXA enzymes, the name 
stemming from the term oxacillinase,288 and they are currently of interest due to their wide 
spread globally as well as due to their ability to inactivate carbapenems. OXAs include five 
subgroups of recognised carbapenemases: OXA-23, OXA24/40, OXA-51, and OXA-58 β-
lactamases are mainly found in Acinetobacter baumannii, while OXA-48-like β-lactamases are 
common in Enterobacterales.221 
Focusing on Enterobacterales, OXA-48 β-lactamases are among the most commonly 
diagnosed carbapenemases in clinical samples.218 Their activity is directed against imipenem, 
but other carbapenem substrates (such as meropenem and ertapenem) are also hydrolysed, 
albeit slowly.226 The specific origin of this imipenemase activity is not well established, even 
though variations in measured hydrolysis rates between OXA-48 variants hint to structural 
moieties contributing to specific hydrolytic phenotypes. In OXA-163, a partial deletion of the 
β5-β6 loop (Arg214-Pro217) and one amino acid substitution (Ser212Asp) expands the 




ceftazidime) at the expense of efficient imipenem breakdown.230 Further studies show that the 
β5-β6 loop plays a role in acquired carbapenemase activity.242, 243, 245 In recent years, structural 
studies have yielded a variety of OXA-48 crystal structures with carbapenems, which shed new 
light on the acylenzyme (AC) intermediate state.71, 233, 239-241 Intriguingly, even when the β5-β6 
loop is suggested to influence carbapenem activity, the only interaction between the substrate 
and loop residues (Thr213-Lys218) are hydrogen bonds to a bridging water molecule between 
imipenem 6α-hydroxyethyl hydroxyl and Thr213.71, 233 Furthermore, carbapenem tail groups 
(C2 substituents) seem to be dynamic and able to adopt multiple conformations, which suggests 
they do not form strong interactions with the protein.241 
 
 
Figure 6.1. Crystal Structures of OXA-48 with Carbapenems. Acylenzyme structures of OXA-48 with 
imipenem (PDB ID 6P97, green sticks) and meropenem (PDB ID 6P98, light pink sticks) show a very 
similar binding pose for both substrates, where mainly the orientation of carbapenem tail group 
differs.71 The Ω-loop is highlighted in orange, the β5-β6-loop in yellow, and relevant active site 






The standard hydrolysis mechanism of SBLs with β-lactams consists of acylation 
followed by deacylation.49 Both acylation and deacylation include the formation of a shortly 
lived tetrahedral intermediate (TI) through a nucleophilic attack; the TI collapses to yield either 
a covalent AC structure (after acylation), or the final hydrolysed product (after deacylation). In 
both reactions, the nucleophile, which is Ser70 in acylation and a water molecule (deacylating 
water, DW) in deacylation, is activated via proton abstraction by a general base. For OXA 
enzymes, this general base is a carboxylated lysine residue (Lys73).222, 223 Notably, Lys73 
needs to be carboxylated for hydrolysis to take place, and its carboxylation is reversible and 
pH dependent, i.e. a carboxylation is observed to a higher degree at higher pH values.223 
Characteristic only for carbapenems, the pyrroline ring can undergo Δ2 → Δ1 tautomerization 
in the AC state, the Δ1 tautomer also having two stereoisomers (R or S). For class A SBLs, the 
Δ2 tautomer has been suggested to be the catalytically competent form, whereas Δ1 would 
essentially inhibit the enzyme.247 For OXA-48s, all three tautomers have been observed in AC 
crystal structures,71, 233, 240, 241 but based on NMR studies, the hydrolysis product is suggested 
to be either the Δ2 or R-Δ1 tautomer.252 
 
Scheme 6.1. Top: Structures of meropenem and imipenem with atom numbering, the 6α-hydroxyethyl 
group highlighted in red. Bottom: Deacylation mechanism in OXA-48 with a carbapenem substrate (Δ2 
tautomer). Starting from the acylenzyme, the antibiotic is deacylated via tetrahedral intermediate 





Kinetics measurements suggest that for OXA-48-like β-lactamases, deacylation is the 
rate-limiting hydrolysis step in carbapenem breakdown.233 The authors suggested that the 
impaired imipenemase activity in the ESBL-like OXA-163 is due to a larger active site, which 
would not constrain the substrate in deacylation-compatible conformations. Molecular 
dynamics simulations of the non-covalent complexes of OXA-48 and OXA-163 with both 
meropenem and imipenem were conducted (a single trajectory for each complex), which may 
indicate differences in stability. However, the measured Km values for OXA-48 with imipenem 
and meropenem are highly similar (according to one assay, 11 and 13 μM, respectively)226, 
which indicates that there is likely no significant difference in the initial Michaelis complex 
stability. The difference in the inactivation efficiency of imipenem compared to meropenem 
should thus be related to a difference in the deacylation step. To inspect differences in catalysis 
for carbapenems on an atomistic level, we simulate the TI formation in deacylation, i.e. the 
identified rate-limiting step, for both imipenem and meropenem with OXA-48 using combined 
quantum mechanics/molecular mechanics (QM/MM) simulations. Our simulations support the 
hypothesis of the dynamic nature of carbapenem substrates in the AC state. We identify which 
conformations of the 6α-hydroxyethyl group allow for efficient deacylation. Additionally, 
active site hydration around the carboxylated Lys73 is observed to affect the calculated free 
energy barriers, as has been noted previously for ceftazidime hydrolysis by OXA-48 
enzymes.257 Based on further analysis of the reaction simulations, efficient carbapenem 
breakdown results both from decreased hydration around carboxy-Lys73 and from subtle 




Computational methods and details for system setup are described in detail in the SI. 
To summarise, models of OXA-48 with imipenem and meropenem were prepared based on 
corresponding acylenzyme (AC) crystal structures (PDB IDs 6P9771 and 6P9871 for imipenem 
and meropenem, respectively). The ff14SB parameter set was used for the protein,100 
parameters and partial charges for non-standard residues (acylated carbapenems and 
carboxylated lysine) were derived with the R.E.D. Server.172 Both systems were briefly 
minimised, heated from 50 K to 300 K (in 20 ps), and then the dynamics in the AC state were 
simulated for 200 ns using Langevin dynamics (collision frequency 0.2 ps-1) with a 2 fs 




hydrogens were restrained using the SHAKE algorithm. Starting structures for QM/MM185 
were chosen from MD simulations based on visual inspection of the active site hydration and 
the 6α-hydroxyethyl orientation; the 6α-hydroxyethyl orientation was kept from changing 
during subsequent US by applying a mild dihedral restraint  (except for orientation I). Free 
energy barriers for the first (rate-limiting) step of deacylation for different active site 
conformations were determined from three separate QM/MM US calculations.297 Two reaction 
coordinates were employed in US, one for the nucleophilic attack and one for the proton 
transfer. Sampling time in each window was 2 ps, and DFTB2 (SCC-DFTB)158, 327, 328 was used 
as the QM method for QM region consisting of 43 and 46 atoms for imipenem and meropenem, 
respectively (including link atoms, depicted in Figure S1, Section 6.6). Free energy surfaces 
were constructed from 399 individual US windows. The Weighted Histogram Analysis Method 
(WHAM)186, 329 was used to construct the free energy surfaces, and the minimum energy paths 
were analysed using the Minimum Energy Path Surface Analysis (MEPSA) program298. All 
simulations and trajectory analysis were done using the Amber18 software package166 
(pmemd.cuda299, 301 for MM MD, and sander for QM/MM calculations). 
 
6.4 Results and discussion 
 
6.4.1 Acylenzyme dynamics 
 
AC dynamics for both imipenem and meropenem complexed with OXA-48 were 
explored by running five 200 ns MM MD simulations for each complex, the first 50 ns were 
excluded from trajectory analysis to allow time for system equilibration. For both carbapenems, 
the salt bridge between C3 carboxylate and Arg250 was preserved during simulations, and the 
C7 carbonyl stayed in the oxyanion hole formed by the backbone amides of Ser70 (part of the 
AC) and Tyr211. The carbapenem tail moieties sampled a range of conformations during the 
simulations, consistent with previous suggestions based on structural analysis.241 Clustering of 
imipenem and meropenem poses based on their heavy atom RMSD yielded four distinct 
clusters, which differ slightly from the poses defined in the deposited crystal structure 
coordinates by 0.8-1.8 Å and 1.7-2.5 Å for imipenem and meropenem, respectively (Figure S2, 
Table S1 and SI section “Acylenzyme Clustering” in Section 6.6). The main deviations 
between cluster centroids and the crystal structure coordinates are due to the C2 tail group 
position, as the pyrroline ring and its substituents are anchored in place by the oxyanion hole 




density beyond the sulfur atom for both imipenem and meropenem in crystal structures 6P97 
and 6P98, so the deposited substrate coordinates may not completely reliably depict the actual 
binding poses. 
During MM MD, the carbapenem 6α-hydroxyethyl group rotated to occupy three different 
orientations, which can be distinguished by the value of the C7-C6-C-O dihedral angle: around 
50°, 180°, or 290°, and these are henceforth referred to as orientations I, II, and III, respectively 
(Figure 6.2). The 6α-hydroxyethyl orientation affects interactions in the active site, because its 
hydroxyl group can hydrogen bond either with the DW (I), Lys73 carboxylate (III), or stay 
close to the crystallographically observed pose, in which its methyl group is positioned next to 
the DW and points towards Leu158 (II, Figure 6.2). The starting orientation of the 6α-
hydroxyethyl for both carbapenems is II, from the crystal structures used in model building. 
During MD, this sidechain is free to move and sample all three orientations. For meropenem, 
orientation I is sampled more than II, while III is sampled only minimally (Figure 6.2). 
Conversely, both orientations II and III are sampled more than I for imipenem. The free energy 
difference between the different orientations of the 6α-hydroxyethyl group was estimated by 
calculating the ratio of MD trajectory frames corresponding to each orientation (Z), and using 
ΔG=RTln(Z), where R is the molar gas constant and T the simulation temperature (300 K). For 
imipenem, the lowest free energy state is orientation II, with slightly higher relative energies 
of 0.6 and 0.2 kcal/mol for orientations I and III, respectively. For meropenem, orientation I 
has the lowest free energy, orientation II is slightly higher (0.6 kcal/mol) but orientation III is 
significantly higher (2.2 kcal/mol). The presence of a methyl group in the 1β-position in 
meropenem (instead of a 1β-proton in imipenem) may explain the relatively higher penalty for 







Figure 6.2. Sampling of the 6α-hydroxyethyl group of carbapenems. Left: The 6α-hydroxyethyl group 
can assume three different orientations, which can be distinguished by the C7-C6-C-O dihedral angle 
values. When the dihedral is around 50° (orientation I), the hydroxyl group is hydrogen bonded with 
the DW, and in the 180° orientation (II) the hydroxyl group can only interact with solvent. In 290° 
orientation (III), the hydroxyl group is donating a hydrogen bond to the carboxylated Lys73. Right: The 
distribution of sampled dihedral values during MM MD (5x150 ns per carbapenem). 
 
Previously, our QM/MM simulations indicated that Leu158 may play an important role 
in modulating active site hydration in the deacylation of ceftazidime by OXA-48-like 
enzymes.257 The orientation of Leu158 also differed initially between the two OXA-
48/carbapenem systems, as the Cβ-Cγ bond has rotated by 180° in the meropenem structure. 
To study if Leu158 has a similar effect in carbapenem hydrolysis as observed for ceftazidime, 
its rotamers were recorded during MD by measuring the χ1 dihedral (N-Cα-Cβ-Cγ). The 
distribution of sampled rotamers is presented in Figure S4 in Section 6.6. After the heating 
phase, Leu158 essentially always rotates away from the crystallographic g- orientation (χ1 ≈ 
290°) to the t orientation (χ1 ≈ 180°) to allow space for the 6α-hydroxyethyl moiety, which in 
turn also permits two water molecules to form hydrogen bonds with K73:OQ1. As the 




scaffold, it is likely that Leu158 does not possess a similar role in carbapenem hydrolysis to 
that suggested for cephalosporins. 
 
6.4.2 Deacylation efficiencies for the 6α-hydroxyethyl orientations 
 
Because the interactions of the 6α-hydroxyethyl group in the active site have been 
suggested to play a role in modulating β-lactamase activity towards carbapenems,222 
deacylation free energy barriers were calculated separately for all three orientations observed 
in MD for both imipenem and meropenem. Starting structures for US were chosen from the 
200 ns MM MD simulations following two criteria: a potential DW was at a suitable distance 
for nucleophilic attack, and the 6α-hydroxyethyl orientation was the desired one. For 
orientations II and III, the sidechain dihedral was restrained close to the reference values to 
avoid the substrate changing between orientations during the reaction (no restraints were 
needed for I, as no sidechain rotation during US was observed). Overall barriers were 
determined by combining sampling from three separate US calculations (with different starting 
structures), with standard deviations calculated between the free energy barriers for individual 
US simulations (Table S3 in Section 6.6). More details of the US setup and analysis are 





Figure 6.3. Free energy barriers for the three different 6α-hydroxyethyl orientations. Each bar includes 
the barrier obtained with a single water molecule hydrogen bonded to Lys73:OQ2 (lowest barrier, in 
colour; see Figure 6.4 for depiction of OQ2) and the barrier obtained with two water molecules 
hydrogen bonded to K73:OQ2 (highest barrier, in grey). Each barrier derived from three individual 
US simulations, standard deviations in parenthesis. Imipenem = green, meropenem = pink.  
 
Figure 6.3 introduces the calculated deacylation free energy barriers for the three 6α-
hydroxyethyl orientations. For all orientations, two barriers are presented, which correspond to 
two different hydration states around the general base. The lower barrier (in color) corresponds 
to a state with only one water hydrogen bonded to Lys73:OQ2 and one or two waters hydrogen 
bonded to Lys73:OQ1, while the higher barrier corresponds to a state with two water molecules 
hydrogen bonded to both carboxylate oxygens (Figure 6.4, carboxylate oxygens labelled in 
Scheme 6.1). For all hydration states, the calculated barriers follow the same trend of I < II < 
III, i.e. the lowest barriers are calculated for orientation I. Notably, the lowest barriers are 
consistently underestimated due to the QM method used (SCC-DFTB), as indicated by our 
benchmarking results (SI section “Benchmarking”). Converting the experimentally determined 
kcat values from one assay to free energy barriers using the Eyring equation gives activation 




However, despite the difference in calculated barriers and those derived from experiment, we 
expect our protocol with semi-empirical QM methods to be a reliable indicator of energetic 
trends between different enzymes active site conformations, as we have demonstrated 
previously for studying β-lactam deacylation by class A and D SBLs.189, 257 
As discussed above and in ref. 257, increased hydration around the proton-accepting 
Lys73:OQ1 is expected to impair deacylation in ceftazidime hydrolysis. A similar phenomenon 
was observed for carbapenems, with the addition that hydration around the second carboxylate 
oxygen affects reactivity as well. In orientation I, the average number of hydrogen bonds 
Lys73:OQ1 accepts during the reaction is 2.1-2.6 (calculated from the US minimum free 
energy path trajectories), which aligns with OQ1 being hydrogen bonded to two waters and 
partly to Trp157. The two subpopulations with different deacylation barriers arise from a 
change in hydration around Lys73:OQ2. For the lower barriers in Figure 6.3, the number of 
hydrogen bonds to OQ2 is 1.3-1.4, and for the higher barriers 2.1-2.3 for orientation I. The 
lowest calculated deacylation barrier, 8.5 kcal/mol, is for imipenem in orientation I with one 
water hydrogen bonded to OQ2 and two to OQ1 (Figure 6.4). The barrier increases by 1.9 
kcal/mol when another solvent molecule donates a hydrogen bond to OQ2. For meropenem, 
the barrier is raised by 3.5 kcal/mol upon introducing an additional water near OQ2. The 
hydration effect around Lys73:OQ2 indicated here has a smaller effect on calculated barriers 
than hydration around Lys73:OQ1, since having an additional water hydrogen bonded to OQ1 
raised the barrier by approximately 5 kcal/mol for ceftazidime deacylation.257 As the electrons 
are delocalised in the carboxylate anion, it is plausible that changing the interactions around 
the non-reactive oxygen affects also the charge distribution, i.e. basicity, of the reactive OQ1. 
Orientation II is observed in most OXA-48/carbapenem crystal structures 
(corresponding dihedral between 147°-192° depending on the structure and protein chain). In 
this orientation, no part of the 6α-hydroxyethyl moiety interacts with the DW or with Lys73, 
so the antibiotic may possibly not interfere with the reactive atoms. However, calculated 
deacylation barriers are increased by 2.0 for imipenem and by 1.8 kcal/mol for meropenem 
when comparing orientation II against I (with only one water hydrogen bonded to OQ2). 
Having two waters donating hydrogen bonds to both OQ1 and OQ2 further raises the barriers 
to 13.6 and 16.0 kcal/mol for imipenem and meropenem, respectively. Therefore, our 
simulations suggest that II is not the most deacylation-compatible AC orientation. 
Additionally, orientation II might hinder the presence of the DW in the active site in proximity 
to the electrophilic acyl carbon. For 93% and 87% of simulation time for imipenem and 




and the closest water falls beyond 4 Å (an arbitrary threshold distance for a feasible 
nucleophilic attack; Figure S5 in Section 6.6). This is likely due to the 6α-hydroxyethyl methyl 
group partly occupying the space in the deacylating water pocket and thereby forcing water 
further away from the AC. This is reflected in deposited crystal structures, as a suitable DW 
positioned for nucleophilic attack is not observed in any OXA-48/carbapenem complex.71, 233, 
239-241 In a previous study, orientation II was observed to obstruct the positioning of the DW in 
the active site. The authors concluded that only slight re-positioning of the methyl group of the 
6α-hydroxyethyl sidechain is needed to better accommodate a water molecule at a suitable 
distance for nucleophilic attack. However, these conclusions are based on one 10 ns MD 
simulation, which provides insufficient conformational sampling of all available substrate 
orientations. Based on our MM MD simulations as well as calculated free energy barriers, 
orientation II is less likely to contribute to efficient deacylation both due to an increase in 
required energy as well as due to the lack of suitable active site configurations to undergo 
nucleophilic attack. 
The largest increase in energetics between the two hydration states is calculated for 
orientation III, where the barriers increase 9.6 and and 5.6 kcal/mol for imipenem and 
meropenem (respectively), when changing the hydration state. For the lower barriers, OQ1 and 
OQ2 form on average 1.9-2.1 and 1.4-1.5 hydrogen bonds, respectively, for imipenem and 
meropenem complexes, while for the higher barriers the same numbers are 2.7-2.9 and 1.8-2.3. 
For the lower barriers, Leu158 has not (yet) rotated from the g- to t rotamer (Figure S4, Section 
6.6), as the starting structures were chosen almost directly after the heating phase. The g- 
rotamer of L158 allows space only for the DW near Lys73:OQ1, which was inserted to the 
active site in the starting model. Further, only one water is donating a hydrogen bond to OQ2. 
Upon MD equilibration, Leu158 rotates, allowing for active site hydration to change to two 
water molecules hydrogen bonding to both carboxylate oxygens. Subsequently, only the “high 
barrier” hydration state is sampled. This explains the large increase in activation free energy 
when comparing the two hydration substates for orientation III, as two water molecules are 
added near Lys73 as opposed to only one near Lys73:OQ2 (as for I and II). Therefore, our 
simulations indicate that III is the least deacylation-compatible AC orientation for the 
equilibrated system (where Leu158 has rotated). Experimentally, this AC orientation is seen in 
the crystal structure of OXA-48 with hydrolysed, non-covalently bound imipenem (PDB ID 
6PK0)240, where the hydroxyl part is donating a hydrogen bond to the newly-formed 
carboxylate group. As observed in our MM MD simulations of the AC, the exchange between 




true also for the hydrolysed antibiotic, in which case the rotation of this moiety can occur post-
deacylation. 
Further analysis of the US trajectories reveals that hydration around Lys73:OQ2 
correlates with the rotamer of Val120. Valine has three rotamers for the χ1 dihedral (N-Cα-Cβ-
Cγ1): g+ rotamer around 50°, t around 180°, and g- around 300° (Figure 6.4, Figure S6 in 
Section 6.6). In the starting structures for simulations, Val120 is in the t orientation for both 
carbapenems (for meropenem, partial occupancy for both t and g– rotamers were observed in 
the deposited structure, but the t rotamer was used in model building).71 The rotameric state 
can switch to either g+ or g- during MD (Figure S6 in Section 6.6). For the g+ rotamer, one of 
the methyl groups points directly to Lys73, which only leaves space for one water molecule 
next to Lys73:OQ2; this water is positioned to accept a hydrogen bond from Gln124 and to 
donate one to Lys73. Conversely, the t rotamer allows for a second water to occupy the space 
between Lys73 and Val120, where the water molecule donates hydrogen bonds to both 
Lys73:OQ2 and the Val120 backbone carbonyl. Val120 is part of motif II, which is formed by 
residues Ser118-Val120 and conserved across class D β-lactamases.222 Together with Leu158, 
it forms the so-called “deacylating water channel” in the vicinity of Lys73; this hydrophobic 
patch essentially partly shields the active site from bulk solvent.71 For other OXAs, a similar 
water channel has been proposed to open upon substrate binding to allow for water ingress into 
the active site and ergo efficient deacylation.251, 330 For OXA-48, previous comparison of 
apoenzyme and acylenzyme structures shows that substrate binding shifts the Val120 and 
Leu158 only slightly, and the water channel is permanently more open than e.g. in OXA-23.71 
Access of water into the catalytic position next to the substrate and Lys73 is necessary for 
antibiotic hydrolysis, but as we indicate above, any additional solvent in the active site will 
impair reactivity. In OXA-48, it appears that the rotamer of Val120 is an important gateway 
residue for bulk solvent to approach Lys73:OQ2, and our previous work (on ceftazidime 
hydrolysis in OXA-48-like enzymes) indicates that Leu158 can module hydration near 
Lys73:OQ1.257 Interestingly, Val120 has been mutated to a leucine in OXA-519, a single point 
mutant of OXA-48. This mutation results in increased measured hydrolysis for some 1β-methyl 
carbapenems, like meropenem and ertapenem, but decreased imipenemase efficiency.331 
Further studies indicate that OXA-519 increases the portion of β-lactone reaction products with 
respect to standard hydrolysis products for meropenem.254 Establishing the role of Val120 
mutations to the hydrolysis efficiency as well as to β-lactone formation remains as a subject 






Figure 6.4. Alternative hydrogen bond configurations found with the 6α-hydroxyethyl in orientation I. 
Left: Active site of OXA-48 with imipenem in hydrogen bond configuration 1. Val120 adopts the g+ 
rotamer, and consequently only one water molecule is forming a hydrogen bond with Lys73:OQ2. The 
6α-hydroxyethyl is in orientation I and donates a hydrogen bond to a water lodged between the Tyr211 
backbone and Thr213. Right: Active site interactions of OXA-48 with meropenem in hydrogen bond 
configuration 2. Val120 is in its t rotameric state, which allows for two waters to hydrogen bond with 
both Lys73 carboxylate oxygens. The 6α-hydroxyethyl is in orientation I but donating a hydrogen bond 
to the DW. 
 
6.4.3 Comparison of carbapenem deacylation in orientation I 
 
As presented above, orientation I of the 6α-hydroxyethyl moiety is calculated to have 
the overall lowest deacylation free energy barriers for both carbapenems. The combined free 
energy surfaces for the hydration state with lower free energy barriers are presented in Figure 
S7 (Section 6.6) for all three substrate conformations. In this section, we focus further on 
orientation I and the ‘reactive’ active site configuration with only one water molecule hydrogen 
bonded to Lys73:OQ1, and two to Lys73:OQ2 (unless otherwise stated). For this AC 
conformation, two different hydrogen bond arrangements in the active site are possible: the 
DW can donate a hydrogen bond to the hydroxyl group (named configuration 1), or the 
hydroxyl group can donate a hydrogen bond to the DW (configuration 2), see Figure 6.4. In 
MM MD, configuration (1) is sampled for 87% and 86% of simulation time for imipenem and 
meropenem, respectively. In addition to donating a hydrogen bond to the DW, the hydroxyl 
group can also donate a hydrogen bond directly to Lys73:OQ1 if the DW is displaced. This 6α-




characterised as a side product for OXA-48 with 1β-methyl carbapenems (such as 
meropenem).253, 254 The β-lactone product has been proposed to form via intramolecular 
cyclisation, where the hydroxyl group acts as a nucleophile and donates a proton to Lys73. If 
the reaction occurs without a bridging water molecule, i.e. by a direct proton transfer between 
-OH and Lys73, lactonisation is most likely lower in energy in orientation I than in III based 
on the trends observed for deacylation energetics. 
For imipenem deacylation, both configurations (1) and (2) were observed in US 
sampling. The lowest free energy barrier of 8.5 kcal/mol was calculated for configuration (1), 
and the barrier was increased by 1.9 kcal/mol for configuration (2). In addition to raising the 
free energy barriers, changing from (1) to (2) shifts the location of the transition state on the 
FES. For (1), the TS is located approximately at values –0.1 Å and 1.7 Å for the proton transfer 
and nucleophilic attack reaction coordinates, respectively. However, for (2), the TS location on 
the FES shifts to around –0.5 Å and 2.0 Å. Free energy surfaces with corresponding TS 
structures for both active site configurations are presented in Figure 6.5 and Figure S8 (Section 
6.6). With active site configuration (2), the proton transfer has progressed further at the TS, 
whereas the approach of the DW oxygen to the acyl carbon less advanced. This is potentially 
due to the additional hydrogen bond from the 6α-hydroxyethyl moiety hydroxyl decreasing the 
nucleophilicity of the DW, which requires the proton transfer reaction to have progressed 
further from the starting structure at the TS. Notably, a similar shift in the TS position on the 
FES is observed also in orientation III, where a water molecule is donating a hydrogen bond to 
the DW instead of the 6α-hydroxyethyl group (Figure S7 in Section 6.6). Mulliken charge 
analysis of the key QM atoms does not reveal many significant differences for the calculated 
charges along the reaction when comparing US calculations with either configuration (1) or (2) 




Lys73:OQ1, the charge is more positive and for DW:O the charge is more negative for 
configuration (2), as expected by the shift in the TS location towards the TI. 
 
 
Figure 6.5. Free energy surfaces and transition state structures for alternative active site hydrogen 
bond configurations. Left: Free energy surface for imipenem deacylation for the lowest calculated 
barrier in orientation I. The DW is donating a hydrogen bond to the carbapenem hydroxyl group. Right: 
Free energy surface for meropenem deacylation with the lowest calculated barrier in orientation I. The 
carbapenem hydroxyl group donates a hydrogen bond to the DW. AC=acylenzyme, TS=transition state, 
TI=tetrahedral intermediate. 
 
For meropenem, the lowest calculated deacylation barrier is 11.8 kcal/mol with an 
average of 2.3 and 1.3 hydrogen bonds accepted by K73:OQ1 and OQ2, respectively. This is 
3.3 kcal/mol higher than the lowest calculated barrier for imipenem, or 2.7 kcal/mol higher if 
the free energy penalty derived from MM MD for imipenem to form orientation I is considered 
as well. In contrast to imipenem, the hydroxyl of the 6α-hydroxyethyl moiety in meropenem 




a hydrogen bond to the DW. This rotation occurs before the TS is reached even when 
configuration (1) is present in the starting structure. Enforcing the DW to donate a hydrogen 
bond to the 6α-hydroxyethyl -OH, i.e. restraining the reaction simulations to configuration (1), 
affects the location of the TS in a similar manner to that observed with imipenem. TS locations 
for configurations (1) and (2) are at –0.2/1.8 Å and –0.5/2.0 Å (proton transfer/nucleophilic 
attack), respectively. However, changing the hydrogen bonding pattern between configurations 
has only a minimal effect on the energetics, as the barrier for (1) is 11.9 kcal/mol. Therefore, 
the decrease in activation energy for configuration (1) vs. (2) does not follow the same trend 
for meropenem as it does for imipenem. Possible reasons for this may include the presence of 
a 1β-methyl in meropenem, as this group may hinder the rotation of the 6α-hydroxyethyl group 
to better optimise further hydrogen bonds between active site residues and water molecules 
nearby. A water molecule lodged between Tyr211 and Thr213 accepts a hydrogen bond from 
the carbapenem -OH moiety in configuration (1) or donates a hydrogen bond to it in 
configuration (2) (Figure 6.5 and Figure S8 in Section 6.6). The 1β-methyl group occupies the 
space above this water and may therefore induce its displacement or the re-organization of the 
surrounding water molecules to optimise hydrogen bonds between them, which could 
subsequently lead to a change from configuration (1) to (2). Additionally, the initial 
nucleophilic approach of the DW (from 3.5 Å to 2.2 Å) with the 6α-hydroxyethyl moiety in 
orientation I and hydrogen bond configuration (1) is calculated to be slightly lower in energy 
for imipenem (Figure S9, Section 6.6). (Notably, the initial approach between the DW and the 
carbapenem is also slightly higher in energy in orientations II and III than in orientation I, 
which may contribute to their overall energetics being less favourable for deacylation). 
However, the reasons for the preference for the imipenem complex to adopt configuration (1), 
but not for the meropenem complex, are likely subtle and can result from small structural 
changes between the active site, substrate, and solvent molecules. 
 
6.4.4 Comparison with experimental data 
 
Most of the variants in the OXA-48 family are carbapenemases, with elevated 
imipenem hydrolysis rates when compared against other carbapenems.205 For OXA-48, 
experimental measurement of kcat values for imipenem hydrolysis vary between 1.5 and 22.5 
s–1, which can be converted to Δ‡G=15.7-17.3 kcal/mol using the Eyring equation. For 
meropenem, the measured kcat values range between 0.07-0.16 s




19.2 kcal/mol. Comparing these experimentally determined free energies of activation, there is 
a difference between imipenem and meropenem hydrolysis (ΔΔ‡G) of 1.4-3.5 kcal/mol, which 
is approximately the same magnitude as the strength of a single hydrogen bond (1-3 
kcal/mol).332 Hence, structural factors contributing to efficient imipenem breakdown over 1β-
methyl carbapenems are most likely to be subtle. Our QM/MM simulations suggest that 
orientation I of the 6α-hydroxyethyl moiety is the most likely AC orientation to undergo 
deacylation, together with decreased hydration around Lys73:OQ2 (i.e., only one water 
molecule donating a hydrogen bond to this carboxylate oxygen). When comparing the lowest 
free energy barriers calculated in orientation I for imipenem and meropenem (Figure 6.3), the 
difference for the two substrates is ΔΔ‡G=3.3 kcal/mol; adding the free energy penalty for the 
imipenem 6α-hydroxyethyl moiety adopting orientation I (0.6 kcal/mol, as determined from 
our MM MD simulations), the obtained ΔΔ‡G value drops to 2.7 kcal/mol. This is in excellent 
agreement with the experimentally determined range of ΔΔ‡G values, which implies that the 
difference between imipenem and meropenem deacylation may indeed be caused by the subtle 
difference in the preferred hydrogen bonding patterns involving the DW and the 6α-





We have modelled carbapenem hydrolysis by the OXA-48 β-lactamase using QM/MM 
reaction simulations. For two carbapenem substrates with differing hydrolysis efficiencies, 
imipenem and meropenem, deacylation reactions were compared to deduct the origin of the 
higher activity towards imipenem compared to other carbapenems. MM MD simulations of the 
acylenzyme complexes support that the carbapenem tail groups do not conform to any 
particular orientation but are able to adopt many different conformations. Furthermore, the 6α-
hydroxyethyl group is able to rotate and to adopt three different orientations, where it either 
interacts with the DW (I), Lys73 (III), or is rotated so that the methyl end is oriented towards 
Leu158 (II). Subsequently, deacylation was modelled for all these three orientations to 
investigate their effect on deacylation efficiency. Our calculated free energy barriers indicate 
that the most deacylation-compatible orientation is I, where the hydroxyl group interacts with 
the DW, and that the orientation III has the highest free energy barriers. 
Detailed comparison of the reaction simulations revealed two factors contributing to 




the DW and substrate. Hydration around the general base has been noted to affect predicted 
hydrolysis rates for other β-lactam substrates,257 and here we extend this argument to include 
hydration around both Lys73 carboxylate oxygens (instead of only the oxygen participating in 
proton transfer). Increase in hydration around the second, non-reactive, oxygen (Lys73:OQ2) 
was observed to correlate with higher calculated barriers, and the rotation of Val120 in turn to 
correlate with the number of water molecules near this oxygen. Another aspect influencing the 
deacylation efficiency are the hydrogen bonds in the active site involving the DW and the 6α-
hydroxyethyl sidechain. Imipenem shows a preference for the configuration where the DW 
donates hydrogen bonds to Lys73 and the 6α-hydroxyethyl hydroxyl group, with an increase 
in barrier when the hydroxyl group rotates to donate a hydrogen bond to the DW instead. This 
preference is not observed for meropenem, where the reaction simulations with both hydrogen 
bond configurations have comparable energy barriers, which are similar to that calculated for 
imipenem in the “less-favorable” orientation. Therefore, we hypothesise that the difference 
between hydrolysis activities for carbapenem substrates stems from subtle differences in the 
active site hydrogen bonding patterns, which affect the reactivity of the DW. Furthermore, our 
results indicate that active site hydration is an important determinant for catalysis in OXA-48 
enzymes, as increasing the hydration around the general base is observed to impair carbapenem 
hydrolysis. Our study highlights the importance of detailed atomistic modelling in addition to 
experimental research to determine origins of activity, as simulation protocols such as ours 
enable studying specific active site interactions during catalysis. 
 
6.6 Computational details 
 




The OXA-48 with imipenem model was set-up starting from a corresponding 
acylenzyme (AC) crystal structure (PDB ID: 6P97)71, as well as OXA-48 with meropenem 
(PDB ID: 6P98)71. In both structures, Lys73 is not carboxylated and was thus replaced by its 
carboxylated form as found in another OXA-48 + imipenem acylenzyme structure (PDB ID: 
5QB4)239. The deacylating water (DW) was added manually to both models, and all 




inspected using propKa 3.1,167 and all residues were kept in their standard state (protonated 
Lys, deprotonated Glu and Asp residues). Histidine tautomers were assigned using the reduce 
program (in Amber): all histidines were singly protonated at the ε-nitrogen except for residues 
38 and 140, which were singly protonated at the δ-nitrogen. Hydrogens were added to the 
structures using tLeap upon system preparation, and the enzyme was solvated in a 12 Å TIP3P 
water box. The systems were neutralized by randomly replacing bulk water molecules with 
Na+ counter ions (using the default TIP3P compatible ion parameters in Amber). The ff14SB 
parameter set was used for the protein.100 
Partial charges and force field parameters for the non-standard Ser70+carbapenem 
residues were derived using the restrained electrostatic potential (RESP) fitting as implemented 
in the R.E.D. Server.172 Analogous gaff parameters were substituted for any missing 
parameters.168 Parameter files for carboxylated lysine and carbapenem ACs are available as 




After system preparation, all models were initially briefly minimized for 2000 steps to 
avoid any steric clashes (1000 steps conjugate gradient and 1000 steps steepest descent). After 
minimization, the systems were heated from 50 K to 300 K in 20 ps, and subsequently 
simulated for 200 ns in the NPT ensemble. Langevin dynamics were used in all simulations 
with a collision frequency of 0.2 ps-1. MD timestep was 2 fs, and all bonds involving hydrogen 
atoms were constrained using the SHAKE algorithm. Structures during MD were recorded 
every 20 ps (10k MD frames/trajectory). The Amber18 package with Ambertools19 was used 
for all calculations,166 and specifically the pmemd.cuda MD engine for all extended MM MD 
simulations.299, 301 All trajectory analysis was done using cpptraj333 (as implemented in 
Ambertools19) excluding 50 ns from the start to allow time for system equilibration. Hydrogen 
bond analysis using cpptraj was done using the default criteria set in cpptraj (donor-acceptor 
distance less than 3.4 Å, the D-H-A angle between hydrogen bond donor and acceptor deviates 
less than 45° from a linear angle). 
Starting structures for QM/MM umbrella sampling (US) were chosen from restart files 
saved during the 200 ns MM MD simulations based on visual inspection (starting structures 




hydroxyethyl orientation and a suitable DW in place, as to not introduce big distortions through 
restraints when starting US calculations. Three different starting structures were used per free 
energy barrier (unless otherwise stated). The DFTB2 (SCC-DFTB)158, 162 method was used for 
describing the QM region consisting of either 43 or 46 atoms for imipenem and meropenem, 
respectively (Figure S1). The ester bond in the AC was restrained with a one-sided harmonic 
restraint to avoid elongation beyond 1.6 Å (force constant 100 kcal mol−1 Å−2), and the 6α-
hydroxyethyl group dihedral was restrained near its initial values during reaction simulations. 
In orientation II, the sidechain dihedral was restrained between values 150-200°, and in 
orientation III between 270-310°, the applied force constant was 50 kcal mol−1 Å−2. No dihedral 
restraints were applied in orientation I, as switching from this orientation to another one was 
not observed during US. However, distance restraints between the meropenem 6α-
hydroxyethyl hydroxyl group and an active site water molecule were applied to enforce the 
active site configuration where the DW donates a hydrogen bond the hydroxyl group. A one-
sided harmonic restraint was added for this hydrogen bond to avoid elongation beyond 2.2 Å 
(force constant of 50 kcal mol−1 Å−2). 
 
 
Figure S1. QM region in US simulations, QM atoms in red. Link atoms based along bonds indicated 
with wavy lines. 
 
Full deacylation free energy surfaces (FESs) were calculated using two reaction 
coordinates to describe the proton transfer (PT) and nucleophilic attack (NA). Reaction 
coordinate values were decreased from 0.8 Å /3.5 Å (PT/NA) in the AC to -1.0 Å /1.5 Å in the 
TI by 0.1 Å. Force constants for both reaction coordinates were 100 kcal mol−1 Å−2. Full 
deacylation free energy surfaces (FESs) were constructed by first performing US along an 




calculating the rest of the US windows using these calculations as a starting point. Initial 
sampling along the diagonal included 36 windows with values: 
 
PT 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.7 0.7 0.7 0.6 0.6 0.5 0.5 0.5 0.5 
NA 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.5 2.4 2.4 2.3 2.2 2.2 
 
PT 0.4 0.3 0.2 0.1 0.0 -0.1 -0.2 -0.3 -0.3 -0.4 -0.5 -0.6 -0.7 -0.7 -0.7 
NA 2.2 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 1.9 1.9 1.9 1.9 1.8 
 
PT -0.7 -0.8 -0.8 -0.8 -0.9 -1.0 
NA 1.7 1.7 1.6 1.5 1.5 1.5 
 
 
The whole FESs consisted of a total of 399 US windows, and the sampling time was 2 
ps/window with a 1 fs timestep. FESs were constructed using the weighted histogram analysis 
method (WHAM, Grossfield lab)329 with 19 and 21 bins for the PT and NA coordinates, 
respectively. The convergence criterium was set to 10−13. Minimum free energy paths on the 
FESs were analyzed using the Minimum Energy Path Surface Analysis (MEPSA) program.298 




Clustering of the AC orientations was done separately for imipenem and meropenem 
MM MD trajectories (excluding 50 ns from the start, five simulations per substrate with 7500 
frames per simulation). Trajectories were aligned on Cα-atoms of residues 70-73, 118-120, 
157, 158, and 209-211, and substrate orientations were clustered into four groups based on AC 
heavy atom RMSD. The kmeans algorithm (as implemented in cpptraj) was used for the 
clustering procedure with a sieve of 10. The representative structures for the four clusters are 






Figure S2. Representative structures from AC clustering for imipenem (left) and meropenem (right). 
Cluster 1, green; cluster 2, pink; cluster 3, yellow; cluster 4, orange, the crystallographic binding pose 
in cyan. 
 
Table S1. Further clustering information for the substrate binding pose for imipenem (IME) and 
meropenem (MER). Fraction represents the fraction of simulation frames belonging to the clusters and 
colour the corresponding sticks representation color in Figure S2. RMSD measured between 
carbapenem heavy atoms in the representative cluster structure and in the crystal structure. 
 







Cluster 1 Green 0.55 0.81 0.36 1.65 
Cluster 2 Pink 0.21 0.82 0.34 1.75 
Cluster 3 Yellow 0.13 1.09 0.25 2.16 
Cluster 4 Orange 0.11 1.75 0.05 2.49 
 
 
In addition to AC clustering, the active site conformations for both imipenem and 
meropenem simulations were compared by combining all trajectories and clustering the 
structures based on the common AC atoms (i.e. all atoms except C2 tail groups beyond sulphur 
and the 1β-group). Solvent molecules, counterions, and parts of the enzyme which were not 
identical between the two models were stripped before clustering. Trajectories were aligned on 




of the remaining carbapenem heavy atoms. The kmeans clustering algorithm was used to divide 
the structures in to four clusters with a sieve of 10 (as in cpptraj). 
 
 
Figure S3. Representative cluster structures for the combined clustering of imipenem and meropenem 
trajectories. Left: Clusters 1 and 2 are sampled for most of the simulation time for meropenem (green) 
and imipenem (purple), respectively. Right: For the rest of time, cluster 3 (brown) is sampled for 
imipenem and cluster 4 (cyan) for meropenem. 
 
Table S2. Combined cluster fractions in imipenem and meropenem trajectories. 
 Color Fraction (IME) Fraction (MER) 
Cluster 1 Green 0.00 0.71 
Cluster 2 Purple 0.65 0.00 
Cluster 3 Brown 0.35 0.00 
Cluster 4 Cyan 0.00 0.29 
 
 





Leu158 has been proposed to modulate the access of bulk solvent near Lys73 in 
ceftazidime deacylation.257  The orientations of Leu158 were analysed by measuring the 
sidechain χ1 dihedral angle (N-Cα-Cβ-Cγ). In both crystal structures used for model building, 
Leu158 is in the g- orientation (in OXA-48/meropenem structure,71 the residue has rotated 180° 
around the Cβ-Cγ bond). Upon MD equilibration, Leu158 essentially always adapts to the t 
state, as depicted by Figure S4. 
 
Figure S4. Sampling distribution for Leu158 rotamers in MM MD for imipenem (green) and meropenem 
(red). Leu158 rotates from the starting g- orientation (red sticks representation in the insert) to the t 
orientation (cyan) for the majority of the simulation time. 
 
MM MD Analysis 
 
To preliminarily study the effect a certain AC conformation has on the nucleophilic 
attack, the distance between the AC electrophilic carbon and the closest water molecule was 
measured. The corresponding scatter plots are presented in Figure S5, where a threshold of 4 
Å is indicated with a dashed line; distances below this threshold are regarded suitable for a 
nucleophilic attack (although the choice of this threshold value is somewhat arbitrary). For 




in all three orientations, even when the majority of the active site configurations fall beyond 4 
Å for orientations II (~180°) and III (290°). 
 
 
Figure S5. The distribution of distances from the AC electrophilic carbon to the closest water molecule 
in the active site. Distances measured for all five 150 ns simulations per system (50 ns were excluded 
from the start for each simulation, total simulation length 200 ns). Each scatter point represents a frame 
in a trajectory, different colours represent different trajectories. Dashed line at 4 Å is the used as an 
arbitrary threshold distance for determining the feasibility of nucleophilic attack, i.e. arrangements 
beyond 4 Å are not likely to undergo deacylation. 
 
Val120 Dihedral Sampling 
 
Val120 adopts three different orientations during MM MD, which can be differentiated 
by the χ1 (N-Cα-Cβ-Cγ1) dihedral angle: g+ at around 60°, t at 180°, and g- at 290°. Val120 is 
situated in the vicinity of Lys73 and Trp157, and its rotamer influences the accessibility of 
water near Lys73 (especially near Lys73:OQ2). The distribution of sampled Val120 χ1 
dihedrals is presented in Figure S6. The t rotamer, which is observed in both crystal structures 
used as starting models, is the most sampled state for both imipenem and meropenem; this 
orientation allows for two water molecules to hydrogen bond with Lys73:OQ2. When the 




OQ2, as the γ2-carbon occupies the space available for water in the case of t rotamer. The g- 
rotamer was observed the least, and it was not present in any starting structure used for US. 
 
 
Figure S6. V120 rotamer distribution in MM MD for imipenem (green) and meropenem (red). Rotamer 
label coloring corresponds to the stick color representation of the rotamer structure in the inset. 
Histograms created using 100 bins, probability distributions (solid line) obtained using the kernel 




Overall free energy barriers for different AC orientations with different hydration states 
are presented in Table S3. Barriers are calculated by combining sampling from three separate 
US calculations into one WHAM calculations (the overall sampling time being 2x3ps = 








Table S3. Free energy barriers for carbapenem deacylation from umbrella sampling. All energies in 
kcal/mol, standard deviations between barriers obtained for the three individual US calculations in 
parenthesis. Hydration state 1 = only one water donating a hydrogen bond to Lys73:OQ2, two waters 
donating a hydrogen bond to Lys73:OQ1 (except orientation III, where only one), hydration state 2 = 
two waters hydrogen bonded to both Lys73 carboxylate oxygens. 
 Imipenem Meropenem 
 Hydration state 1 Hydration state 2 Hydration state 1 Hydration state 2 
Orientation I1 8.5 (0.9) 10.4 (0.4) 11.9 (0.7) - 
Orientation I2 10.4 (0.4) 13.5 (1.0) 11.8 (0.7) 15.3 (1.1) 
Orientation II 10.5 (1.1) 13.6 (0.9) 13.6 (1.1) 16.0 (1.1) 
Orientation III 11.2 (0.6) 20.8 (1.4) 12.4 (2.0) 18.0 (0.5) 
1 DW donates a hydrogen bond to the carbapenem hydroxyl group 
2 DW accepts a hydrogen bond from the carbapenem hydroxyl group 
 
The FESs for both imipenem and meropenem for all three 6α-hydroxyethyl orientations 
are presented in Figure S7. The minimum free energy paths are illustrated with black dots. All 
surfaces are for the active site configuration, where only one water donates a hydrogen bond 
to Lys73:OQ2. In orientation I, the DW donates a hydrogen bond to imipenem 6α-hydroxyethyl 






Figure S7. Calculated free energy surfaces for imipenem (left) and meropenem (right) deacylation in 
substrate orientations I (top), II (middle), and III (bottom. The minimum free energy paths marked with 






Figure S8. Transition state structures for imipenem and meropenem in orientation I. In configuration I 
(top row), the DW donates a hydrogen bond to the 6α-hydroxyethyl group, which in turn donates a 
hydrogen bond to a water molecule between Tyr211 and Thr213. For imipenem, this water can accept 
an additional hydrogen bond from another water molecule near the imipenem 1β-proton. For 
meropenem, this additional water is shifted due to the larger 1β-methyl group. 
 
To further inspect possible differences causing the observed difference in efficiency 
between imipenem and meropenem, the initial approach of the DW to the substrate was 
inspected by US, where only the distance between the DW oxygen and the carbapenem carbon 
was used as a reaction coordinate. This was done for both imipenem and meropenem in active 
site configuration (1), where the DW donates a hydrogen bond to the 6α-hydroxyethyl group. 
Based on the calculated free energies, the energetic cost for the initial approach of the DW is 
lower for imipenem than for meropenem, which partly explains the lower calculated barriers 





Figure S9. The calculated free energy profile for the initial approach of the deacylating water molecule 
to the carbapenem electrophilic carbon. Sampling was done for 20 ps/window for three snapshots 




DFTB2 (SCC-DFTB) was used as the QM method in all US simulations. Previously, 
this method has been shown to depict deacylation in serine β-lactamases well and to distinguish 
between carbapenemases and carbapenem-inhibited class A enzymes.189 For OXA-48, the 
minimum free energy paths on DFTB2//ff14SB free energy surfaces indicate that the proton 
transfer and nucleophilic attack occur in a concerted fashion after the initial approach of the 
DW (from ~3.5 Å to 2.2 Å). The lowest calculated free energy barrier, which we expect to be 
a representative barrier for the most efficient deacylation reaction, was 8.5 kcal/mol, which is 
a significant underestimation from the experimental barrier of 16.6 kcal/mol (converted from 
a kcat of 5 s
-1 using the Eyring equation)226. To benchmark the performance of DFTB2, we 
performed transition state optimization for a representative small molecule model in the gas-
phase as well as calculated a representative deacylation potential energy surface using a higher-





Figure S10. Small molecule model of the active site used in benchmarking calculations. The transition 
state corresponds to a concerted proton transfer between K73 carboxylate and C-O bond formation 
between the substrate and water (both indicated with arrows). Notably in the gas-phase, the 6α-
hydroxyethyl group has been optimized to orientation III (with a 290° dihedral). 
The small molecule model used in benchmarking is presented in Figure S10. The gas-
phase model included methyl-capped Lys73 and imipenem acylenzyme with the DW taken 
from a representative full enzyme structure. TS corresponding to the tetrahedral intermediate 
(TI) formation in deacylation was first optimized using Gaussian16 on the M06-2X/6-31+G(d) 
level using looser criteria (with keywords Opt=(TS,calcfc,noeigentest)), and the final structure 
was optimized with tighter convergence criteria (Opt=(TS,VTight) SCF=Tight), ultrafine 
integration grid was used in all calculations (Int=UltraFine). TS was validated by visual 
inspection and normal mode calculation (one imaginary frequency at -296.63 corresponding to 
the reaction coordinates). The reactant (AC) and product (TI) structures were obtained with 
IRC calculations in both directions starting from the optimized TS, and the final IRC endpoints 
were further optimized on the same level as the final TS. TS optimisation and subsequent IRC 
calculations were done using Gaussian16.334 Single-point energies were calculated on the 
higher SCS-MP2/aug-cc-pVTZ level149, 316 (using the RIJK approximation with aug-cc-
pVTZ/C and aug-cc-pVQZ/JK auxiliary basis sets), as well as using DFTB2. RI-SCS-MP2 
calculations were done using orca 4.2.0,317, 318 and semi-empirical calculations using sqm (part 
of the Amber18 and Ambertools19 package). Since the gas-phase model was optimized to the 





Table S4. Benchmarking energies for the small molecule gas-phase system. The approximate TS 
location from US is shown for the 290° orientation (as opposed to 50°), as the gas-phase system was 
optimized to this orientation. 






M06-2X/6-31+G(d) 1.89 -0.37 19.9 kcal/mol 
RI-SCS-MP2/aug-cc-pVTZa - - 22.5 kcal/mol 
DFTB2a,b - - 14.5 kcal/mol 
DFTB2/ff14SB FES (OXA-48)c 2.0 -0.4 11.2 kcal/mol 
a Energy difference from single-point energies on M06-2X/6-31+G(d) optimized AC and TS structures. 
b TS could not be optimized in the gas-phase with DFTB2 as no saddle point is indicated between the AC minimum 
and the tetrahedral intermediate. 
c The approximate TS location on the QM/MM free energy surface. 
 
To study the performance of DFTB2 in the whole enzyme model, deacylation potential 
energy surfaces were calculated for imipenem in the 50° dihedral orientation using DFTB2 and 
M06-2X/def2-TZVP134, 335 levels of theory (Figure S11). The LBFGS algorithm was used for 
energy minimization with a convergence criterium of 0.01 mol-1 Å-1. Force constants for 
restraints used in US were increased to 5000 kcal mol−1 Å−2, and residues further than 5 Å from 
the substrate were restrained (50 kcal mol−1 Å−2 force constant). Energy correction using DFT 
was obtained by calculating single-point energies for the QM region on the M06-2X/def2-
TZVP level (using Orca 4.2) and taking the difference between the M06-2X and DFTB2 
energies (interactions terms between the QM and MM regions were thus calculated using 






Figure S11. Potential energy surfaces for OXA-48/imipenem in orientation I calculated using DFTB2 
(left) or M06-2X/def2-TZVP (right). Energy at the approximate TS position (-0.1/1.7 for PT and NA 
RCs, respectively) is 9.0 kcal/mol for DFTB2, and 15.3 kcal/mol for M06-2X. SCF did not converge 
satisfactorily for two structures in the high energy region and were hence left out from the M06-2X 




Mulliken charges for the key atoms in the QM region were calculated from extended 
US at the AC, TS, and TI minima, values determined from the minimum free energy path. Each 
state was sampled for 20 ps (starting from the last structure after the initial 2 ps sampling), and 
charges were calculated every 20 fs and averaged to obtain one value per atom. Key atoms with 






Figure S12. QM region atoms (for meropenem) with link atoms highlighted in cyan. Names shown for 
the key atoms, for which Mulliken charges were recorded along the reaction. 
 
All Mulliken charges show the same trend, where during a reaction a positive charge 
emigrates to Lys73 carboxylate (proton acceptor), and the substrate carbonyl oxygen becomes 
more negative due to negatively-charged TI formation. The transition state location shifts 
slightly when the hydrogen bond pattern between the DW and the 6α-hydroxyethyl group 
changes, which results in different charges at the transition state. When the DW accepts a 
hydrogen bond from the carbapenem hydroxyl, the transition state location shifts to more 
negative values for the proton transfer reaction coordinate, i.e. closer to the TI structure. This 
results in more positive Lys73 carboxylate oxygen charges and more negative DW:O charges. 
No significant changes are seen between different active site conformations when comparing 
the change between endpoint charges (AC → TI). 
 
Table S5. Mulliken charges for the key QM region atoms for imipenem in the 50° orientation. DW 
donates a hydrogen bond to the 6α-hydroxyethyl hydroxyl group. Locations for the minima and TS 
(proton transfer/nucleophilic attack values): AC 0.8/3.4, TS -0.1/1.7, TI -1.0/1.5. 
QM atom 
Enzyme 
QAC QTS QTI ΔQTS-AC ΔQTI-AC 
K73-OQ1 -0.84 -0.65 -0.51 0.19 0.33 
K73-OQ2 -0.76 -0.73 -0.67 0.04 0.09 
K73-C 0.74 0.72 0.71 -0.02 -0.03 
DW-O -0.69 -0.61 -0.59 0.08 0.10 
IME-O -0.60 -0.80 -0.87 -0.20 -0.26 
IME-C 0.66 0.73 0.74 0.06 0.08 





Table S6. Mulliken charges for the key QM region atoms for imipenem in the 50° orientation. DW 
accepts a hydrogen bond from the 6α-hydroxyethyl hydroxyl group. Locations for the minima and TS: 




QAC QTS QTI ΔQTS-AC ΔQTI-AC 
K73-OQ1 -0.85 -0.59 -0.52 0.26 0.33 
K73-OQ2 -0.76 -0.68 -0.67 0.08 0.09 
K73-C 0.74 0.72 0.71 -0.02 -0.03 
DW-O -0.66 -0.74 -0.58 -0.08 0.08 
IME-O -0.60 -0.74 -0.87 -0.14 -0.27 
IME-C 0.66 0.70 0.74 0.04 0.08 
IME-O(H) -0.58 -0.60 -0.57 -0.02 0.01 
 
Table S7. Mulliken charges for the key QM region atoms for meropenem in the 50° orientation. DW 
accepts a hydrogen bond from the 6α-hydroxyethyl hydroxyl group. Locations for the minima and TS: 
AC 0.8/3.4, TS -0.5/1.9, TI -1.0/1.5. 
QM atom 
Enzyme 
QAC QTS QTI ΔQTS-AC ΔQTI-AC 
K73-OQ1 -0.85 -0.57 -0.52 0.28 0.33 
K73-OQ2 -0.75 -0.69 -0.66 0.07 0.09 
K73-C 0.74 0.71 0.71 -0.03 -0.03 
DW-O -0.67 -0.76 -0.59 -0.08 0.08 
MER-O -0.58 -0.72 -0.85 -0.14 -0.27 
MER-C 0.66 0.70 0.74 0.04 0.08 
MER-O(H) -0.54 -0.59 -0.58 -0.05 -0.03 
 
Table S8. Mulliken charges for the key QM region atoms for meropenem in the 50° orientation. DW 
donates a hydrogen bond to the 6α-hydroxyethyl hydroxyl group. Locations for the minima and TS: AC 
0.8/3.4, TS -0.1/1.7, TI -1.0/1.5. 
QM atom 
Enzyme 
QAC QTS QTI ΔQTS-AC ΔQTI-AC 
K73-OQ1 -0.84 -0.67 -0.53 0.18 0.32 
K73-OQ2 -0.76 -0.72 -0.68 0.03 0.07 
K73-C 0.74 0.72 0.71 -0.02 -0.03 
DW-O -0.69 -0.62 -0.60 0.07 0.09 
MER-O -0.58 -0.78 -0.85 -0.20 -0.27 
MER-C 0.66 0.72 0.74 0.06 0.08 






Chapter 7 - Acylation mechanism of the β-lactamase inhibitor 




As briefly discussed in Section 1.2, a common treatment option for severely resistant 
bacterial infections is combination therapy.25 This means that an antibiotic is administered 
together with a β-lactamase inhibitor, which prevents β-lactamases from inactivating the drug 
prior to it binding to the target proteins. As combination therapy has proven to be useful in 
clinical practice,261, 336-338 the field of β-lactamase inhibitor development is evolving fast.283 
Avibactam (depicted in Figure 1.1), a non-β-lactam β-lactamase inhibitor belonging to 
diazabicyclooctanones (DBOs), is a recent example of this.31 Avibactam was approved for 
clinical use in 2015 in combination with ceftazidime (Figure 1.1), and the combination is sold 
under tradename Avycaz.339 As shown in Figure 4.5, the β-lactam is replaced by cyclic urea in 
the DBO scaffold. Generally, avibactam exhibits broad-spectrum inhibition against SBLs, such 
as KPC-2 and OXA-48, but lacks inhibitory activity against MBLs.34, 260, 340 Even though 
avibactam resembles β-lactams, its inhibition mechanism has been shown to be distinctly 
different. Avibactam is acylated in an analogous fashion to β-lactams to form a covalent 
acylenzyme (AC), but the AC is not deacylated using a water nucleophile like β-lactams. 
Instead, avibactam recyclizes to form an intact inhibitor molecule, which can react with further 
enzymes.31 This is excluding KPC-2 β-lactamases, where an additional route involving 
avibactam fragmentation was observed.34 Similar recyclization is not observed for any 
“traditional” mechanism-based inhibitors, and it is most likely enabled by decreased ring strain 
in the five-membered urea ring compared to the corresponding four-membered β-lactam ring.31 
OXA-48 inhibition by avibactam is discussed in depth in Section 4.6. To summarise, 
in vitro kinetics indicate that avibactam is readily acylated by OXA-48, but that the 
recyclization occurs slowly. The measured acylation efficiency k2/Ki is 1.4 ± 0.1 x 10
3 M-1 s-1, 
whilst the recyclisation rate constant koff is measured to be 1.2 ± 0.4 x 10
-5 s-1 with a half-life of 
1000 ± 300 minutes.34 Multiple crystal structures of OXA-48 with covalently-bound avibactam 
(AC state) are deposited in the Protein Data Bank, and these structures yield information of the 
binding pose and interactions with active site residues (see Figure 4.10).235, 255, 264 However, 




mechanism. At least two different reaction pathways have been proposed, and these are 
presented in Figure 7.1. The first mechanism incorporates a neutral, non-carboxylated Lys73 
as a general base, which acts as a proton acceptor activating the nucleophilic Ser70. 
Subsequently, avibactam ring opening and nitrogen protonation occur by shuffling a proton 
from Lys73 to avibactam via Ser118.235 This mechanism is henceforth again referred to as 
pathway 1, and it is derived from a suggested “universal” reaction scheme for avibactam with 
SBLs. However, it is known that for β-lactam hydrolysis, Lys73 needs to be in its carboxylated 
form for efficient catalysis to take place.223 Another proposed pathway employs a carboxy-
Lys73 as the initial proton acceptor, and avibactam is subsequently protonated by Lys208 via 
Ser118.264 This mechanism will be referred to as pathway 2. For pathway 2, slow recyclization 
rates are attributed to the preference of Lys73 being decarboxylated in the AC state, which 
would essentially hinder reactivity.264 Pathways 1 and 2 are summarised again in Figure 7.1. 
 
 
Figure 7.1 Three proposed mechanisms for avibactam acylation by OXA-48. Top: In pathway 1, the 
nucleophilic Ser70 is activated via proton transfer to a neutral Lys73 (in its standard amine form). After 
TI formation, the five-membered ring in avibactam opens and avibactam nitrogen is protonated by 
Lys73 via Ser118. Bottom: In pathway 2, a carboxylated Lys73 acts as the proton acceptor going from 
MC to TI. Subsequent avibactam protonation occurs by Lys208 via Ser118. 
 
In this chapter, we utilise both MM MD and QM/MM methods to compare the 




models for OXA-48 with either a decarboxylated and neutral Lys73 (for pathway 1) or a 
carboxylated Lys73 (for pathway 2) were constructed. The stabilities of the formed MCs were 
inspected by 10x50 ns MM MD simulations. Further, the presented reaction pathways were 
compared by calculating their corresponding potential energy profiles using QM/MM 
calculations with the nudged elastic band (NEB)341 method. Both pathways were broken down 
into two separate NEB calculations, where the first calculation corresponds to the tetrahedral 
intermediate (TI) formation via a nucleophilic attack, and the second the subsequent avibactam 
ring opening and nitrogen protonation. Both the MM MD and QM/MM NEB calculations 
indicate that pathway 2, where a carboxylated Lys73 acts as a general base, is more feasible 
than pathway 1. 
 
7.2 Computational methods 
 
7.2.1 System set-up 
 
Non-covalent Michaelis complexes of OXA-48 with avibactam were prepared using a 
crystal structure of covalently-bound avibactam as a template (PDB ID 4S2K).235 Ser70-
avibactam AC was replaced by an intact serine residue and non-covalently coordinated 
avibactam. Lys73 was either kept in its neutral form or replaced by a carboxylated lysine as 
found in analogous systems (e.g. in OXA-48/imipenem complex, PDB ID 5QB4).239 Partial 
charges (RESP) and force field parameters for carboxy-Lys73 were derived using the 
constrained charge derivation as implemented in the R.E.D. Server,172 any missing parameters 
were taken from analogous gaff168 parameters. For avibactam, gaff parameters with AM1-BCC 
partial charges were derived using antechamber (part of Ambertools19).170, 171 Any clashing 
water molecules (closer than 2.5 Å to any avibactam heavy atom) were removed, otherwise all 
crystallographic waters were retained. Both systems were solvated in a 10 Å box of TIP3P 
water, and existing charges were neutralised by replacing water molecules by counterions. The 
protonation states of ionisable residues were inspected using propKa3.1167, and subsequently 
kept in their standard state based on the predicted pKa values (Glu/Asp deprotonated, Lys 
protonated apart from Lys73). All histidine residues were singly protonated at the ε-nitrogen, 
except His140, which was singly protonated at the δ-nitrogen. Hydrogens were added using 




calculations. Both prepared systems consisted of 32292 atoms. Active sites of both starting 
structures are illustrated in Figure 7.2. 
 
 
Figure 7.2 Starting MC models for the two studied OXA-48/avibactam systems. Left: Lys73 is kept in 
its neutral form. Right: Lys73 is carboxylated, Lys208 is protonated in both systems. 
 
7.2.2 Molecular dynamics simulations 
 
After initial preparation, the systems were minimised in three parts: i. only water 
molecules allowed to move, other parts restrained, ii. all atoms except Cα allowed to move, 
and finally iii. all atom positions minimized (restraint weights of 50 kcal/mol/Å2 applied in i. 
and ii.). Each minimisation step consisted of 1000 steps using the steepest descent method 
followed by 1000 steps of the conjugate gradient method. After minimisation, systems were 
heated from 50 K to 300 K in 50 ps, and subsequently simulated for 50 ns in the NPT ensemble. 
All simulations were performed using Langevin dynamics with a 0.2 ps-1 collision frequency 
and a 2 fs timestep. Ten independent replicas were run for both systems to inspect the stability 
of the non-covalent MC model. In addition, a 10 ns MD run straight after heating using 
restraints was run to equilibrate the structure before QM/MM MD. To preserve the desired 
initial binding pose, restraints were applied for the Ser70-Lys73 hydrogen bond (<2.0 Å, 10 
kcal/mol/Å2), avibactam carbonyl oxygen and Tyr211 backbone amide (<2.5 Å, 10 
kcal/mol/Å2), and carbonyl carbon and sulphur to ensure positioning of the sulphate group 




with the same restraints, but also enforcing the distance between Ser70 and avibactam 
electrophilic carbon staying below 4.0 Å (restraint weight 10 kcal/mol/Å2) to ensure a suitable 
conformation for nucleophilic attack (only for the system with a neutral Lys73). The QM region 
consisted of avibactam and the sidechains of Ser70, Lys73, Ser118, and Lys208 as depicted in 
Figure 7.3. This resulted in a QM region consisting of 56 atoms for the system with a 
carboxylated Lys73, and 54 atoms for the system with a neutral Lys73 (including link atoms). 




Figure 7.3 . QM region used in QM/MM MD and NEB calculations. Red and blue atoms included in 
the QM region, black atoms described using MM, link atoms placed along the bonds indicated with 
wavy lines. For a carboxylated Lys73, the terminal amine in Lys73 was replaced by -NCOO−. The 
carbonyl oxygen used as a reference point when stripping atoms for QM/MM NEB calculations is 
shown in blue. 
 
7.2.3 QM/MM potential energy calculations 
 
The activation energies and minimum energy paths (MEPs) for the discussed reaction 
mechanisms were calculated using the nudged elastic band (NEB) method as implemented in 
orca 4.2.0317, 318. For NEB calculations, the systems were stripped of any residues with any 
atom further than 17 Å from the avibactam carbonyl oxygen (Figure 7.3). Atoms closer than 
10 Å to the same oxygen were included in the active region, which was allowed to move during 
optimisation. Coordinates for the rest of the system were frozen. The stripped systems consisted 
of 1735 and 1723 atoms for the neutral Lys73 and carboxy-Lys73 systems, respectively. 
Reaction pathways were separated into two NEB calculations: TI formation from the MC (MC 




initially created by doing a brief constrained minimisation to change the bonding arrangement, 
and the created structures were then subjected to a full minimisation using the L-BFGS 
optimiser and the GFN2-xTB342 method (referred to as XTB2). The RMS gradient tolerance 
was set to be below 5x10−5 a.u. during this minimisation. The minimised structures were used 
as starting points for reaction path inspection using the climbing image NEB method (CI-NEB). 
The L-BFGS optimiser was used for constructing the NEB, and the images were re-distributed 
along the path every 50 iterations using linear interpolation. The default convergence criteria 
were kept for all images. MEPs were initially constructed using XTB2, and single-point 
energies (SPEs) were calculated on the ωB97XD/def2-TZVP and M06-2X/def2-TZVP 
levels.134, 135, 150 Two MEPs for both MC→TI reactions were re-optimised using the 
ωB97XD/def2-SVP method for the QM region. The RIJCOSX approximation343 with the 
default auxiliary def2/J basis set344 was applied both during NEB optimisation and upon 
calculating single-point energies for all DFT calculations. All NEB and SPE calculations were 
done using orca 4.2.0.317, 318 
 
7.3 Results and Discussion 
 
7.3.1 Dynamics of the formed Michaelis complexes 
 
After the initial minimisation and heating phases, the stability of the formed MCs was 
inspected by 50 ns MM MD simulations. Ten independent simulations were run for both 
systems. With a neutral Lys73, avibactam moved away from the initial “productive” pose in 
nine of the ten simulations (with the distance between avibactam carbonyl oxygen and Tyr211 
backbone amide increasing beyond 3.5 Å). In the remaining simulation, avibactam stayed in 
the original pose for the whole 50 ns. Notably, in one trajectory avibactam re-bound to the 
initial pose after shifting away. Upon repositioning, avibactam does not completely diffuse out 
of the active site during the simulations. It changes its orientation so that the carbonyl group 
shifts out of the oxyanion hole, but so that the -OSO3
- group stays near Lys208, Thr209, and 
Arg250. Representative structures of avibactam in its original non-covalent binding pose and 
the shifted position are presented in Figure 7.4. In the eight trajectories where avibactam shifts 
away from its initial pose for the rest of the simulation, this repositioning occurs within the first 
13 ns. In the trajectory where avibactam shifts away and then moves back to the oxyanion hole, 




oxyanion hole, Ser70 is observed to donate a hydrogen bond to Lys73 throughout the 
simulation, but it does so whilst rotating further away from the avibactam electrophilic carbon. 
For the initial Ser70 rotamer, the distance between Ser70:O and avibactam carbon is below 3.3 
Å, which is deemed feasible for a nucleophilic attack. Upon rotation, this distance increases to 
above 4 Å, which hinders the possibility of Ser70 hydroxyl forming a TI with avibactam. Ser70 
would need to first rotate back to its initial rotameric state before the nucleophilic attack could 
occur (Ser70 rotamers also illustrated in Figure 7.4). 
 
 
Figure 7.4 Representative structures of avibactam in MM MD simulations with a neutral Lys73. 
Important active site interactions highlighted with dashed black lines. Left: Avibactam orientation in 
the MM MD simulations, where it stays positioned in the oxyanion hole (formed by the backbone amides 
of Ser70 and Tyr211). The sulphate group is interacting with Lys208, Thr209, and Arg250. For the grey 
Ser70 rotamer, the distance to AVI:C is less than 3.3 Å, and for the pink rotamer, this distance is beyond 
4 Å. Right: Avibactam position after shifting away from the oxyanion hole. The inhibitor is kept in the 
active site by electrostatic interactions and hydrogen bonds between the sulphate group and Lys208, 
Thr209, and Arg250. 
 
For carboxy-Lys73, avibactam stays positioned in the oxyanion hole in five out of ten 
simulations, and shifts away in five simulations. In one trajectory, a similar shifting away and 
re-binding was observed as previously for the MC with a neutral Lys73. If avibactam shifts 
away from its initial pose, this shifting happens within 22 ns of the simulation start, except for 




simulations, where avibactam stays close to its original position, Ser70 is observed to rotate 
between three different orientations. Two are the same ones as depicted for the system with a 
neutral Lys73, and the third one involves the Ser70 hydroxyl group donating a hydrogen bond 
to the avibactam sulphate moiety (Figure 7.5). In the five simulations where avibactam re-
positions away from the oxyanion hole, it is still kept in the active site by electrostatic 
interactions and hydrogen bonds analogous to simulations with a neutral Lys73. 
 
 
Figure 7.5 Representative structures of avibactam in MM MD simulations with a carboxy-Lys73. 
Important interactions between the inhibitor and active site residues indicated with dashed black lines. 
Left: Avibactam positioned in the oxyanion hole. The three possible orientations for Ser70 indicated 
with sticks representation. Right: After shifting away from the oxyanion hole, avibactam is kept in the 
active site by electrostatic and hydrogen bond interactions between the sulphate group and Ser70, 
Lys208, Thr209, and Arg250. 
 
Further analysis of the MM MD data focuses on the subset of trajectories, where 
avibactam stays in the oxyanion hole (one trajectory for neutral Lys73, five for carboxy-
Lys73). As briefly mentioned previously, Ser70 can adopt three different orientations, which 
can be distinguished by measuring the sidechain χ1 (N-Cα-Cβ-OG) dihedral. The most 
acylation-compatible initial active site configuration is achieved, when i. Ser70 donates a 
hydrogen bond to Lys73, and ii. the distance between Ser70:OG and AVI:C is less than 3.5 Å. 
These criteria ensure both a feasible proton transfer and nucleophilic attack going from the MC 




approximately 300° (g- rotamer), with the majority of the sampled distances between 
Ser70:OG and avibactam carbon falling mostly under 3.5 Å for this rotamer (Figure 7.6). When 
the dihedral is approximately 180° (t), Ser70 is still donating a hydrogen bond to neutral Lys73, 
or analogously to the amine nitrogen in carboxylated Lys73. However, the distance between 
Ser70:O-AVI:C increases to ~4 Å or beyond, and for bond formation between Ser70 and 
avibactam, rotation to the g− state would be required. For the third rotamer, where χ1 is 
approximately 60°, Ser70 has rotated to donate a hydrogen bond to the sulphate group and is 
unable to transfer a proton to Lys73. Even though all three Ser70 orientation are observed in 
the simulations with the carboxylated Lys73, the g− rotamer is sampled the most. This, 
combined with the more stable non-covalent pose for avibactam, indicates that the carboxylated 
form of Lys73 is likely to participate in the acylation reaction. 
 
Figure 7.6 Distributions of the sampled Ser70 dihedrals and the corresponding distance between Ser70 
oxygen and avibactam electrophilic carbon. The label colour for the different Ser70 rotamers matches 




7.3.2 Energetics of the proposed pathway 1 
 
As discussed in section 7.1, at least two different pathways have been proposed for 
avibactam acylation. The compared reaction mechanisms are presented in Figure 7.1, and 
potential energy profiles for the approximate MEPs were calculated for models of the enzyme 
system (as described in Section 7.2.3). For pathway 1, the initial minimisation yielded only the 
MC and AC minima, as no stable minimum was found for the TI using the L-BFGS optimiser 
(the initial TI model changed back to the reactants during structure optimisation). Therefore, 
the MEP was first optimised from the MC all the way to the AC using 12 images, which helped 
to locate a better initial structure for the TI intermediate. This approximate TI structure was 
subsequently minimised prior to a new NEB optimisation in two parts going either from the 
MC to the TI, or from the TI to the AC. For the MC → TI calculation, the NEB consisted of 
14 images including the endpoints, and for the TI → AC of 22 images including the endpoints. 
The XTB2/MM optimised MC/TI/AC structures are presented in Figure 7.7. 
 
 
Figure 7.7 XTB2/ff14SB minimised structures for OXA-48 and avibactam with a neutral Lys73 
(pathway 1). 
 
All NEB calculations were done using the CI-NEB implementation in orca 4.2.0, where 




highest-energy saddle point along the MEP, which yields an approximate TS structure. This is 
not guaranteed for standard NEB, where the obtained images may not necessarily provide a 
good estimate of the TS as there may not be an image close to the saddle point. The obtained 
MEPs using XTB2/ff14SB for the NEB optimisation together with the DFT/MM single-point 
energy (SPE) values are presented in Figure 7.8 for both NEB calculations. Going from MC 
→ TI, the activation energy obtained with XTB2 as the QM method is 13.6 kcal/mol, and the 
reaction energy 10.6 kcal/mol. Analogously, the activation and reaction energies for the TI → 
AC conversion are 16.0 and −10.6 kcal/mol, respectively. Notably, the calculated energetics 
for the MC → TI reaction are underestimated using XTB2 with respect to the SPEs using either 
M06-2X/def2-TZVP or ωB97X/def2-TZVP for the QM region. Using M06-2X, the activation 
barrier is 23.2 kcal/mol, which is 9.6 kcal/mol higher than the corresponding XTB2 energy. 
The difference is even higher with ωB97X, where the calculated barrier is 27.4 kcal/mol, a 13.8 
kcal/mol increase with respect to XTB2. The opposite is observed for the second NEB 
calculation going from TI to the AC. Here, the XTB2 barrier is 16.0 kcal/mol, when M06-2X 
and ωB97X yield barrier heights of 6.0 and 9.8 kcal/mol, respectively. Even though the 
activation energies differ largely between XTB2 and the chosen functionals, XTB2 accurately 
predicts the forming TI to be high in energy with respect to the MC. The overall combined 
activation free energy barrier from the MC to the AC is 29.6 kcal/mol for XTB2, 29.2 kcal/mol 
for M06-2X, and 37.2 kcal/mol for ωB97X. The corresponding overall reaction energies are 0 





Figure 7.8 Potential energy along the MEP for the tetrahedral intermediate formation (MC → TI, left), 
and the subsequent avibactam ring opening and protonation (TI → AC, right) for pathway 1. QM/MM 
NEB calculations were performed using XTB2/ff14SB, and QM/MM SPEs were calculated using the 
ωB97X or M06-2X functional with the def2-TZVP basis set for the QM region. For both reactions, the 
structure of the climbing image, which corresponds to the highest energy saddle-point, is depicted 
(labelled NEB CI). 
 
Key distances together with the full interpolated XTB2/MM energy profiles are 
presented in Figure 7.9. For the MC → TI transition, the distances between the transferred 
proton and both the donor and acceptor were recorded, as well as the nucleophilic attack 
distance between Ser70 and the avibactam carbon. The first steep rise in the energy curve 
corresponds both to the proton transfer and the nucleophilic attack, which happen in a concerted 
fashion. However, the calculated energy still increases slightly, as the protonated Lys73 moves 
closer to hydrogen bond with Ser118. This explains why the Ser70:O – Ser70:H distance 
increases even after the proton transfer has occurred. For the TI → AC reaction, the two proton 
transfers are concerted and happen simultaneously with the elongation of the avibactam C-N 






Figure 7.9 Key distances along the calculated MEP for the MC → TI (left) and TI → AC (right) 
reactions in pathway 1. Left y-axis: measured key distances along the MEP, depicted with dots 
connected by lines. Right y-axis: XTB2/ff14SB energy along the MEP, depicted by yellow circles. 
 
7.3.3 Energetics of the proposed pathway 2 
 
The procedures for calculating MEPs for pathway 2 are the same as discussed for 
pathway 1, with the exception that the QM/MM NEB calculations were done in two parts from 
the beginning, as the TI minimum was identified already during the initial minimisation. 
However, re-positioning of some active site solvent molecules was observed between the 
minimised MC and TI structures, and therefore the MC → TI MEP was optimised in two parts. 
As water movement in the active site occurred before any bonding changes in the initial MEP, 
a MC structure with newly positioned waters (closer to the arrangement in the TI structure) 
was subsequently minimised and used as a starting point for a new NEB calculation. This 
ensured that the calculated barrier excludes any re-organisation in the active site and mainly 
corresponds to the actual enzymatic reaction itself. The minimised structures used as NEB start 





Figure 7.10 XTB2/ff14SB minimised structures for OXA-48/avibactam acylation with a carboxylated 
Lys73 (pathway 2). 
 
The calculated potential energies along the MEP for both reactions in pathway 2 are 
presented in Figure 7.11. The MEPs consisted of 14 and 22 images for the MC → TI and the 
TI → AC reactions, respectively. Notably, the XTB2 method seems to vastly underestimate 
the barrier to forming a TI. Calculated energies using XTB2/ff14SB imply that the MC → TI 
reaction is essentially barrierless, as the required energy is only 0.6 kcal/mol, and that the TI is 
−9.5 kcal/mol lower in energy than the starting non-covalent MC. As the TI structure is 
expected to be higher in energy than the MC, XTB2 does not appear to give reliable energetics 
for the formation of this intermediate. However, this is partly overcome by obtaining SPEs 
using DFT for the QM region. The activation energy with M06-2X/def2-TZVP is 7.5 kcal/mol, 
and with ωB97X/def2-TZVP 11.3 kcal/mol. The reaction energies are also in better accordance 
with their expected values, as they are 0.7 and 5.4 kcal/mol for M06-2X and ωB97X, 
respectively. For the TI → AC reaction, XTB2/ff14SB yields an activation energy barrier of 
23.8 kcal/mol. This is higher than the calculated QM/MM SPEs with DFT, as the M06-2X 
barrier is 12.5 kcal/mol and the ωB97X barrier 14.9 kcal/mol. Based on the energies, the TI 
minimum is also shifted to image 8 when using DFT as the QM method. The total activation 




kcal/mol using M06-2X, and 26.2 kcal/mol using ωB97X. However, just based on the 
XTB2/ff14SB energetics, the forming TI would be the stable intermediate structure. The total 
reaction energies for MC → TI are 4.3 kcal/mol for XTB2, −1.0 kcal/mol for M06-2X, and -
0.8 kcal/mol for ωB97X. 
 
Figure 7.11 Potential energies for the tetrahedral intermediate formation (MC → TI, left), and the 
subsequent avibactam ring opening and protonation (TI → AC, right) for pathway 2. NEB calculations 
were performed using XTB2/ff14SB, QM/MM SPEs calculated using either ωB97X or M06-2X 
functionals with the def2-TZVP basis set for the QM region. The converged structure of the climbing 
image depicted for both reactions (labelled NEB CI). 
 
Key distances for both reactions involved in pathway 2 are presented in Figure 7.12. 
They follow largely the same pattern observed for pathway 1, where the proton transfer and 
nucleophilic attack in the MC → TI reaction are concerted. This aligns with the slight increase 
in the calculated XTB2/ff14SB energy at the TS. For the TI → AC reaction, the proton transfers 
from Lys208 to Ser118 and from Ser118 to avibactam occur almost simultaneously, and 





Figure 7.12 Key distances along the calculated MEP for the MC → TI (left) and TI → AC (right) 
reactions in pathway 2. Left y-axis: measured key distances along the MEP, depicted with dots 
connected by lines. Right y-axis: QM/MM energy with XTB2 as the QM method along the MEP, 
depicted by yellow circles. 
 
 
7.3.4 Comparison of the pathways 
 
The activation free energies calculated with all QM methods used are listed in Table 
7.1. Energies are tabulated for the separate reactions as well combined to give the overall 
activation energy for the whole acylation reaction. Going all the way from MC to the AC, 
DFT/MM energies on the XTB2/MM optimised MEPs indicate that the overall barrier for 
pathway 2 is either 11.0 kcal/mol (ωB97X/def2-TZVP) or 9.2 kcal/mol (M06-2X/def2-TZVP) 
lower in energy than for pathway 1. Notably, the calculated energy barrier for the MC → TI 
reaction in pathway 1 is significantly higher than for pathway 2. In pathway 1, the TI formation 
requires either 16.1 kcal/mol (ωB97X) or 15.7 kcal/mol (M06-2X) more energy than the TI 
formation in pathway 2. Comparison of the calculated activation energy barriers implies that 
of the studied mechanisms, pathway 2 is the most likely mechanism for avibactam acylation. 
The activation energy barrier for the MC → TI conversion in pathway 2 was re-calculated using 
ωB97X/def2-SVP for the QM region during NEB optimisation, and calculating SPEs using 




(ωB97X) and 6.6 kcal/mol (M06-2X) are in good agreement with the previously obtained 
corresponding energetics on the XTB2 optimised structures. Comparison of the CI and TI 
structures reveals the proton transfer between Ser70 and Lys73 to have progressed further when 
optimising the structured using ωB97X/def2-SVP//MM. The distances between Lys73:O – 
Ser70:H and Ser70:O – Ser70:H are 1.1 and 1.3 Å in the ωB97X/MM optimised TS, and 
conversely 1.3 and 1.1 Å in the TS optimised using XTB2/MM (respectively). The 
ωB97X/MM reaction energy is 4.2 kcal/mol, and the M06-2X/MM reaction energy is -0.7 
kcal/mol. The TI structures are virtually identical when optimised either using XTB2/MM or 
ωB97X/MM, implying that whilst XTB2 does not give reliable energetics for the forming TI, 
the structures can be used for obtaining better energetics using a higher-level method for the 
QM region. Further, the barrier for the MC → TI conversion in pathway 1 using the same DFT 
methods for the QM region in NEB optimisation and subsequent SPEs yields barriers of 27.2 
and 23.0 kcal/mol for ωB97X and M06-2X, respectively. This further support the hypothesis 
of a proton transfer from Ser70 to a neutral Lys73 being energetically unfeasible in comparison 
to a proton transfer to a carboxylated Lys73. 
 
Table 7.1 QM/MM activation energy barriers (Δ‡E) for pathways 1 and 2 with all QM methods used. 
All energies in kcal/mol. The combined barrier is obtained by summing together the individual barriers 
for MC → TI and TI → AC. 








1 MC → TI 13.6 27.4 23.2 
1 TI → AC 16.0 9.8 6.0 
1 MC → AC 
Combined 
29.6 37.2 29.2 
2 MC → TI 0.6 11.3 7.5 
2 TI → AC 23.8 14.9 12.5 
2 MC → AC 
Combined 
23.8 26.2 20.0 
 
A kcat value for avibactam acylation by OXA-48 has not been measured, as only the combined 
k2/Ki = 1.4 ± 0.1 x 10




constant for recyclization is measured to be koff = 1.2 ± 0.4 x 10
-5 s-1 with a half-life of 1000 ± 
300 minutes. This deacylation rate constant corresponds to a free energy barrier of 
approximately 24.3 kcal/mol (converted using the Eyring equation). As the free energy barrier 
for acylation is lower than for deacylation, it is likely that the calculated combined potential 
energy barriers of 23.8/26.2/20.0 kcal/mol (with XTB2/ωB97X/M06-2X as the QM method, 
respectively) for pathway 2 overestimate the actual acylation barrier. If recyclization occurs 
via the same reaction “backwards”, the activation energy for the AC → TI reaction is 10 
kcal/mol for XTB2, 15.0 kcal/mol for ωB97X, and 12.8 kcal/mol for M06-2X. 
Correspondingly, the TI → MC conversion to give intact avibactam requires 10.1 kcal/mol 
using XTB2, 10.6 kcal/mol using ωB97X, and 6.8 kcal/mol using M06-2X. The combined 
barriers for the whole AC → MC recyclization reaction are 10.1 kcal/mol with XTB2 as the 
QM method, 25.6 kcal/mol with ωB97X, and 19.6 kcal/mol with M06-2X. These are all lower 
than the corresponding overall barriers calculated for the whole MC → AC conversion in 
acylation. Therefore, avibactam inhibition most likely relies on Lys73 being preferentially in 
its decarboxylated form in the AC state, and thus unable to act as a general acid in recyclization. 
This hypothesis is further supported by experimental data from enzyme kinetics, 
crystallography, and NMR spectroscopy. Based on the crystallised OXA-48/avibactam 
complexes, Lys73 is preferentially decarboxylated when covalently-bound avibactam is 
present. For example, in structures obtained at pH values 6.5 and 7.5, none of the OXA-48 
monomers displayed Lys73 carboxylation, and at 8.5 only partial carboxylation was 
observed.235 This is expected, as increasing the pH of the solution favours Lys73 carboxylation. 
Further, 19F NMR measurements suggest that Lys73 is decarboxylated in the OXA-
48/avibactam AC complex.236 Enzyme kinetics measurements indicate that avibactam 
recyclization is slower for class D β-lactamases than for classes A and C.34 A distinct difference 
between class D and class A/C enzymes is that for the former, a reversibly carboxylated Lys73 
acts as an acid/base in the reaction instead of a “standard”, unmodified amino acid residue. 
“Inactivation” of this Lys73 through decarboxylation could explain the relative slow rates of 




In this chapter, the possible mechanisms of OXA-48 inhibition by the DBO inhibitor 




Two main reaction mechanisms were inspected. In pathway 1, a neutral Lys73 acts as the initial 
proton acceptor, but subsequently also donates a proton to Ser118, which further protonates 
avibactam. In pathway 2, a carboxy-Lys73 is the initial proton acceptor, and avibactam 
protonation occurs by Lys208 via Ser118. Accordingly, non-covalent MC models for OXA-48 
with either a standard, neutral Lys73 or with a carboxylated Lys73 were constructed. The 
stabilities of these complexes were inspected by ten independent 50 ns MM MD simulations. 
With a neutral Lys73, avibactam shifted away from its initial acylation-compatible pose in nine 
out of ten simulations. With a carboxylated Lys73, the same avibactam re-positioning was 
observed in five simulations. Comparison of the reaction energetics for acylation was done by 
constructing MEPs for both pathways using the CI-NEB method. Energetics along the 
calculated MEPs indicate that the initial proton transfer and nucleophilic attack are more 
feasible for OXA-48 with a carboxylated Lys73; the activation energy barriers are 13.0-16.1 
kcal/mol lower for the MC → TI reaction in pathway 2 (with a carboxy-Lys73) than in pathway 
1 (neutral Lys73). Based on the combination of MM MD and QM/MM NEB calculations 
presented here, we suggest that avibactam acylation happens analogous to β-lactam hydrolysis, 
where a carboxy-Lys73 acts as the general base. The efficient inhibition of OXA-48 (and other 
class D β-lactamases) with avibactam is enabled by slow recyclization rates, which are likely 






8. Conclusions and outlook 
 
In this thesis, I have outlined my research on selected serine β-lactamases, which have 
been identified among the most common enzymes in resistant bacterial infections globally. In 
Chapter 3, carbapenem hydrolysis by eight class A β-lactamases is compared using different 
types of computational assays. These computational assays are essentially simplified 
simulation protocols, which still distinguish between different hydrolytic phenotypes (i.e. 
correctly differentiate between carbapenemases and carbapenem-inhibited enzymes). Chapters 
5 to 7 present simulations of class D β-lactamases, specifically the OXA-48 family. 
Cephalosporinase inactivation by selected OXA-48 enzymes is compared in Chapter 5, and the 
differences in carbapenem breakdown between imipenem and meropenem for OXA-48 in 
Chapter 6. Finally, Chapter 7 discusses the inhibition mechanism of OXA-48 by avibactam, a 
DBO-based β-lactamase inhibitor. In this last section, I will briefly outline the main 
conclusions of these chapters, consider their potential impact, and discuss possible future work 
in the corresponding research areas. 
 
8.1 Class A β-lactamases 
 
In Chapter 3, meropenem breakdown was simulated for four carbapenemases (KPC-2, 
NMC-A, SFC-1, and SME-1) and for four carbapenem-inhibited enzymes (TEM-1, SHV-1, 
BlaC, and CTX-M-16), all belonging to class A serine β-lactamases. A previous study, where 
QM/MM umbrella sampling (with DFTB2) was used to calculate full free energy surfaces for 
all enzymes, was used as a starting point for constructing more simplified simulation 
protocols.190 The aim here was to limit both the sampling time in each umbrella sampling 
window, and the conformational sampling along the free energy surface. The sampling time 
was shortened from 20 ps/window to 2 ps/window, and the number of umbrella sampling 
windows was decreased from 374 to 28. The 28 windows correspond to structures near the 
approximate minimum free energy path, which was largely similar across all eight enzymes. 
This new simulation protocol used less than 99% of the computational resources required for 





This study highlights, how simulations can be used as computational assays to compare 
enzyme activities. In addition to correctly distinguishing between known hydrolytic 
phenotypes, i.e. carbapenemases and non-carbapenemases, these type of in silico assays could 
be applied to study the phenotypes of new, emerging variants e.g. from sequence data. In 
addition to assaying new β-lactamase variants, newly designed β-lactam antibiotics or β-
lactamase inhibitors could be inspected in a similar fashion e.g. prior to synthesising them. This 
underlines the paradigm shift in computational chemistry, where the role of simulations is 
moving from mainly rationalising experimental data to being fully predictive and guiding 
decision making. Further automation of these protocols could provide rough estimates of 
enzyme activities within hours with relatively modest computational resources. Establishing 
how much these computational assays could still be simplified and shortened remains as future 
work. Some possible ideas could include moving from periodic box simulations to a more 
simplified system descriptions (with fewer atoms), and using GPU accelerated QM programs 
or new, more efficient methods for the QM region (e.g. utilising machine learning potentials). 
 
8.2 OXA-48 β-lactamases 
 
8.2.1 Cephalosporinase activity 
 
Generally, OXA-48 β-lactamases are either carbapenemases exhibiting low level 
carbapenem hydrolysis with a specific preference towards imipenem, or they are more ESBL-
like, i.e. they have acquired activity against oxyimino cephalosporins like ceftazidime (usually 
at the expense of efficient imipenem breakdown). In Chapter 5, the cephalosporinase activities 
of carbapenemases OXA-48 and OXA-181 are compared against OXA-163, which has an 
ESBL-like hydrolytic phenotype. Comparison of the expected rate-limiting step (deacylation) 
in ceftazidime hydrolysis revealed that for cephalosporinases, the active site tends to be less 
hydrated. Hydration around the general base (carboxy-Lys73) correlated with the calculated 
free energy barriers: the fewer water molecules were hydrogen bonding to the proton accepting 
carboxylate oxygen, the lower the barriers were. Additionally, two further hypotheses were 
tested using our simulation protocols. Firstly, the effect of a single mutation (Arg214Ser) on 
the calculated deacylation barriers was analysed, as deletion of Arg214 was hypothesised to be 
the main determinant in the acquired activity in OXA-163. Secondly, the effect of the Ω-loop 




In this study, we demonstrated the power of our simplified simulation protocols 
presented in Chapter 3. All reaction simulations were performed using short simulation times 
(2 ps per US window) with semi-empirical QM methods. Whilst replicating the experimentally 
measured kcat values within chemical accuracy was not possible with this approach, it is 
sufficient to discriminate between inhibited and active enzymes. Additionally, this modelling 
approach was used to indicate the ceftazidime orientation most compatible with deacylation. 
We were also able to complement existing experimental research by analysing the effect of Ω-
loop distortion on the calculated rates. No visible electron density was observed for the Ω-loop 
region in a crystal structure of OXA-48 with ceftazidime (in the AC state), and hence Ω-loop 
distortion was hypothesised to be important for ceftazidime hydrolysis. However, our 
simulations show that this distortion is likely to lead to diminished catalytic rates, as the active 
site is fully exposed to solvent molecules. Therefore, the observed Ω-loop distortion most likely 
relates to the initial binding of ceftazidime, a relatively bulky cephalosporin substrate, instead 
of offering any rate enhancement beyond aiding in the formation of the initial non-covalent 
complex. In addition to rationalising experimental findings, we predicted the activity of an in 
silico Arg214Ser point mutant. This is an example of computational assays being used to study 
activities of new enzyme variants, as discussed in Section 8.1. Finally, this was the first work 
to highlight the effect active site hydration has on the catalytic efficiency of serine β-
lactamases, aside the obvious need for a deacylating water to reach a position suitable for 
nucleophilic attack. We illustrated that whilst the argument concerning deacylating water 
movement is accurate, there is a more careful balance between the active site being accessible 
and additional hydration around the reactive residues impairing catalysis. 
Our simulations focus on modelling the rate-limiting enzymatic reaction starting from 
the covalent AC intermediate. For this, we assume the initial non-covalent MC to have been 
formed and undergone acylation. However, experimental kinetics indicate that in addition to 
the actual rate constant, also ceftazidime binding differs for OXA-48 and OXA-163. Studying 
the role of the Ω-loop (and its possible distortion) in binding remains for future studies. Another 
interesting prospect is developing more broad-spectrum cephalosporin antibiotics against 
serine β-lactamases. E.g. the ceftazidime/avibactam combination is one of the recommended 
treatment options for OXA-48 infections,259 as OXA-48 remains susceptible for both 
ceftazidime and avibactam. In addition to ceftazidime, another treatment option against OXA-




likely that the cephalosporin scaffold could be improved to yield even more broad-spectrum 
antibacterial drugs. 
 
8.2.2 Carbapenemase activity 
 
As mentioned in the previous section, the OXA-48 β-lactamase exhibits a preference 
for imipenem over other carbapenem substrates. The origin of this imipenemase activity 
remains unclear, although the β5-β6 loop has been demonstrated to be integral for acquired 
carbapenemase activity in general.242, 245 In Chapter 6, the rate-limiting step in carbapenem 
breakdown (deacylation, as for ceftazidime) is compared for imipenem and meropenem by 
MM MD and QM/MM reaction simulations. To briefly summarise, we observed carbapenem 
substrates to be able to accommodate three different conformations, which differ by the 
position of the 6α-hydroxyethyl group. The effect of changing the orientation of the 6α-
hydroxyethyl group on the deacylation reaction was calculated by restraining this sidechain 
during QM/MM US simulations. For both carbapenems, the lowest free energy barriers were 
obtained, when the 6α-hydroxyethyl group is rotated near the oxyanion hole and either donates 
or accepts a hydrogen bond from the deacylating water. For imipenem, the lowest free energy 
barriers were calculated in this orientation upon the 6α-hydroxyethyl accepting a hydrogen 
bond from the deacylating water, and the barrier is increased if hydrogen bonds change so that 
the 6α-hydroxyethyl hydroxyl group donates a hydrogen bond to the water nucleophile. The 
same effect was not calculated for meropenem, where both hydrogen bond patterns had very 
similar barriers. Further, we were able to extend our argument concerning hydration around the 
general base, as increased hydration around both carboxylate oxygens was calculated to affect 
the barriers (not just around the proton accepting one). 
Many arguments about the source of carbapenemase activity have been presented in 
existing literature, and whilst some have been related to the orientation of the discussed 6α-
hydroxyethyl group,222, 254 our simulations illustrate the precise effect a certain substrate 
conformation has on the deacylation efficiency. We are also able to pinpoint the exact 
orientation that is most likely to contribute to efficient deacylation. Additionally, we can deduct 
a very subtle difference between the preferred hydrogen bond networks in the active site, which 
in turn most likely leads to the observed difference between imipenem and meropenem 
hydrolysis efficiency. Finally, we further extended our findings of active site hydration 




both Lys73 carboxylate oxygens. The free energy barriers were calculated to increase even 
when hydration around the second carboxylate oxygen, which does not participate in the 
reaction, increased as well. 
Even though carbapenem hydrolysis by the OXA-48 β-lactamase was dissected rather 
exhaustively, the exact reason for the calculated lower energy barriers for imipenem in the most 
deacylation-compatible substrate orientation remains elusive. This is expected to relate to the 
1β-methyl group in meropenem, which is replaced by a 1β-proton in imipenem. The larger 
methyl group might favour re-orienting water molecules near the substrate or the substrate 
itself, but establishing the validity of this hypothesis remains for future studies. Additionally, 
comparing carbapenem hydrolysis between the wildtype OXA-48 and its variants with 
enhanced carbapenemase activity could further indicate if similar patterns with respect to active 
site hydrogen bonds are observed. Another interesting aspect for future research would be 
inspecting a common side reaction for carbapenems, as in addition to standard hydrolysis, 
OXA-48 has been shown to degrade carbapenems additionally by β-lactone formation.253, 254 
Originally lactone formation was observed for the wildtype OXA-48 only with 1β-methyl 
carbapenems,253 but later some OXA-48 variants were shown to lactonise 1β-proton 
carbapenems as well.254 Comparison of deacylation vs. lactone formation for different 
carbapenem substrates, as well as establishing the role of amino acid mutations enhancing or 
diminishing lactone formation, would be an intriguing (albeit most likely challenging) subject 
for computational modelling. 
 
8.2.3 Avibactam inhibition mechanism 
 
To combat the growing resistance against β-lactam antibiotics, new β-lactamase 
inhibitors are in active development. Avibactam is one of these newer non-β-lactam β-
lactamase inhibitors, which efficiently inhibits OXA-48.34 Experimental studies indicate that 
avibactam is acylated in an analogous way to β-lactam substrates, but instead of being 
inactivated via deacylation, it undergoes recyclization to re-form the intact inhibitor.34 
However, the exact mechanisms for avibactam acylation and recyclization are not known, but 
two main hypotheses have been presented in existing literature. In the first proposed pathway, 
avibactam is acylated using a neutral, non-carboxylated Lys73 as the general base, which 
subsequently also protonates avibactam via Ser118.235 In the second proposal, a carboxylated 




compared these two pathways by calculating their potential energy profiles using QM/MM 
nudged elastic band calculations, and concluded the pathway incorporating a carboxylated 
Lys73 to be more likely than the alternative mechanism with a neutral Lys73 as the proton 
acceptor. 
Even though it is known that Lys73 needs to be in its carboxylated form for β-lactam 
hydrolysis, this has so far not been verified for DBOs like avibactam. The hypothesis of a 
neutral Lys73 acting as a proton acceptor is mainly based on crystal structures, where Lys73 is 
observed to favour its standard, non-carboxylated form in the presence of a covalently-bound 
avibactam.235 Here, we show that a proton transfer to a neutral Lys73 is energetically not 
feasible, in contrast to proton transfer to a carboxy-Lys73. Therefore, avibactam most likely 
utilises a similar mechanism for the initial proton transfer and nucleophilic attack as is known 
for β-lactam antibiotics. The inhibition power of avibactam is likely to come from post-
acylation decarboxylation of Lys73, which traps the covalently-bound inhibitor in the 
acylenzyme state. This suggested mechanism aligns well with other experimental observations, 
such as class D β-lactamases exhibiting slower recyclization rates than class A or C β-
lactamases.34 
Even though we provide a mechanistic suggestion for avibactam acylation, different 
possible pathways for recyclization are not inspected in detail. Rather, recyclization is expected 
to happen via the same mechanism in the reverse direction; verifying if this expectation is true 
remains for future studies. Additionally, calculating free energy profiles (as opposed to 
potential energy) for the fully solvated enzyme system using e.g. the adaptive string method345, 
will possibly provide more accurate energetics for the whole acylation reaction. Finally, 
studying the origin of Lys73 decarboxylation post-acylation can guide the design of new types 
of inhibitors, which essentially inhibit class D β-lactamases by enforcing Lys73 
decarboxylation at the acylenzyme state. 
 
8.3 Broad impact 
 
Atomistic simulations of enzyme/substrate complexes complement experimental 
research, e.g. x-ray crystallography, by offering a more complete picture of the dynamic nature 
of these macromolecules. As illustrated in Sections 8.2.1-8.2.3., biomolecular simulations are 




which are originally derived from experimental data.  Simulations also provide a cost-effective 
and straight-forward way of testing new hypotheses or screening through large data libraries. 
As an example, serine β-lactamases can acquire activity against β-lactam antibiotics or β-
lactamase inhibitors through point mutations. As new enzyme variants emerge e.g. from 
environmental or clinical samples, their phenotypes could be characterised in silico directly 
from sequence data. Simulations can also be used to elucidate the molecular level interactions, 
which lead to increased hydrolysis against certain antibiotics for enzyme variants emerging 
from experimental research.346 Further, identified mutational sites in new variants could be 
screened for any alternative amino acid replacements, therefore identifying possible new 
variants before they have been detected. This would help to understand the evolution of broad-
spectrum β-lactamase resistance on a more fundamental level. Combining further automation 
of simulation protocols with modest required computational resources enables using a standard 
laptop as a diagnostic tool for predicting enzymatic activities against a certain antibiotic. This 
in turn can be used to guide antibiotic prescriptions in a clinical setting. This kind of evidence-
based antibiotic prescription is an integral part of antibiotic stewardship, as it reduces selection 
pressure for bacteria and slows down evolving resistance. 
The subtle effects of solvation, highlighted by the studies of carbapenem and 
cephalosporin breakdown by OXA-48 enzymes, aid in gaining a better understanding of 
features contributing to antibiotic hydrolysis. Serine β-lactamases seem to enhance their 
activity by expulsing water away from the active site, especially away from the general base. 
Changes in active site hydration are especially important in class D β-lactamases, where the 
general base is not a part of a highly organised hydrogen bond network. A comparison of active 
site hydration between different enzyme variants could already be used as a relatively simple 
indicator of enzyme activity. Further, the findings concerning hydration have implications for 
future antibiotic and inhibitor design purposes. An ideal β-lactamase inhibitor is acylated 
efficiently and forms a very long-lived covalent acylenzyme structure post-acylation. One way 
to achieve this is to design ligands, which modulate the access of water molecules to the active 
site: as lack of catalytic water molecules essentially traps the ligand in the acylenzyme state. 
The use of reliable and efficient QM/MM protocols may also aid in designing new mechanism-
based inhibitors as well as elucidating inhibition mechanisms for inhibitors with a new mode 
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